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Abstract 
Viral infections are a significant source of morbidity and mortality following 
allogeneic haemopoietic stem cell transplantation (HSCT). HSCT constitutes the only 
curative therapy for many haematological malignancies. Global transplant practices 
are evolving with drive to meet demand leading to increased use of ‘alternative’ and 
‘mismatched’ donors. These factors contribute to the delayed T-cell recovery with 
increased vulnerability to latent viral reactivation. Use of antiviral therapy can be 
limited by resistance or toxicity. HSCT donor-derived virus-specific T-cells (VST) 
are an alternative for the prophylaxis or treatment of infection. Despite promising 
early phase trial results this form of therapy is unlikely to be adopted as a standard of 
care. A HSCT donor-derived product will not be available to all patients, and may not 
be available in situations of clinical urgency. On a broader scale, VST manufacture is 
not economical, as products are intended for a specific recipient and there is risk that 
products will not be used. The use of third-party donor VST is an alternative option. 
Feasibility has been demonstrated in a small number of studies using partially human 
leucocyte antigen (HLA)-matched third-party donor VST to treat viral infection in 
HSCT recipients.  This thesis investigated optimal procedures for establishing a third-
party bank of cryopreserved CMV, EBV, and Adv-specific T-cells within an existing 
HSCT program. Banked VST products were fully characterized for HLA type and 
antiviral activity. The long-term efficacy and safety of these VST products for 
treatment of refractory viral infection post-HSCT were investigated in a phase I multi-
centre trial. The immunological impacts of third-party VST infusion were examined 
by measuring immune cell frequencies, cytokine activity, virus-specific T-cell 
frequency, and persistence of infused-third party cells in the post-treatment period.  
It is envisaged that the results of these investigations will contribute to the evaluation 
of third-party donor cell banks as a safe and pragmatic therapeutic approach worthy of 
later phase studies, in turn improving accessibility to highly efficacious and low 
toxicity antiviral treatment for all HSCT patients.  
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Introduction 
2 
Chapter 1. Introduction 
1.1 Introduction  
Adoptive cellular therapy (ACT) is the transfer of native or manipulated immune cells 
into a recipient to prevent or treat disease. Examples of manipulation include expansion of a 
rare immune cell subset or modification of immune cell function prior to transfer. ACT is 
frequently used to enhance protective immunity against infection or malignancy. Allogeneic 
haematopoietic stem cell transplantation (aHSCT) is the archetypal cellular therapy, and the 
only one to have been successfully adapted to large scale, routine clinical practice. More than 
20,000 allogeneic HSCTs are now being performed world-wide each year1. Haematopoietic 
stem cells (HSC) are isolated from healthy related or unrelated allogeneic donors for transfer 
into an immunosuppressed recipient. Despite recent diagnostic and treatment advances, 
aHSCT remains the only curative option for many haematological malignancies and diseases. 
Notwithstanding this success, aHSCT is associated with significant limitations due to 
immunosuppression and adverse effects arising from transplantation of foreign donor immune 
cells. Relapse of primary disease, graft versus host disease (GVHD), and infection are the 
leading causes of mortality in the first two years after transplant2. Infection occurs due to 
immunosuppression and slow immune reconstitution post-transplant.  
These limitations highlight the need to explore new cellular therapy approaches which 
enhance efficacy and minimise toxicity. This thesis will investigate the efficacy, safety, and 
feasibility of manufacturing and administering virus-specific T-cell therapy derived from a 
third-party donor to treat persistent viral infection in allogeneic stem cell transplant patients. 
The use of third-party donors may expand cellular therapy applications to other therapeutic 
scenarios such as virus-driven malignancies, or adaption to tumour antigen targeting.  
 3 
1.2 Allogeneic haemopoietic stem cell transplantation (aHSCT) 
1.2.1 Background and rationale for aHSCT  
An increasing number of aHSCTs are being performed globally each year3. The 
indications for allogeneic transplantation have expanded to include non-malignant disorders 
such as inherited and acquired aplastic anaemia, immunodeficiency syndromes, and 
haemoglobinopathies.  
HSCT is contingent on the self-replenishing and pluripotent characteristics of HSC. 
Pluripotency describes the ability of immature HSCs to differentiate into all the mature myeloid 
and lymphoid cell types that encompass a functioning haemopoietic system4. Bone marrow 
infusions following lethal dose irradiation were found to allow recovery of the haemopoietic 
system in animals5. However, HSC from genetically non-identical donors led to death due 
immunological destruction of recipient tissue by donor immune effectors, termed graft versus 
host disease (GVHD)5,6. Intensification of the chemo-radiation regimens used to treat 
haematological malignancy was possible by using HSC from an identical twin to salvage the 
recipient’s haemopoietic system7,8. Donor lymphoid cells were discovered to have a direct 
cytotoxic effect on the recipient’s malignant cells9-11 referred to as graft versus leukaemia 
(GVL) effect. The discovery of the human leucocyte antigen (HLA) system enabled the use of 
HLA-matched sibling donors for HSCT12 but GVHD caused significant mortality presumed to 
be due to minor histocompatibility antigen mismatch13. GVHD and GVL appear to be 
intimately related; HSCT recipients with severe GVHD were shown to have a significantly 
reduced risk of relapse, suggesting a GVL effect14. Minor histocompatibility antigens may play 
a role in mediating both the GVL and GVHD effect as reviewed by Bleakley and Riddell15. 
Research efforts have focused on manipulating various aspects of the transplant process to 
separate the GVL effect from GVHD, however GVHD continues to be major impediment to 
improving transplant outcomes. 
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Pre-transplant conditioning therapy is intended to deplete malignant or diseased cells, 
and prepare the stem cell niche environment for acceptance and expansion of the infused cells. 
Regimens include chemotherapy, radiotherapy or a combination of both, and vary in intensity. 
Myeloablative conditioning (MAC) include a high dose alkylating agent and is expected to 
ablate the marrow with no possibility of autologous haemopoietic cell recovery whereas less 
intensive, non-myeloablative (NMA) protocols may cause cytopenias but can be given without 
HSC support as autologous recovery is expected16. The decision of conditioning intensity is 
based on factors such as patient fitness, disease type and assessment of relapse risk, and 
institutional practice. Myeloablative conditioning is usually reserved for fit (usually younger) 
recipients with high risk disease. Reduced intensity conditioning (RIC) does not fit the 
definition for either MAC or NMA conditioning. RIC protocols were developed with an 
emphasis on minimising transplant-related toxicity for older recipients and those with 
comorbidities precluding MAC, with efficacy reliant on the GVL effect17.  
Donor HSC can be sourced either directly from the bone marrow or from peripheral 
blood apheresis following HSC mobilisation with granulocyte colony stimulating factor (G-
CSF). HLA-matched sibling donors were once the standard donor used for HSCT. Eligibility 
for transplantation has been expanded by the use of ‘alternative’ donors such as unrelated, 
umbilical cord blood (UCB), HLA-mismatched and haploidentical donors. The majority of 
aHSCTs are now performed using alternative donors2. The choice of donor and cell source can 
have significant implications for post-transplant immune cell recovery and impacts on the risk 
of infection, risk of GVHD, and potential for primary disease relapse18.  
1.2.2 Infection and immune reconstitution post-allogeneic HSCT  
Death due to infection occurs in up to 16% of aHSCT patients within 100 days of 
transplant. Although the majority of infectious deaths occur in the first year, late infectious 
deaths persist at a rate of 2-3% per year even up to 10 years post-transplant19,20. The type of 
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infective organism and risk of infection is influenced by the tempo of immune reconstitution 
of the different immune cell subsets as reviewed by Peggs21 and Mackall22. Neutrophil recovery 
occurs within 2-4 weeks, other innate immune cells such as natural killer cell recover within 
1-3 months. Adaptive cellular immune recovery is usually more delayed. B-cell reconstitution 
does not occur until 1-2 year post-transplant. T-cell reconstitution occurs in two phases with 
early CD8+ recovery after three months, and later CD4+ recovery after 12 months. Early 
recovery involves homeostatic clonal expansion of mature donor T-lymphocytes transferred 
with the graft along with any residual recipient T-lymphocytes, yielding an inverted 
CD4+/CD8+ ratio due to predominant CD8+ memory phenotype, and narrow T-cell receptor 
repertoire23,24. This is later followed by thymic dependent de novo generation of naïve donor T 
lymphocytes, particularly CD4+ T-cells, with broader antigen specificity23,25.  
Profound neutropenia during the pre-engraftment period leads to high risk of infection 
with bacteria and Candida species. Breakdown in mucosal and skin barriers can result in 
transfer of the recipient’s own commensal organisms to the bloodstream26, and increases the 
risk of nosocomial infection27. Bone marrow and UCB HSC are associated with prolonged 
neutrophil engraftment (median 19 and 30 days respectively) compared to peripheral blood 
HSC (median 14 days)28,29,30. Viral and fungal infections occur in the early and late post-
engraftment periods due to slow recovery of adaptive immunity31. The risk is compounded by 
the use of immunosuppressant medications to prevent and treat graft versus host disease, as 
well as the immune-modulatory effect of graft versus host disease in its own right32,33. Factors 
affecting T-cell immune recovery will be discussed in detail in Section 1.2.6. 
1.2.3 Viral infections post-allogeneic HSCT  
Viral infection is the second most common cause of infectious death (31%) in aHSCT 
after bacterial infection (36%)19. Recipients of aHSCT are at high risk from double-
stranded(ds)-DNA virus including: the herpes viruses (cytomegalovirus (CMV), Epstein-Barr 
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virus (EBV), herpes simplex virus, varicella zoster virus, human herpes virus HHV-6 and 
HHV8), adenovirus and polyomavirus (BK and JC)34-36. Primary self-limited viral infection 
usually occurs early in life resulting in a high community seroprevalence 37-39. In the case of 
the herpesviruses, this is a followed by life-long viral latency where the viral genome persists 
but viral gene expression and lytic viral replication is suppressed. Asymptomatic latency is 
usually controlled by the adaptive immune system which prevents progression to clinically 
significant reactivation as discussed in Section 1.2.4. However, impaired cell-mediated 
immunity following allogeneic HSCT leads to a high risk of latent reactivation with the 
potential for invasive tissue disease. High sensitivity molecular monitoring has shown that 90% 
of aHSCT patients had ≥1, 62% had ≥ 2, 28% had ≥ 3, and 5% had 4-5 ds-DNA viruses detected 
in the 100 days post-HSCT. CMV was the most frequently detected virus. Cumulative burden 
of viral exposure was an independent risk factor for mortality35.  
1.2.4 T-cell response to viral infection  
CD8+ T-cells are the principle effector cells responsible for the control of acute and 
latent viral infection. CD4+ T-cells are important in ensuring the survival and efficient 
functioning of virus-specific CD8+ T-cells40,41. As reviewed by Kaech42, three phases of T-cell 
response to viral infection have been proposed: antigen-induced activation and expansion of 
T-cells, contraction of T-cells once viral control is achieved, and generation of a memory T-
cell pool. T-cell differentiation following antigen exposure is proposed to occur along a linear 
continuum with T-cell memory subsets of different functional capacities separated on the basis 
of cell surface markers42. Gene expression profiling supports the notion of the developmental 
continuum and highlights the close relationship between subsets43. Table 1 describes the 
functions and characteristics of the 4 subsets originally defined using CD45RA and the lymph 
node homing markers CD62L or CCR-744, additional makers such as CD27, 28, 95 have been 
suggested to further define the subsets45,46. The initial ‘expansion’ phase occurs in lymphoid 
 7 
tissues where naïve T-cells (TN) recognise their cognate antigen; a viral epitope presented in 
the context of a class I MHC molecule to CD8+ T-cells or a class II MHC molecule to CD4 T-
cells. Recognition of the MHC-epitope complex occurs via the T-cell receptor (TCR) resulting 
in clonal expansion, homing to peripheral blood and infected tissue, and differentiation into a 
terminal effector memory cells expressing CD45RA (TEMRA). These cells have low 
proliferative capacity but are capable of cytokine secretion or cytolytic killing via perforin and 
granzyme or Fas-induced apotosis46. Following resolution of the acute viral infection, the 
majority of the TEMRA die as part of the ‘contraction’ phase. The small number of surviving 
TEMRA differentiate to effector memory (TEM) and central memory (TCM) T-cell and form the 
memory pool capable of rapid response and development of effector function upon antigen 
rechallenge. TEM display immediate cytotoxic effector functions, whereas TCM exhibit stem-
cell like properties showing the capacity for self-renewal, high proliferative potential, and the 
ability to differentiate into effector cells as required43,44,46. 
Chronic viral infection (or malignancy) with persistent antigen stimulation can lead to 
functional T-cell exhaustion followed by T-cell deletion, as demonstrated in a murine 
model47,48. An absence of CD4 T-cell assistance in the setting of persistent viremia contributes 
to CD8+ T-cell exhaustion41,49. PD-1, CTLA-4, TIM-3, and LAG-1 are inhibitory T-cell 
receptors thought to contribute to T-cell exhaustion, blocking these receptors in mice has been 
shown to improve T-cell responses and reduce viral load48. T-cell exhaustion has been 
demonstrated in HIV, CMV, and other chronic viral infections in humans50-52. PD-1 
upregulation has also been demonstrated on T-cells following allogeneic stem cell transplant 
suggested to be due to persistent alloantigen and/or viral antigen stimulation53-55. 
No consensus has been reached regarding the best combination of phenotypic markers 
to define the exhausted T-cell, however the absence of cytokine secretion in response to antigen 
stimulation, loss of proliferative capacity, and loss of cytotoxic capacity is the functional 
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definition56. Putative characteristics of the exhausted T-cell phenotype are described in Table 
1. Monoclonal antibodies targeting the inhibitory receptors PD-1 and CTLA-4, termed
checkpoint inhibitors, have been used to reverse tumour-specific T-cell exhaustion to treat 
some cancers57.  
Table 1. Phenotypic and functional characteristics of T-cell subsets 45,56,58,59 
Naive 
(TN) 
Central 
Memory 
(TCM) 
Effector 
Memory 
(TEM) 
Terminal 
Effector 
(TEMRA) 
Exhausted 
CD45RA + - - + 
CCR-7 or 
CD62L + + - - - 
Homing to 
lymphoid tissue 
Proliferative 
capacity 
Regenerative/ 
multipotency 
Cytokine 
Secretion None None High Moderate None 
Cytotoxic 
effector function None None Moderate High None 
Rapid response 
to 2nd infection - High High - None 
PD-1* - Low Mod/High Low High 
TIM-3* - - Low Low High 
* PD-1 and TIM-3 may identify different subsets of exhausted cells, and are not
necessarily coexpressed on the same cell.
1.2.5 Measurement of T-cell immune reconstitution post-HSCT 
Different facets of T-cell immunity can be measured in the post-HSCT setting using the assays 
described in Table 2. 
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Table 2. Measurement of T-cell reconstitution post-HSCT 
 Assay Description Type and purpose of assessment Advantages/Disadvantages 
T-cell subsets 
Flow cytometry or 
Mass cytometry 
(CYTOF) 
Single cells are labelled with fluorescent 
monoclonal antibodies (flow) or heavy 
metal ion tags (CYTOF) for cell surface 
or intracellular markers and assessed by 
laser enumeration (flow) or time of flight 
mass spectrometry (CYTOF)60,61 
Quantitative 
assessment of 
specific subsets 
x quick and simple 
x phenotypic assessment on a 
single cell 
x flow cytometry is limited by 
fluorescent spectral overlap 
x CYTOF enables use of an 
increased number of markers 
 
HLA multimers 
(tetramers or 
pentamers) 
Fluorescently tagged HLA multimers are 
folded around a viral peptide of interest, 
which bind the T-cell receptor of a virus-
specific T-cell, measured by flow 
cytometry62 
Quantitative 
assessment of 
VST 
x quick and simple method  
x phenotypic assessment on a 
single cell 
x requires knowledge of 
immunodominant viral 
epitopes HLA restrictions  
x not available for all HLA 
types 
Cytokine 
production 
Enzyme-linked 
immunosorbent assay 
(ELISA) or cytokine 
bead array (CBA) 
bulk extracellular assessment of cytokine 
production, CBA measurement is via 
flow cytometry or other light/spectral 
signal measurement63  
Functional 
x CBA requires flow cytometer 
x no phenotypic or single cell 
assessment 
x CBA can test multiple 
cytokines  
 
Interferon(IFN)-γ 
enzyme-linked 
immunospot (ELIspot) 
single cell cytokine (IFN-γ) production 
in response to antigen stimulation 
measured by immunosorbent assay64,65 
Quantitative and 
functional 
assessment of 
virus-specific T-
cells 
x highly sensitive 
x not restricted by HLA type 
x single cell assessment 
x no phenotypic assessment 
x automated image analysis  
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 Intracellular cytokine flow 
Fluorescently tagged intracellular 
cytokine accumulation in single cells in 
response to viral antigen stimulation65,66 
Quantitative and 
functional 
assessment of 
VST 
x assessment of multiple 
cytokines from a single cell  
x phenotypic assessment 
x less sensitive than ELIspot  
 Quantiferon-CMV 
IFN-γ production in response to CMV 
antigen stimulation measured by ELISA 
67 
Quantitative and 
functional 
assessment of 
VST 
x simple and quick 
x standardised commercial assay 
x only measures CD8 cytokine 
production 
x no phenotypic information 
Cytotoxicity Cytotoxicity assay 
Measurement of fluorescent or 
radioisotope maker following target cell 
lysis by effector CTLs 68 
Functional 
assessment of 
VST 
x radiation safety issues 
x requires maintenance of target 
cell lines 
 Flow cytometry 
fluorescent tagged antibodies to CD107a 
(vesicle membrane protein that marks 
degranulation) or cytolytic granules 
(perforin and granzyme) in response to 
viral antigen stimulation60 
Quantitative and 
functional 
assessment of 
VST 
x requires flow cytometer 
x phenotypic assessment of 
single cells 
Naïve T-cell 
reconstitution 
(thymic output) 
Flow cytometry 
Fluorescent CD31 monoclonal antibody 
is used to tag naive CD4 T-cells - CD31 
expression is high on recent thymic 
emigrants 69 
Quantitative 
measure  
x requires flow cytometer,  
x phenotypic assessment on a 
single cell 
 T-cell receptor excision circles (TREC) 
Thymic TCR rearrangement generates 
extra chromosomal DNA episomes or 
TRECs detectable by PCR 70 
Quantitative x no single cell assessment 
T-cell repertoire 
analysis 
CDR3 spectratyping or 
T-cell receptor (TCR) 
Vβ family analysis by 
flow cytometry 
Spectratype analysis of CDR3 lengths of 
TCR Vβ family by PCR or of Vβ usage 
by flow cytometry71,72 
Quantitative 
analysis of TCR 
repertoire 
diversity 
x doesn’t analyse single TCR 
clones 
 TCR sequencing 
Multiplex PCR targeting of CDR3 to 
determine T-cell receptor gene 
rearrangement 73 
 
x highly sensitive  
x investigation of single TCR 
clones 
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1.2.6 Risk factors for viral infection post-aHSCT. 
Risk of viral infection post-aHSCT is affected by patient, donor, and transplant-specific 
variables that impact on t-cell reconstitution as shown in Table 3. Early post-transplant risk is 
moderated by factors affecting homeostatic clonal expansion of transferred donor memory T-
cells such as UCBD grafts or T-cell depletion74,75. Factors impacting on thymic-dependent T-
cell reconstitution affect late viral risk such as chronic graft versus host disease 76. Current 
transplant practices are associated with a high risk of viral infection. These practices include 
an increasing use of alternative donors, allogeneic recipients age over 50 years, and a 
resurgence in the use of T-cell depletion strategies2,19,20,77. Transplant scenarios involving less 
desirable donors such as haploidentical donors require more immunosuppressive regimens to 
prevent graft rejection and GVHD78. T-cell depletion techniques such as ex vivo (CD34 
selection) or in vivo (conditioning with antilymphocyte globulins) abrogate GHVD but delay 
T-cell recovery post-transplant79.  
Table 3. Risk factors for viral infection post-aHSCT 
Risk Factor Proposed mechanism for delayed T-cell reconstitution 
Grat
wahl 
2005
19 
Sringi
vasan 
201280 
Schon
berger 
2010 81 
Hiwa
rkar 
2013 
36 
Inaza
wa 
2015
82 
Hill 
201
735 
Recipient age 
diminished thymic function 
due to age related thymic 
involution76,83 
X      
Unrelated, 
HLA- 
mismatched 
and 
haploidentical 
donors 
HLA disparity, increased 
immune suppression and 
increased risk of GVHD 
78,84,85, 
 X X X  X 
UCBD immunologically naive donor T-cells75     X X 
MAC toxicity to thymus and bone marrow microenvironment 86      X 
PBSC  transfer of antigen-specific memory T-cells in the graft 
Decr 
risk  
Decr 
risk    
T-cell 
depletion 
reduced numbers of memory 
donor T-cells for 
expansion74,87 
X  X X X  
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Acute or 
chronic 
GVHD 
delayed T-cell reconstitution 
due to increased use of 
immunosuppressant 
medication, primary 
immunomodulatory effect of 
GVHD, reduced thymic 
function76,88 
 X  X  X 
Abbreviations: GVHD, graft versus host disease; MAC, myeloablative conditioning; PBSC, 
peripheral blood stem cell; UCBD, umbilical cord blood donor 
 
1.2.7 Cytomegalovirus  
1.2.7.1 Epidemiology of CMV infection 
CMV is a highly prevalent virus with estimated global seroprevalence of 45-100% by 
adulthood, dependent on the region and age of the cohort89. The age-weighted seroprevalence 
in Australian adults is 76%37. Primary infection occurs in childhood and is usually mild or 
asymptomatic in an immunocompetent individual, but the consequences of infection or latent 
reactivation in those with immunocompromise can be severe. Congenital or neonatal CMV can 
manifest with microcephaly, growth restriction, jaundice, hepatosplenomegaly, and seizures, 
with late complications of sensorineural hearing loss, vision impairment, and developmental 
delay90. The risk of life-threatening tissue invasive disease in HIV, has been greatly improved 
by the introduction of highly active antiretroviral therapy91. Infection and disease in solid organ 
and HSCT transplant recipients continues to be associated with significant morbidity and 
mortality92-96.  
1.2.7.2 CMV infection and disease in HSCT recipients 
The definition of CMV infection and disease have recently been updated97. In this 
thesis, the terms ‘viremia’, ‘reactivation’ or CMV DNAemia have been used interchangeably. 
The major changes to the current definitions reflect the incorporation of new diagnostic 
modalities that have become available since the previous definitions were set in 200298 and the 
addition of a new probable disease category. CMV infection is now defined as virus isolation 
or detection of viral proteins (antigens) or nucleic acid from any body fluid or tissue 
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specimen97, and occurs frequently in aHSCT. Peripheral blood CMV detection and monitoring 
in the current era is predominantly performed using quantitative polymerase chain reaction 
(PCR) or other methods of nucleic acid testing (NAT). PCR demonstrates high sensitivity and 
rapid results when compared to other assays such as shell vial culture and CMV pp65 
antigenemia99,100. Plasma CMV PCR has the advantage of accuracy unaffected by low white 
cell counts unlike pp65 antigenemia measures derived from peripheral blood leukocytes101. 
Plasma CMV PCR has a higher positive predictive value for recurrence after antiviral treatment 
compared to whole blood PCR102.  
In the first 100 days post-transplant, CMV DNA is detected in the blood or plasma 
(CMV DNAemia) of 63-69% of CMV seropositive recipients or those with a CMV 
seropositive donor67,94,96,100,103. CMV DNAemia or antigenemia is usually asymptomatic, but 
it is a risk factor for CMV disease, and is associated with increased non-relapse mortality and 
reduced overall survival36,94,104-106. CMV disease is diagnosed when symptoms and signs of 
infection occur in conjunction with documented tissue involvement97. CMV disease in HSCT 
patients most commonly manifests with gastrointestinal disease, CMV pneumonia, or 
retinitis95,96. Other rarer manifestations include hepatitis, oesophagitis, cystitis, and 
encephalitis. CMV pneumonia is associated with the highest rate of mortality. It is diagnosed 
on the basis of lung infiltrates, hypoxia, and demonstration of CMV infection in lung tissue97. 
In a large study of CMV pneumonia in 421 patients treated between 1986 and 2011, all cause 
mortality was 70%, and CMV-attributable mortality was 44% at 6 months. Overall mortality 
at 6 months in the era 2000-2011 was 61%. Lymphopenia was an independent risk factor for 
all-cause and CMV-attributable mortality107. Other studies have confirmed the high mortality 
rate of CMV pneumonitis108-110. Unlike CMV pneumonitis, gastrointestinal CMV disease is 
not associated with increased non-relapse mortality111. CMV disease in the era of pre-emptive 
therapy occurs at rate of 6-17% in seropositive recipients and those with a seropositive donor, 
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and varies according to duration of follow-up67,94,96,100,103,108,112,113. Late CMV infection and 
disease occurs more than 100 days after transplant and is seen at an increased rate after 
prophylactic or pre-emptive therapy. In a prospective study of late CMV disease the incidence 
was 18% at a median of 169 days post-transplant was associated with 46% mortality. Of those 
surviving the first episode, 38% of patients had a recurrent episode of CMV disease109.  
1.2.7.3 CMV Virology 
CMV is a beta-herpesvirus. The CMV virion is composed of a double-stranded linear 
DNA core surrounded by tegument and enclosed in lipid bilayer envelope114. The viral proteins 
CMV pp65 and IE (intermediate early)-1 and 2 appear to be the main targets of the cellular 
immune response115,116. Other proteins capable of generating subdominant immune responses 
include viral glycoprotein gB, pp28, pp50, and pp150117. CMV show high levels of cellular 
tropism with a variety of cell surface proteins implicated in cellular infection. The binding of 
viral envelope glycoproteins gH/gL/g0 trimer or gH/GL pentamer with platelet derived growth 
factor (PDGF)-α receptor or neuropilin-2(Nrp-2), respectively are thought to be important 
routes of viral entry in epithelial and endothelial cells118. Annexin II may also play a role in 
facilitating viral entry119. Fusion with the cell membrane results in release of nucleocapsids 
which travel to the cell nucleus. Viral DNA is released in the nucleus resulting in immediate 
early (IE) gene expression. Capsids of replicated viral DNA leave the nucleus and undergo 
envelopment, and virions are released by exocytosis114. Infection is characterised by three 
phases of gene expression: IE genes are required for replication, and delayed-early and late 
genes are required for production of virions. Myeloid lineage cells (CD34+ and CD14+ cells) 
are thought to be the principle site of viral latency120. The latent viral genome is packaged into 
a circular episome associated with cell-derived histones121. Latency and inhibition of lytic 
replication is maintained by epigenetic repression of the major IE promoter (MIEP)122. 
Repression of IE prevents recognition of latently infected cells by IE-specific cytotoxic CD8+ 
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T-cells. Triggers for reactivation and return to lytic gene expression include cell differentiation 
and inflammation123. Histone deacetylase inhibitors have recently been shown to promote 
clearance of latent reservoirs in cultured cells by targeting MIEP repression and permitting IE-
restricted CD8 cytotoxicity122. This presents a possible therapeutic target for future study.  
1.2.7.4 T-cell immune response to CMV infection 
Cellular mediated immunity is essential in the long-term control of latent CMV 
reactivation and prevention of CMV disease following allogeneic HSCT. There is a probable 
role of the humoral response and NK cells in controlling CMV following HSCT124,125 but it is 
beyond the scope of this thesis. Detection of CMV-specific CD8+ T-cell responses is associated 
with reduced incidence of CMV DNAemia and lower peak viral loads125,126. Thresholds for the 
absolute number of CMV-specific CD8+ T-cells required for protection vary by method and 
study127-130. An increase in CMV-specific CD8+ T-cell number or functional response (IFN-γ) 
during or after the initial episode of CMV DNAemia or antigenemia predict for reduced risk 
of recurrent CMV infection129,131-133, reduced duration of recurrent episodes132, and delayed 
time to recurrence134. Conversely, low CMV-specific CD8+ T-cell numbers or absence of 
functional response after first reactivation is associated with recurrent reactivations129,131,134,135. 
One study showed 69% of patients had recurrent DNAemia despite further treatment with 
secondary viral prophylaxis131. Patients with CMV disease demonstrate poor CMV specific 
immunity, both low frequencies of CMV-specific CD8+ T-cells135 and reduced functionally 
active IFN-γ+CD8+ T-cells67,126. Detection of CMV-specific CD8+ T-cells confers protection 
against CMV disease136,137.  
Ability to control infection requires both quantitative and functional recovery of the 
CMV-specific T-cell population138,139. Transition to a functional CD8+ T-memory phenotype 
was studied in a group of D-R+ recipients with recurrent CMV infection134. In patients with 
multiple controlled episodes of viremia, CMV-specific CD8+ T-cells were shown to progress 
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from an early effector memory (CD45RO+CCR-7-, CD27+CD28+/-) to intermediate effector 
memory (CD45RO+CCR-7-,CD27-CD28-) to a late differentiation terminal effector response 
(CD45RA+CCR-7-,CD27-CD28-). The shift to terminal effector phenotype correlated with 
viral control and functional IFN-γ T-cell response on ELIspot. This was in contrast to patients 
with multiple, prolonged episodes of viremia where differentiation appeared to be impaired 
and did not progress beyond the early effector memory phenotype (CD45RO+CCR7-
,CD27+CD28+/-), and IFN-γ T-cell responses were not demonstrated134. Delayed CMV-specific 
CD8+ T-cell recovery, compounded by the inability to transition to a functional phenotype, 
may explain the increased risk of recurrent CMV episodes and CMV disease in D-/R+ 
compared to D+/R+ pairs96,140-142.  
Evidence suggests the CD4+ T-cell response to CMV is equally important in achieving 
control of CMV viremia133,143,144. A similar number of CMV open reading frames were found 
to generate CD4+ T-cell responses as CD8+ T-cell responses in healthy seropositive 
individuals116. Early studies of CMV specific CD8+ T-cell therapy to treat CMV infection 
suggested CD4+ T-cell assistance was required to maintain survival of CD8+ T-cells40. CMV 
reactivation is more common in patients with CD4 lymphopenia in the first two months post-
transplant36. In contrast, early reconstitution of CD4+ T-cells is protective against CMV 
reactivation124. The reconstitution of CMV CD4+ T-cells after initial reactivation prevents 
further reactivations133. Late onset CMV disease and death is associated with undetectable 
levels of CMV-specific CD4 positive T-helper responses present at three months post-
transplant109.  
The role of CMV-specific adoptive T-cell therapy in rectifying CMV immune function 
will be discussed in Section 1.3.  
A growing area of interest is the impact of CMV recipient serostatus and CMV 
replication in shaping the T-cell immune repertoire in both immunocompromised and healthy 
17 
individuals. Correspondence analysis performed on high parameter flow cytometry samples at 
one year post-HSCT showed a dose dependent effect for increased CMV replication episodes 
on clustered dimensions of global reconstitution reflecting balance of CD8+ T-cell and B-
cells145. In HSCT patients with prior CMV infection, TCR deep sequencing at one year post-
transplant, revealed expanded numbers of CD8+ T effector memory clones and contracted 
numbers of CD4+ naïve T-cells clones, resulting in a narrow and skewed TCR repertoire146. 
Expansions of late differentiation effector memory CD8+ T-cells have also been demonstrated 
in CMV seropositive HIV patients147. These changes may represent an accelerated version of 
the CMV immune response to aging. Progressive expansion of clonal CMV-specific CD8+ 
effector memory T-cells termed ‘memory inflation’ have been shown to dominate the CD8+ T-
cell repertoire in elderly seropositive individuals148-150.  
1.2.7.5 Risk factors for CMV infection and disease in aHSCT 
The most significant risk factor for post-transplant CMV infection and disease is the 
pre-transplant CMV serostatus of the donor and recipient pair; seropositive recipients are at the 
highest risk of CMV infection105,151-153. A registry study of almost 10,000 HSCT recipients 
reported the incidence of CMV reactivation/infection at one year post-transplant according to 
serostatus: 4% for donor(D)-/recipient(R)- pairs, 11% for D+/R- pairs, and 32% for 
seropositive recipient pairs104. Primary CMV infection arising in D-/R- pairs is rare, partially 
explained by reduction in transfusion-associated CMV using seronegative or leucodepleted 
blood products154,155. Recipient CMV seronegativity has been associated with a significant 
survival advantage106,156. Although mismatched, unrelated D+/R- pairs demonstrate decreased 
overall survival compared to D-/R- pairs157. CMV seropositivity of either donor or recipient is 
associated with reduced overall survival and increased non-relapse mortality152. The use of a 
seropositive donor for a seropositive recipient may provide a survival advantage compared to 
use of a seronegative donor in some transplant scenarios, but conditioning, donor type and use 
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of T-cell depletion are modifying factors153,157-160. The survival advantage is most clear with 
an unrelated donor and myeloablative conditioning where early CMV protection is derived 
from donor CMV-specific T-cell expansion157,161.  
Many of the risk factors for viral infection discussed in Section 1.2.6., have been shown 
to be independent risk factors for CMV infection post-allogeneic transplant. These include: 
unrelated and mismatched donors162,163, T-cell depletion164, increasing recipient age162,165, 
aGVHD151,162-164,166. Steroid administration is an additional risk factor for CMV infection and 
disease135,159,165. Risk factors for CMV disease include: unrelated donor/mismatched donor111, 
CMV detection prior to 100 days109,111, peak viral load167, and GVHD95,96,109,111. 
1.2.7.6 CMV directed pharmacologic therapy in aHSCT recipients 
Current HSCT guidelines suggest the institution of a CMV prevention program up to 
day 100 or until the cessation of immunosuppression, using a strategy of either prophylaxis or 
pre-emptive therapy168. Ganciclovir, it’s prodrug valganciclovir, and foscarnet are highly 
active against CMV. Early studies of post-engraftment ganciclovir prophylaxis showed 
reduced rates of CMV infection. However, administration was complicated by myelotoxicity 
and increased rates of bacterial infection, and no survival benefit was demonstrated99,169. High 
rates of renal impairment and electrolyte derangement have limited the use of foscarnet for 
prophylaxis and treatment170,171. Pre-emptive antiviral therapy, initiated following detection of 
asymptomatic CMV in peripheral blood, minimises toxic drug exposure. Routine weekly or 
biweekly monitoring is performed using highly sensitive testing such as quantitative CMV 
DNA PCR and less commonly pp65 antigenemia. The pre-emptive strategy has been shown to 
reduce rates of CMV disease, CMV mortality and transplant-related mortality, and improve 
overall survival100,112,170,171. There is no consensus on the appropriate thresholds for treatment, 
and protocols vary by institution94,111,172,173. 
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There has been renewed interest in the use of CMV prophylaxis, with three Phase III 
trials published on prophylaxis using new antiviral agents. Letermovir showed a reduced 
cumulative incidence of CMV events (CMV disease or infection requiring pre-emptive 
therapy) when compared to placebo at 24 weeks (38% versus 61%, P<0.001). Brincidofovir 
prophylaxis at 100mg twice weekly was not proven to be significantly different from placebo 
for the same CMV endpoint at 24 weeks, and was associated with severe diarrhoea that could 
not be clinically or histopathologically separated from gut GVHD174. Maribavir similarly did 
not show a benefit over placebo for reduction of CMV disease at 6 months post-transplant175. 
The question of whether inadequate Maribavir dosing may have contributed to the lack of 
efficacy does not appear to be substantiated with a recent publication showing no apparent 
dose-related effect in the treatment setting176, which concurs with the original dose-finding 
study in the prophylactic setting177. In a systematic review including these recent studies, CMV 
prophylaxis was effective in reducing the overall rate of CMV infection (Odds ratio OR 0.49, 
95% confidence interval CI 0.42-0.58) and disease (OR 0.56, CI 0.4-0.8) and reducing the need 
for pre-emptive therapy (OR 0.51, CI 0.42-0.62), but was not associated with a survival benefit 
(0R 0.96, CI 0.78-1.18)178. The letermovir prophylaxis study was a notable exception and 
showed all-cause mortality was significantly reduced compared with placebo at 24 weeks post-
transplant (10.2% versus 15.9%, p=0.03). The efficacy and low toxicity of letermovir 
prophylaxis may see a return to the use of prophylaxis from the current widespread use of the 
pre-emptive approach179.  
Late CMV infection and disease has been shown to occur at increased frequency 
following treatment with ganciclovir and letermovir when CMV monitoring is continued for 
more than 6-12 months post-transplant99,169,171,174. No benefit was shown for valganciclovir 
prophylaxis compared to a pre-emptive strategy with weekly monitoring for the prevention of 
late CMV disease. The cumulative incidence of 6% CMV disease was the same in both arms180. 
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There is currently no consensus on the frequency of monitoring or duration of CMV monitoring 
that should occur after day 100 in patients no longer on immunosuppression. Detection of a 
CMV-specific CD8+ T-cell functional response using the Quantiferon-CMV (Qiagen) assay 
was shown to have a high correlation with CMV infection and disease events up to one year 
post-transplant67. Measurement of CMV-specific T-cell functional responses has also been 
successfully used in the early discontinuation of antiviral treatment in short-term follow-up 
129,131. Use of an algorithm incorporating assessment of functional CMV-specific T-cell 
recovery (preferable CD4+ and CD8+ T-cells) prior to monitoring cessation at day 100 would 
be worthy of future investigation. 
There are few studies that specifically address the rates or outcomes of antiviral therapy 
failure or antiviral drug resistance mutations. Two small studies (<50 patients) have shown a 
lack of viral clearance after 3-6 weeks of antiviral therapy in 33-36% of patients treated for 
CMV antigenemia134,181. In a study of 118 seropositive recipients who received T-cell depleted 
transplants, 39% had prolonged detection of CMV after 21 days of pre-emptive therapy for 
first or subsequent episodes of CMV antigenemia. Of these, 22% of patients developed CMV 
disease113. In a large study of 488 predominantly HLA-mismatched related recipients who had 
received in vivo T-cell depletion, 50% of patients had persistent CMV DNAemia detected after 
two weeks of antiviral treatment. Of patients with recurrent CMV infection, 74% had a prior 
episode of refractory infection. CMV disease occurred in 11.9% of patients with refractory 
infection compared to a risk of 0.8% in those who demonstrated viral clearance (P<0.001). 
Non-relapse mortality was significantly higher in patients with refractory infection compared 
to those without (17 vs. 8%, P=0.012)95. A variety of factors may contribute to antiviral 
treatment failure. Adequate dosing of antiviral medications is an important consideration. 
Systemic inflammation impacts on CMV antiviral treatment efficacy in solid organ transplant 
recipients but has not been studied in HSCT recipients182. Drug resistance mutation screening 
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in refractory infection in three small studies of HSCT patients revealed rates of between 13 and 
50%173,181,183. Other risk factors for refractory infection include: unrelated or mismatched 
donor95, peak viral load or high viral load at treatment initiation113,173,184, use of concurrent 
immunosuppressant medications185, low CD4+ and CD8+ or lymphopenia at day 90-100113,184, 
delayed recovery of CMV-specific T-cells > 65 days128, T-cell depletion184, and acute GHVD95. 
These findings suggest CMV infection refractory to antiviral therapy is associated with 
profound and persistent derangement of CMV immunity. This warrants further investigation.  
1.2.8 Epstein-Barr Virus  
1.2.8.1 Epidemiology of EBV infection  
Epstein-Barr virus (EBV) infection is common within the community; adult 
seroprevalence is greater than 85% with little regional variation39,186-189. Infection in early 
childhood is usually asymptomatic, while primary infection in adolescents and healthy adults 
often results in infectious mononucleosis, characterised by the triad of fever, lymphadenopathy, 
and pharyngitis, along with a rise in peripheral blood mononuclear cells. These symptoms are 
usually self-limiting, although complications such as hepatitis, myocarditis, splenic rupture, 
and neurological complications can occur190. Memory B cells act as a reservoir for latent virus, 
and persistent B-cell proliferation leads to a number of disorders190. Chronic active EBV 
infection is a rare entity characterised by severe recurrent mononucleosis symptoms for at least 
6 months with evidence of EBV DNAemia and EBV-associated organ disease, only curable by 
HSCT. X-linked lymphoproliferative disease is an inherited disorder resulting in the inability 
to control EBV infection190. There is a pathological role for EBV in many malignancies; the 
association is well-established in a subset of lymphomas, gastric and nasopharyngeal 
cancers191. EBV-driven malignancies may occur in people with or without overt 
immunodeficiency but the risk is increased in those with profound immunodeficiency 192. HIV 
is associated with an increased risk of lymphoma, many of which are EBV-associated 193. In 
 22 
solid organ and HSCT patients uncontrolled proliferation of latently infected B-cells can result 
in oncogenic transformation manifested as EBV-associated post-transplant 
lymphoproliferative disease (PTLD). EBV may play a role in the development of autoimmune 
diseases such as multiple sclerosis and systemic lupus erythematosus194,195. Patients with 
autoimmune disease are at higher risk of lymphoma including EBV-associated lymphomas, 
irrespective of immunosuppressive treatment196,197, suggesting a possible interplay between 
immune dysregulation, EBV, and oncogenesis.  
1.2.8.2 EBV infection and disease in aHSCT 
EBV is detected in the peripheral blood of 8-65% of HSCT recipients in the first year 
post-transplant; incidence varies by the type of transplant donor and use of T-cell depletion in 
the population studied198-203. Post-transplant EBV associated disease can be categorised as 
either EBV-associated post-transplant manifestations (i.e. end-organ disease) or EBV-
associated post-transplant lymphoproliferative disease (PTLD)204. The cumulative incidence 
of EBV end organ disease (EBV-associated pneumonia, hepatitis, and encephalitis) at 12 
months was 3% in 263 recipients of a T-cell replete HSCT205. PTLD refers to the uncontrolled 
neoplastic proliferation of lymphoid or plasmacytic cells post-transplant and is usually EBV-
associated in HSCT recipients204. 
The incidence of PTLD was studied in 18,014 T-cell replete predominantly sibling 
transplants prior to the institution of current monitoring and treatment strategies. The 
cumulative incidence of PTLD at 10 years was 1%+/-0.3%, and the mortality rate was 
84.6%206. The majority of cases presented in the first year post-transplant206. The incidence of 
PTLD may have risen since that time207. More recent studies describe an incidence of 1-15%, 
with the highest rates seen in T-cell depleted HSCT populations200-202,207-209. Despite the 
introduction of intensive monitoring and pre-emptive therapy with Rituximab, PTLD continues 
to be associated with high rates of mortality (30-72%)207,208,210. Four independent risk factors 
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predict for PTLD mortality: age at transplant over 30 years, extranodal involving, acute GVHD 
more than grade I, lack of immune suppression withdrawal at diagnosis. These prognostic 
variables were compounding, 0-1 or three variables were associated with 7% or 72% mortality, 
respectively208.  
PTLD results from uncontrolled proliferation due to impaired cellular immunity post-
transplant. PTLD usually arises from donor derived B-cells as recipient B-cells are diminished 
by pre-transplant conditioning therapy. Recipients of RIC transplants are at higher risk of 
recipient-derived PTLD211. A diagnosis of PTLD requires symptoms or signs of organ 
involvement with significant EBV DNAemia (probable PTLD) or detection of EBV in tissue 
with either disrupted cellular architecture by a lymphoproliferative process or evidence of 
monoclonal or oligoclonal cell population (definite PTLD). Histological detection of EBER by 
in situ hybridization is recommended204. The world health organisation (WHO) morphological 
classification of PTLD includes: plasmacytic hyperplasia and infectious mononucleosis-like, 
polymorphic, monomorphic, and classical Hodgkins lymphoma-like. Polyclonal lesions have 
the best prognosis. 
1.2.8.3 EBV Virology  
EBV is a human herpes virus, like CMV. The EBV viral genome consists of linear 
DNA, surrounded by a nucleocapside, within the viral envelope190. Following primary 
infection of naïve B-cells in the oropharynx, activated B-cells form a germinal centre in lymph 
nodes and undergo class switching and somatic hypermutation to become memory B 
cells212,213. The genome encodes over 100 viral proteins, but only a small number are expressed 
by the latently infected B cells including: EBV nuclear antigens (EBNA) 1 to 6, EBNA leader 
protein, latent membrane protein (LMP) 1 and 2, non-translated EBV-encoded RNA(EBER), 
and viral RNA BART214. Latent viral gene expression occurs in specific patterns through the 
EBV latent life cycle and is associated with particular disease phenotypes as illustrated in Table 
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4. Epitopes from the EBNA-3 protein engenders strong immune responses across several HLA 
class I and II alleles215. Responses to LMP 1 and 2 are subdominant particularly in the CD8+ 
subset216. 
Table 4. EBV latency program (Adapted from Heslop 2009211,214) 
Latency program Type 3 Type 2 Type 0 Type 1 
Normal 
counterpart 
Primary naïve B-
cell infection and 
proliferation 
Germinal centre 
B cell 
Peripheral 
circulation, 
resting memory 
B cell 
Persistent, 
dividing memory 
B cell 
Disease 
association 
Infectious 
mononucleosis, 
PTLD 
Hodgkin’s 
disease, 
nasopharyngeal 
cancer 
 Burkitt’s 
lymphoma, 
gastric cancer 
Immunogenicity High intermediate  low 
EBNA 1 X X  X 
EBNA 2, 3A, 3B, 
3C 
X    
EBNA leader 
protein 
X    
LMP 1 X X   
LMP 2  X  X 
EBER X X  X 
BART X X  X 
 
1.2.8.4 T-cell immune response to EBV 
Both humoral and cellular responses occur with EBV infection, but the cellular immune 
response appears to be most important in the control of EBV reactivation217. The reconstitution 
of EBV-specific CD8+ T-cells has been correlated with EBV viral clearance198. Whereas 
patients requiring pre-emptive treatment had reduced or absent EBV-specific CD8+ T-cell 
responses198. Low absolute CD8+ T-cell counts at day 30 post-transplant are associated with 
increased risk for PTLD218. EBV-specific CD4+ T-cells with strong responses against EBNA-
1 and -3c are found in healthy donors215 and are thought to possibly facilitate the CD8+ T-cell 
response or act as effectors themselves219. A CD4+ T-cell count greater than 50μL at 30 days 
post-transplant was shown to be protective against EBV DNAemia202.  
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1.2.8.5 Risk factors for EBV infection and disease in aHSCT 
Significant independent risk factors for PTLD include: unrelated or mismatched 
donors, EBV mismatch R-/D+, use of reduced intensity conditioning, radiation during 
conditioning, pre-transplant splenectomy, infusion of mesenchymal stromal cells, T-cell 
depletion of donor marrow, use of anti-thymocyte globulin or anti-CD3 monoclonal antibody 
for acute GVHD prophylaxis or therapy, occurrence of acute GVHD grade II-IV, and extensive 
chronic GVHD (associated with late onset PTLD)206,207. Risk factors were compounding; rates 
of PTLD among patients with two, or three or more risk factors were 8.0% +/- 2.9% and 22% 
+/- 17.9%, respectively206. The risk of PTLD associated with T-cell depletion is higher for 
ATG than the anti-CD52 antibody (Campath), as Campath depletes both B and T-cells200,206. 
T-cell depletion with ATG is also an independent risk factor for significant EBV 
reactivation203. 
1.2.8.6 EBV monitoring and antiviral therapy in aHSCT 
Molecular monitoring for EBV DNAemia on a weekly basis to day 100 is suggested 
for those at high risk of EBV reactivation and disease168. Pre-emptive therapy is commenced 
following detection of EBV DNAemia. Published thresholds for treatment initiation are 
variable by laboratory and assay; thresholds for plasma EBV DNA range from 500-10000 
copies/mL220,221. An international reference value for EBV has only recently become available 
for standardisation of EBV molecular monitoring assays, and this may assist with 
harmonisation of thresholds for treatment222. EBV DNA is detected with higher sensitivity in 
whole blood or PBMC rather than plasma223. However, plasma EBV monitoring has a higher 
sensitivity and specificity for predicting EBV disease224.  
Reduction of immunosuppression (RI) is the initial treatment for EBV infection or 
disease, however this is not possible in all patients particularly those with active GVHD204,225. 
One study showed RI resulted in significantly improved response when added to Rituximab 
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(antiCD20 antibody) therapy for PTLD208. Pooled data suggests use of Rituximab has benefit 
in 90% of patients treated pre-emptively and 65% of patients with PTLD204. Significantly 
improved two year overall survival has been shown for patients who were treated with 
Rituximab for PTLD compared to those who weren’t (42.8% vs. 13.2%, p=0.02)218. 
Chemotherapy in combination with Rituximab is recommended for more aggressive PTLD 
subtypes204. There are no specific agents used for prophylaxis of EBV DNAemia and PTLD. 
One small study reporting promising results using modified-dose Rituximab as part of 
conditioning therapy, with reduced EBV detection and incidence of PTLD226. 
Cellular therapy approaches including use of donor lymphocyte infusion for EBV 
treatment are discussed in Section 1.3. 
1.2.9 Adenovirus  
1.2.9.1 Epidemiology of Adv infection 
Similar to the herpes viruses, the seroprevalence of adenovirus is very high (up to 
96%)186. Self-limited adenoviral infections are endemic in young children (usually under the 
age of 5 years) with few clinical sequelae in most cases unless immunocompromised. Persistent 
virus turnover has been identified in tonsillar and pharyngeal tissue of children, but it is unclear 
whether this is the result of frequent reinfection or viral latency227. Persistence in the 
gastrointestinal tract has also been identified with asymptomatic faecal viral shedding apparent 
for months to years after infection228. Spread is via aerosolised droplets or faecal-oral spread 
with viral shedding possible for months after infection, resulting in difficulty preventing 
infection amongst close contacts. Over 50 serotypes are recognised associated with human 
infection, and they are split into subgroups A-F. Some serotypes are linked with particular 
clinical manifestations; serotypes B and C are more commonly seen following HSCT and are 
associated with respiratory and gastrointestinal symptoms227. However, manifestations can 
 27 
present in virtually any organs and include febrile respiratory tract infections and pneumonias, 
keratoconjunctivitis, hepatitis, gastroenteritis, myocarditis, and haemorrhagic cystitis229.  
1.2.9.2 Adv infection and disease in aHSCT 
Adenoviral infection in HSCT patients usually occurs in the early post-transplant 
period, and incidence rates for symptomatic infection range from 3-68%230-232, dependent on 
surveillance period, frequency, techniques, and most importantly on population studied, with 
paediatric patients significant more likely to have virus detected than their adult counterparts 
(23% versus 9%233). Mortality in HSCT patients with Adv infection is reported from 26-44%, 
and usually involves disseminated infection232-235. Adenoviral pneumonia is associated with 
very high mortality in both localised and disseminated disease232. Detection of adenoviral 
reactivation by PCR in blood post-transplant has shown to be an independent risk factor for 
mortality35,36.  
1.2.9.3 Adv virology, immune response, and risk factors in aHSCT 
  Adenoviruses are non-enveloped double-stranded DNA viruses. The adenovirus virion 
is composed of an icosahedral protein capsid, comprising 252 capsomers (240 hexons and 12 
pentons with fibre-like projections), and a nucleoprotein core housing the DNA viral genome 
and internal proteins229. The immune response includes both a humoral arm where neutralising 
antibodies recognise fibre-specific epitopes (providing serotype specific immunity) as well as 
hexon proteins, and a cellular arm where adenovirus-specific T-cell responses (both CD4+ and 
CD8+ T-cell responses are important) develop in response to hexon epitopes229,236. Adv hexon 
protein is one of the most immunodominant T-cell targets, and is generic across serotypes, 
allowing the development of broad cross-reactive T-cell responses irrespective of primary 
infective serotype236. Unlike the herpesviruses, it has been unclear whether adenovirus exists 
in a latent form. In a manner similar to MIEP repression, it has recently been shown that Adv 
uses interferon to repress transcription of the E1A gene. The resulting asymptomatic persistent 
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infection is characterised by diminished cytopathy and reduced production of infective virus237. 
Adenoviral infection in immunocompromised patients appears to result from either 
acceleration of persistent virus or primary reinfection, where uncontrolled replication occurs 
in the face of deficient humoral and cellular immunity. A significantly increased progression 
to invasive disease post-transplant has been shown in patients with asymptomatic pre-
transplant viral shedding compared to individuals negative for virus at the time of 
transplantation228. Studies of adenovirus-specific immune recovery post-transplant 
demonstrate that in some patients adenovirus-specific T-cells appear in response to rising viral 
loads. This increase in adenovirus-specific T-cells appears to be linked to the clearance of 
adenoviral infections230,238. In contrast, low numbers of CD4+ Adv-specific -cells or lack of 
functional IFN-γ-secreting Adv-specific T-cells present have been associated with infection 
and death36,238. Many of the risk factors for adenoviral infection in HSCT patients are common 
to the viruses already discussed such as lymphocytopenia36 and prolonged 
immunosuppression232 and predictably relate to delayed cellular immune reconstitution due to 
mismatched and unrelated donors, T-cell depletion, and GVHD36,232,239,240.  
1.2.9.4 Pharmacological antiviral therapy 
There are few effective options for treatment of adenoviral infections, and there is little trial 
data examining the various antiviral pharmacotherapies in a systematic fashion. Ribavirin and 
Cidofovir are the agents used most frequently, with Cidofovir having the most efficacy data in 
predominantly retrospective studies, as reviewed by Lindemans et al241. Concerns regarding 
the possibility of nephrotoxicity due to tubular necrosis242, and lack of efficacy in established 
adenoviral disease243,244, have led investigators to look for alternative approaches, with 
adoptive T-cell therapy showing some promising results as discussed in Section 1.3. 
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1.3 Virus-specific T-cell therapy in HSCT 
1.3.1 Background  
Post-transplantation viral infection is clearly linked to impaired cellular immunity. 
Riddell and colleagues245 provided the first evidence that adoptive T-cell therapy could restore 
cellular immunity and prevent viral infection. Three HSCT patients were treated with 
prophylactic infusion of in vitro stimulated CMV-specific CD8+ T-cell clones derived from 
their respective CMV positive donors. There was no infusional toxicity, and no CMV viremia 
or disease post-infusion. CMV-specific CD8+ T-cell responses reconstituted to similar levels 
as healthy controls. These initial results were confirmed in a Phase I trial of 14 patients. T-cell 
receptor Vβ gene rearrangement studies in two recipients suggested persistence of infused cells 
for at least 12 weeks. Three patients developed mild (≤Grade II) treatment-responsive GVHD 
following T-cell infusion40. 
 Unmanipulated HSCT donor lymphocyte infusion is another form of cell therapy used 
to provide EBV cytotoxic T-lymphocytes for the treatment of EBV-related PTLD. Early trials 
showed success in controlling PTLD in six patients, but infusion was complicated by severe 
GVHD in one patient presumably due to high numbers of alloreactive donor T-cells in the 
unmanipulated product246,247. Other studies have confirmed the high frequency of GVHD 
complicating DLI as reviewed by Frey and Porter248. DLI can only be successful if the HSCT 
donor is seropositive for the virus of interest, with adequate frequencies of antigen-specific T-
cells present to permit in vivo antigen-driven expansion after infusion into the recipient. Given 
these limitations, research on adoptive cell therapies for reconstitution of post-transplant viral 
immunity have focused on the use of antigen-specific T-cell products. 
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1.3.2 Manufacture of virus-specific T-cells  
1.3.2.1 Background  
A knowledge of the immunogenic epitopes that stimulate immunodominant T-cell 
responses is helpful for successful manufacture of virus-specific T-cells. For viruses such as 
CMV and EBV many common HLA-restricted immunodominant epitopes are known and 
reagents available for use in VST manufacture. Adenovirus is an example of a pathogen where 
the necessity to develop reagents for use in cellular therapy manufacturing has actually driven 
the research to identify epitopes249,250. A number of Adv reagents are now becoming available 
for manufacture and post-ACT immune monitoring.  
Many of the early VST trials demonstrated promising clinical results, but there were a 
number of manufacturing challenges. Early studies involved the expansion of CD8+ T-cell 
clones via limiting dilution, requiring up to 12 weeks of ex-vivo culture and expansion to 
produce the large numbers of cells required for repeated infusions245. This method did not 
provide CD4+ T-cells, suggested as a requirement to facilitate persistence of virus-specific 
CD8+ T-cell responses40. CMV-infected fibroblasts, CMV lysate, and EBV transformed B 
lymphoblastoid cell lines (EBV-LCL) were used to present antigen to stimulate T-cells or act 
as feeder cells40,251-254. These early techniques were labour-intensive, complex, and prolonged, 
and had regulatory implications due to safety concerns associated with the use of 
live/attenuated virus. These factors constrained manufacture to highly specialised centres and 
limited the potential for widespread uptake of this therapy. Methods have since evolved in 
terms of speed of production and safety. Scalability (and thus the potential for 
commercialisation) has been enhanced by advances in production consumables and equipment 
such as the use of gas permeable rapid expansion (G-rex) cultureware (Wilson Wolf 
Manufacturing, Saint Paul, Minnesota)255 and closed automation manufacturing systems such 
as the Xuri (GE Healthcare, Little Chalfont, Buckinghamshire)256, and CliniMACS Prodigy 
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(Miltenyi Biotec, Bergisch Gladbach, Germany)257. A number of choices are required when 
considered manufacturing options including: choice of antigen; choice of technique such as ex 
vivo culture or direct isolation; and choice of mono-specific versus multi-specific VST 
generation. The regulatory implications of these manufacturing choices must also be 
considered.  
1.3.2.2 Ex vivo culture and virus-specific T-cell expansion  
This is the original method of VST manufacture, and is favoured by many adoptive cell 
therapy groups. Low-frequency virus-specific memory T-cells are expanded from the 
peripheral blood or apheresis product from a seropositive donor. Viral antigen presentation on 
an antigen presenting cell (APC) activates the donor VST triggering expansion of the VST 
population. The culturing process increases the frequency of virus-specific T-cells and 
decreases the frequency of non virus-specific and potentially alloreactive T-cells258. Some 
examples of different antigens and combinations with APCs that have been used to 
manufacture VST are described in Table 5. 
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Table 5. Choice of antigen for manufacture of VST  
Reference Antigen APC Comments 
Live/attenuated virus x broad antigen stimulation 
x potential risk of infection 
Riddel40, 245 CMV-infected fibroblasts x CD8+ T-cell cloning by limiting dilution 
x Up to 12 weeks manufacture 
x required donor skin biopsy to establish 
fibroblast culture 
Peggs258 CMV lysate monocyte 
derived 
dendritic cell 
(moDC) 
x exogenous antigen presentation to class I & 
II HLA molecules 
x polyclonal CD4+ and CD8+ T-cell product 
x 2-3 weeks manufacture 
Einsele253 CMV lysate Monocytes x skewed to CD4+ phenotype 
Rooney251 EBV lymphoblastoid cell line 
(LCL) 
x presentation of all dominant and 
subdominant antigens 
x polyclonal CD4+ and CD8+ T-cell product 
x Up to 12 weeks manufacture 
Whole viral protein x Must be immunogenic 
Icheva259 whole protein 
EBNA-1 
peripheral blood 
mononuclear 
cells (PBMC) 
x combined with IFN-γ capture direct 
selection 
x polyclonal product functionally active VST 
 
Gene modification (viral vectors) x concerns of vector-mediated gene transfer 
and oncogenic potential 
x can generate multi-virus specific VST 
x cost 
 
Leen260 EBV LCL transduced with 
chimeric adv5f35-CMVpp65 
vector 
x can transduce bi-specific vector into EBV 
LCL to generate trispecific VST 
 
Peptides and peptide mixtures x GMP-grade available, safe 
x must be immunogenic 
x restricts T-cell response to narrow epitope 
response 
Kleihauer261 synthetic 
CMVpp65 
NLVPMVAT 
peptide 
moDC x only applicable for use in individuals with 
the relevant HLA type 
x requires knowledge and availability of the 
immunodominant peptides for the targeted 
pathogen 
x theoretical risk of immune escape due to 
single epitope targeting 
Trivedi262 Overlapping 
15mer 
peptides 
spanning the 
entire CMV 
pp65 protein 
moDC x safe and GMP-grade reagents available 
x technically simple 
x polyclonal CD4+ and CD8+ T-cell product 
Artificial APCs  
Papanicolao
u263, 264 
Murine 3T3 cells transduced to 
express human costimulatory 
x can tailor HLA-restricted antiviral T-cell 
responses 
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Ex vivo culture and expansion has shown consistent success in VST generation 
irrespective of the antigen/APC combination but has been reliant on the use of a seropositive 
donor. Attempts to expand VST from seronegative donors using routine ex vivo culture 
methods have been largely unsuccessful258,261. More advanced techniques have now been 
described that allow VST to be generated using a seronegative donor, however they are 
complex and labour intensive266-268.  
Advantages of the ex vivo culture and expansion technique include:  
x flexible choice of antigen and antigen presenting cell 
x successful VST generation possible with very low donor starting VST frequencies  
x generation of a mixed T-cell (CD4+ and CD8+) product 
x requires a relatively small volume of donor starting material (100mL peripheral blood 
or <2.5% of apheresis product269) 
Disadvantages of the ex vivo culture and expansion technique include: 
x duration of manufacture (10-14 days), potentially precluding availability in urgent 
clinical scenarios 
x expertise and infrastructure required for GMP manufacture 
x theoretical concerns of ex vivo stimulation and culture leading to terminally 
differentiated or exhausted end-culture T-cell phenotype with risk for reduced 
functional and/or proliferative capacity270  
molecules, HLA-A*0201, β2 
microglobulin and CMVpp65 
protein 
x can be used to generate T-cells against 
dominant and subdominant antigens 
x doesn’t require autologous donor cells 
Ngo265 Overlapping 
peptide 
mixture 
LMP1, 
LMP2, 
EBNA1 
Autologous 
activated T-cells 
and HLA 
negative K562 
transduced with 
human 
costimulatory 
molecules 
x enhanced expansion due to K562 
costimulation 
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1.3.2.3 Direct selection techniques 
1.3.2.3.1 HLA multimer-selection  
 HLA multimers are fluorescently tagged complexes of HLA molecules refolded around 
a viral peptide of interest, which bind the T-cell receptor of the virus-specific T-cell, and can 
be quantitated by flow cytometry. The rapid provision of CMV specific T-cells without the 
need for ex-vivo culture and expansion can be performed using MHC class I CMV-specific 
tetramers271,272. Donor CMV-specific CD8 T-cells were stained using CMV-specific HLA 
tetramers and positively selected with magnetic beads for direct infusion into patients within 
four hours of selection. The average VST cell dose (5 x 103/kg) achieved from 250mls of donor 
peripheral blood was approximately an order of magnitude lower than a prior trial of ex vivo 
expanded CMV-specific VST (0.5-1 x 105/kg)273, however positive clinical responses were 
observed272. Higher doses (104/kg) were achievable with selection from two apheresis products 
in the same trial. Clinical response despite the low cell dose may be due to improved capacity 
for in vivo expansion of unmanipulated VST with a less differentiated VST phenotype. 
Alternatively a small cell dose may be all that is required in a post-HSCT lymphopenic 
environment likely to favour T-cell proliferation272. Alternatives to tetramer have been 
developed using modifications of the original tetramer design including pentamers274, 
dextramers275, and streptamers276. Streptamer technology involves the reversible binding of the 
peptide-multimer complex to the VST cell which allow these reagents to be considered GMP-
grade for regulatory purposes as they can be removed from selected cells prior to infusion.  
1.3.2.3.2 Cytokine capture  
 Magnetic technology has been used for the selection of interferon-gamma secreting T-
cells for direct adoptive transfer, following an overnight ex vivo antigen stimulation step277,278. 
Stimulated donor cells were labelled with an anti-IFN-γ monoclonal antibody conjugated to a 
leukocyte-specific (CD45) antibody and then underwent magnetic selection using IFN-γ 
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capture magnetic microbeads, resulting in a polyclonal CD4+ and CD8+ VST product. Similar 
to the multimer selections, low VST dose (average 1.4 x 104/kg) was adequate for clinical 
response277. This was thought to be due to the occurrence of in vivo expansion of the infused 
cells stimulated by the presence of viremia277. A fusion method of cytokine capture followed 
by two weeks of culture and expansion has been described by Meij et al.279 with improvement 
in the purity of the product, irrespective of the starting VST frequency.  
Advantages of the direct selection techniques include:  
x rapid production (hours) 
x minimal technical expertise/infrastructure required for manufacture 
x theoretical advantage of a less differentiated VST phenotype with better proliferative 
capacity  
x only functional T-cells are chosen (cytokine capture)  
Disadvantages of the direct selection techniques include:  
x restriction of available reagents to viruses with well-known immunodominant epitope-
HLA restrictions (HLA multimer selection) 
x restricted CD8+ phenotype of the product due to availability of predominantly class I 
MHC tetramers (HLA-multimer selection)  
x theoretical risk of targeting a single epitope may allow viral mutation and immune escape 
(HLA-multimer selection)  
x necessity for high VST frequency in the seropositive donor as final dose and purity is a 
function of the VST starting frequency271. Purity is lower for cytokine capture than 
multimer-selection due to low VST starting frequency and contaminating IFN-γ 
producing cells277,280,281 
x relatively large volumes of blood (>250mL) or leukapheresis required to achieve 
relatively low-dose VST272,282  
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1.3.2.4 Multi-virus specific T-cell manufacture  
Leen and colleagues260 reported the use of a monoculture method to produce a T-cell 
product with tri-virus specificity for CMV, EBV, and Adv. A clinical grade chimeric 
adenovirus vector backbone was used where the subgroup C type 5 vector fibres were 
substituted for subgroup B serotype 35 resulting in improved transduction efficiency in human 
haemopoietic cells283. VST generation involved the use of donor PBMCs infected with the 
chimeric adenovirus5f35-CMVpp65 vector after overnight adherence, followed by repetitive 
stimulation with autologous EBV-LCLs transduced with the same vector and interleukin-2. 
This resulted in a CMV-dominated T-cell product with lower frequencies of EBV- and Adv-
specific T-cells. A later study reported the use of similar methodology with a different vector, 
Adenovirus5f35null, whereby exclusion of the immunodominant CMVpp65 stimulus reduced 
antigenic competition, resulting in an increased Adv-specific T-cell frequency in the product 
284. Products from both studies resulted in in vivo CMV- and/or EBV-specific T-cell expansion 
in the weeks following infusion. However, Adv-specific responses were only generated in the 
presence of adenoviral antigenemia260,284. In vivo expansion of virus-specific T-cells 
corresponded to reductions in viral load for all viruses irrespective of the VST frequency of the 
infused product260,284. This has led to the expansion of the number of viruses targeted, with 
clinical evidence that multi-specific products targeting five viruses can be clinically 
effective285. This study also showed that direct stimulation of PBMC by overlapping peptide 
libraries could be used for the rapid and successful generation of a multi-specific VST 
product285.  
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1.3.3 HSCT donor-derived VST for virus-specific immune reconstitution post-HSCT 
1.3.3.1 Safety 
 Many early phase trials have reported the efficacy and safety of HSCT-donor derived 
T-cell therapy used for the prophylaxis and treatment of viral infections post-transplant. The 
outcomes of some key trials are described in Table 6. 
Minor acute infusion-related toxicity of self-limited fevers and chills occurred in a single 
study40. In another study, two of 114 patients developed localised swelling at sites of PTLD 
following VST infusion, which led to partial airway obstruction requiring intervention286. All 
other reported adverse events were minor and self-limited.  
The major theoretical safety concern is the induction of GVHD. A long-term follow-up 
study of 114 patients treated with prophylactic EBV-specific T-cells reported no de novo 
aGVHD and eight patients with recrudescence of aGVHD post-infusion. The cumulative 
incidence of 14% cGVHD was not significantly lower compared to 24% in a contemporaneous 
T-cell depleted cohort286. In a study of 50 patients who received prophylactic CMV T-cell 
therapy, the rate of acute and chronic GVHD was similar to contemporaneous controls287. The 
low rate of GVHD may be due to loss of alloreactivity with increasing antigen-specificity of 
the T-cell product253 or very low frequency of alloreactive T-cells in the final product277. A 
review of 153 recipients of virus-specific T-cells, including 73 from HLA mismatched donors, 
suggested up to a rate of up to 10% cell line allorecognition of 44 HLA-disparate targets. 
Irrespective of this allorecognition no instances of de novo GVHD occurred and the incidence 
of GVHD reactivation was low288.  
1.3.3.2 Efficacy 
Following the initial trial of CMV-specific VST245, EBV-specific T-cells were 
manufactured for use in post-transplant EBV-PTLD. Mixed CD4+ and CD8+ phenotype T-cell 
lines were used to treat three patients with evidence of uncontrolled EBV replication or PTLD, 
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and seven patients prophylactically251. All patients demonstrated complete clinical responses 
or remained EBV disease free throughout follow-up, and no patient developed de novo GVHD. 
Safety and positive clinical responses were also demonstrated in 41 patients treated with EBV 
T-cell therapy, and the incidence of EBV PTLD was significantly lower in patients who 
received prophylactic infusions compared to contemporaneous controls252. Convincing 
evidence for efficacy was provided in a 15-year long-term follow-up study of 114 patients 
receiving EBV specific T-cell therapy286. None of 101 treated prophylactically developed EBV 
PTLD, and 11 of 13 patients treated for EBV PTLD achieved sustained complete remissions. 
The 10 year overall survival was 67% (57-76%)286. Functional responsiveness of marked EBV 
CTLs was demonstrated by in vivo expansion correlated with EBV reactivation up to 42 
months after infusion. Ex vivo antigen-stimulated expansion on isolation and testing, in some 
cases long after the loss of detectable marked cells in peripheral blood254,286. Genetically 
marked EBV-specific T-cell could be detected for up to nine years post-infusion.  
Long-term follow-up of 50 patients treated with prophylactic CMV-specific T-cells 
showed a significant reduction in CMV directed therapy, with no significant difference in 
overall or progression-free survival when compared to contemporaneous controls287.  
Adenovirus has also been targeted either as a mono-specific VST product acquired by 
direct selection or part of multi-specific products. Of seven patients treated with the mono-
specific product for viremia or disseminated disease, four demonstrated viral clearance in 
association with the development of Adv-specific T-cell responses277. 
The available data suggests HSCT derived VST therapy is safe and effective with no 
increase in rates of GVHD. Infusion of HSCT-derived VST results in a proportion of patients 
who graduate from absent or undetectable virus-specific T-cell responses to measurable 
responses assessed by a variety of assays. The development of these responses is frequently 
correlated with a reduction in viral load and clinical improvement, or protection from 
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reactivation of virus or progression to disease. In vivo expansion appears to be reliant on the 
presence of in vivo antigenic stimulation277,280,289. A randomised trial of CMV-specific VST 
has been completed but not yet reported beyond conference abstracts290. The data from 
randomised studies will provide more rigorous assessment of safety and efficacy of HSCT-
derived VST treatment.  
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Table 6. Outcomes of HSCT donor-derived VST trials 
Authors, 
Location 
Treatment 
setting, (N) 
Method Cell Dose  Outcome Toxicity (infusion, GVHD*, 
other) 
Walter et al. 
199540  
CMV 
Prophylaxis 
(14) 
Ex vivo 
Culture 
 
3.3 x 107/m2 
escalating to 
1 x 109/m2  
up to 4 
infusions  
14/14 No CMV viremia or disease 
11/14 Recovery CMV-specific T-cell 
responses 
 
 
2/14 post-infusion chills or 
transient fever  
3/14 GVHD I-II 
Peggs et 
al.2001,2003
258,273 
CMV  
Pre-emptive 
(16) 
Ex vivo 
Culture 
 
0.5 - 1 x 
105/kg, 
single 
infusion 
8/16 CR without antiviral 
8/16 CR (coincident antivirals) 
4/5 CMV-specific T-cell response (tetramer) 
CD4+ and CD8+ T-cell count recovery 
Significantly less subsequent reactivation than 
controls (14% vs. 63%, P=0.001)  
No toxicity  
3/14 GVHD I-II 
Mackinnon 
et al. 2008278 
CMV 
Prophylactic 
(2) 
Pre-emptive 
(21) 
Ex vivo 
culture 
(16 patients) 
IFN-γ direct 
isolation  
(7 patients) 
1 x 105/kg 
cultured cells 
or  
1 x 104/kg 
directly 
isolated cells 
Ex vivo culture 
8/16 CR without antivirals 
IFN selected infusion 
5/7 CR with antivirals (2 prophylactically)  
7/7 CMV-reactive T-cell response  
CD4+ and CD8+ T-cell count recovery 
 
No toxicity 
3/23 GVHD grade I 
 
Blyth et al. 
2013287 
CMV 
Prophylaxis 
(50) 
Ex vivo 
culture 
2 x 107/m2,  
single 
infusion  
26/50 early reactivation, 5/50 reactivations 
after CTL infusion 
Reduction in CMV directed therapy compared 
to controls, 17 vs. 36%, p=0.01, 
Reduction in therapy days compared to 
controls, 3.4 vs. 8.9 days, p=0.03 
No difference in overall survival or 
progression free survival 
 
No toxicity 
No increase in GVHD compared 
to contemporaneous controls 
Rooney et al. 
1998252 
EBV 
Prophylaxis 
(33) 
Pre-emptive 
(6) 
Ex vivo 
culture 
1 x 107/m2 
escalating to 
5 x 107/m2 
 
Significantly less frequent EBV PTLD in 
prophylactic group (0%) than controls (11.5%) 
6/6 with high viral load had 3-5 log reduction 
and no progression to PTLD 
2/2 with PTLD had CR 
No toxicity 
1 GVHD exacerbation  
PTLD tumour local 
inflammation  
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PTLD 
Treatment 
(2) 
Expansion of EBV-specific T-cells 
Persistence for median of 11 weeks 
Heslop et al. 
2010286 
EBV 
Prophylaxis 
(101) 
Treatment 
(13) EBV 
PTLD 
Ex vivo 
culture 
1-5 x 107/m2, 
up to 5 
infusions 
 
0/101 complete success EBV PTLD 
prophylaxis 
11/13 with EBV PTLD CR  
2/13 died of PTLD refractory to EBV CTL  
Persistence up to 9 years (gene marking) 
 
 
No infusion toxicity 
0/114 de novo aGVHD  
8/114 aGVHD recurrence 
11/108 limited cGVHD,  
2/108 extensive cGVHD 
Localised swelling at sites of 
responsive disease  
1 lobar pulmonary infiltrate  
1 transient hepatic transaminitis 
Feuchtinger 
et al. 2006277 
Adv 
Pre-emptive 
(2) 
Treatment 
(7)  
IFN-γ direct 
isolation 
1.2-50 
x103/kg,  
single 
infusion  
 
4/9 CR at 30 days 
3/9 Adv-related death or progression 
2/9 death - 1 relapse with Adv viremia, 1 
unrelated death post-infusion  
5/6 Adv t-cell responses post-infusion  
 
No toxicity 
2/9 GVHD II  
 
Feucht et al. 
2015291 
Adv 
Treatment  
(30) 
IFN-γ direct 
isolation 
4.1 x 103/kg, 
up to 3 
infusions 
21/30 responded (14 CR, 3 PR, 4 resolved 
viral shedding) 
1/30 early death 
8/30 non-responders (100% mortality) 
2/30 GVHD I 
Abbreviations: CR, complete response; GVHD, graft versus host disease (a, acute; c, chronic); N, number; PR, partial response. 
* GVHD grading is described in Chapter 3, Supplementary Table S1 
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1.3.4 Third-party donor-derived VST for treatment of viral infection post-HSCT 
1.3.4.1 Background  
Historically, use of the HSCT donor for manufacture of VST was convenient because 
the majority of transplants were from a sibling donor. This was feasible where the HSCT donor 
was accessible and seropositive for the virus of interest. However, transplant practices have 
changed significantly and the use of unrelated, geographically distant donors is now far more 
common. A HSCT-derived VST product may not be readily accessible in a number of 
scenarios. Donor cells may be seronegative for the virus of interest; this is a particular issue for 
umbilical cord blood donor cells. Logistical or consent issues may prevent collection of donor 
cells required for generation of VST. When infection occurs in the very early post-transplant 
period, an HSCT-derived VST product may not be available due to manufacturing lag times of 
2-4 weeks for some manufacturing methods. The potential for delay in the timely availability 
of a HSCT-derived product must be weighed up against the cost of pre-emptive manufacturing 
of a product that is destined for a single recipient and ultimately may not be required.  
The use of third-party healthy donors to generate VST products circumvents a number 
of these issues. The concept of an ‘off-the-shelf’ bank of cryopreserved VST products provides 
the flexibility to treat patients at any time post-transplantation without the delay of waiting for 
product generation. It also has the potential to improve accessibility to treatment for unrelated, 
cord blood, and seronegative donor transplant recipients where manufacture of HSCT-donor 
derived VST product may not have been possible. The potential advantages of banked third-
party VST over DLI and HSCT-derived VST products are described in Table 7. 
  
 43 
Table 7. Comparison of VST by donor source and type 
Abbreviations: DLI, donor lymphocyte infusion; GVHD, graft versus host disease; UCBD, 
umbilical cord blood donor 
* Refers to use of ex vivo culture and expansion method 
 
1.3.4.2 Trials utilising virus-specific T-cells from third-party donors  
In 2002, Haque and colleagues292,293 described the initial proof of principle studies 
confirming that treatment with partially HLA-matched VST from third-party donors was 
feasible. Of 33 patients (31 solid organ transplant and two HSCT patients) treated for refractory 
EBV PTLD, the overall response rate (ORR) was 64% at five weeks, which was maintained at 
six months (ORR 52%). In the two initial studies, two of three HSCT patients with refractory 
EBV PTLD achieved a complete remission at six months post EBV-specific T-cell 
infusion292,293. There was no toxicity or GVHD. HLA-typed VST products were characterised 
for EBV-specificity, phenotype, and cytotoxicity, and cryopreserved as single dose products 
enabling rapid product choice and distribution to the treating centre294.  
Third-party donor cells have been used to treat a small number of HSCT patients with 
refractory viremia and infection as described in Table 8. There are a number of patients who 
have been reported to achieve a complete virological response but the data cannot be 
 
Cryopreserved 
HSCT-DLI HSCT-derived VST 
Banked third-party 
donor VST 
Availability 
Not always 
(low cell dose, 
seronegative donor) 
Not always 
(seronegative or 
UCBD) 
Nearly always 
(1/6 HLA match) 
Time to 
treatment 
Immediate Manufacturing delay 
2-4 weeks* 
Immediate 
Risk of 
GVHD High Low Low 
Long-term 
persistence 
Yes Yes Probably not 
Prophylaxis or 
treatment 
Treatment only 
(high risk of GVHD) 
Prophylaxis or 
treatment 
Treatment 
(short persistence) 
Relative cost 
of production Low 
High 
(for a single recipient ) 
Moderate (batched 
processing, numerous 
possible recipients) 
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aggregated due to differences in methods of measurement and the timing of endpoints274,281,295-
297. The two largest studies, from Baylor College of Medicine, reported cumulative complete 
virological response at six weeks post VST infusion298,299. When results for CMV, EBV, and 
Adv-specific VST are combined for the two trials the ORR is 84% (CR 42%, PR 42%) in 71 
evaluable patients. The ORR for 36 patients treated with CMV-specific VST was 91% (CR 
42%, PR 50%). The ORR for 11 patients treated with EBV-specific T-cells was 72% (CR 36%, 
PR 36%). The ORR for 24 patients treated with Adv-specific T-cells was 79% (CR 46%, PR 
33%). There was no reported difference in efficacy for CMV, EBV, and Adv between the two 
trials, despite moving from a trivalent to a pentavalent multi-virus specificity VST. A small 
bank of 32 virus-specific cell lines restricted by common HLA polymorphisms was adequate 
to cover 90% of screened patients in the tri-valent VST trial. A bank of 59 pentavalent VST 
covered 96% of patients screened.  
The safety profile of third-party VST therapy has been favourable. Infusional adverse 
events are rare. When other toxicities have been reported, none have attributed causality to the 
third-party VST product, and all are toxicities frequently seen in HSCT patients. The major 
concern has been the induction of GVHD, given that VST products are only partially HLA-
matched to recipients. As previously mentioned, virus antigen specificity in the product is 
thought to reduce the potential for in vivo alloreactivity253. Although the numbers of patients 
treated in early phase studies is low, GVHD incidence has been within expectations for the 
HSCT population. The two largest studies included 71 people with a reported rate of acute 
GVHD of 16%. Of the 15 patients who developed GVHD, only two patients had grade III-IV 
GVHD298,299. There has been one case report of liver GVHD following infusion of cytokine 
captured Adv-specific300. There was no pathological evidence of third-party donor T-cells in 
the liver by XY fluorescence in situ hybridisation, only cells from the HLA-C antigen 
mismatched HSCT donor were present. The authors hypothesised that liver GVHD that 
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occurred six weeks post VST treatment, may have been potentiated by the inflammatory milieu 
associated with third-party donor T-cell expansion. An alternative hypothesis would be that 
severe GVHD was coincidental but unrelated to the VST treatment in a patient with high risk 
due to HSCT donor antigen mismatch. Randomised studies are required to confirm this 
relatively low rate of GVHD. 
Many of the publications reporting third-party VST treatment describe unmeasurable 
or very low VST activity in the recipient prior to infusion reflecting the use of VST in the 
setting of refractory infection and disease. In the majority of (but not in all) partial and complete 
responders virus T-cell expansion is demonstrated at variable times following third-party VST 
treatment274,281,295,298-300. Persistence of the infused third-party cells has been tested in a small 
subset of patients both responders and non-responders. Despite the HLA mismatch between 
third-party VST and the recipient, third-party VST have been detected at low levels in some 
patients for up to 12 weeks after VST infusion274,295,298,299,301. Aside from degree of HLA 
match, it not known which factors are likely to impact on persistence but use of 
immunosuppressants may influence longevity of engraftment. It is unknown whether 
persistence of infused third-party VST is required for efficacy in viral control. 
There is lack of detail in the third-party T-cell trials published regarding coincident use 
of antiviral therapy after VST treatment, VST-recipient HLA matching, and phenotype of the 
VST products. All of these factors may affect efficacy. Longer-term virological and immune 
responses post-VST have not been studied or reported in detail.  
Overall third-party donor-derived VST products appears to be a promising strategy for 
treatment of refractory viral infection, although recipients numbers are small and the only trials 
>10 patients have been reported from a single institution. Larger controlled trials are required 
to confirm the safety and efficacy of this treatment. Further assessment of the impact of third-
party VST treatment on usage of antiviral drugs, characterisation of post-infusion T-cell 
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compartment reconstitution, and analysis of longevity of anti-viral protection and safety, are 
also required. 
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Table 8. Outcomes of published third-party donor VST trials 
Authors, 
Location N^ Virus Method 
Cell Dose, 
purity, 
infusions 
Outcome 
VST 
expansi
on 
Third-party 
T-cell 
Persistence 
Toxicity (infusion, 
GVHD*, other non-
infectious) 
Haque et al.292  
2002  
Edinburgh  
1 
EBV 
PTLD 
  
EBV LCL 
  
2x 106/kg 
single 
infusion 
not evaluable  not reported not performed 
Infusion toxicity 
none 
GVHD 
not evaluable 
Haque et al.293  
2007, 2010 
Edinburgh 
2 
2 x 106/kg,  
up to 4 
infusions  
CR 2/2  not reported not performed 
Infusion toxicity 
none 
GVHD 
none 
Uhlin et al.274,302  
2010, 2012 
Karolinska 
5 
CMV 3 
EBV 
PTLD 1 
Adv 1 
HLA-pentamer 
selection 
HLA-A*02, 
B*07,B*35 CMV 
HLA-A*02 EBV 
HLA-A*01 Adv 
1-11 x 104/kg,  
purity 24-
75%,  
up to 2 
infusions  
CR 3/5  
NR 2/5 
Yes 4/5  
 
Yes 4/5  
(4d-12w)  
Infusion toxicity 
none 
GVHD 
none 
Schottker et 
al.3032008 
Feuchtinger et 
al.281 2010,  
Tubingen  
2 CMV disease 
IFN-γ capture 
(CMVpp65 
stimulation) 
0.1-2.8x104 
CD3+/kg, 
purity 58-
82% 
CR 1/2  
PR 1/2  Yes 2/2 
Yes 2/2  
(up to 16d)  
Infusion toxicity 
none 
GVHD 
1 grade I gut 
Qasim et al.296,300  
2011, 2013 
Great Ormond 
Street 
2 Adv IFN-γ capture (Adv C lysate) 
1x104/kg,  
purity 48-
64% 
CR 1/2  
PR 1/2  Yes 2/2 
<1% third 
party donor 
detected in 
CD3+ T-cells, 
expansion - 
MHC specific 
Adv-T-cell 
persistence 
>6wks 
Infusion toxicity 
none 
GVHD 
1 liver grade IV (late) 
Other 
1 cytopenia (late) 
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Barker et al.304 
2010, Doubrovina 
et al.305 2012  
MSKCC 
5 EBV PTLD EBV LCL 
1 x 106/kg, 
up to 9 
infusions 
CR 2/2  Yes 2/2 No 
Infusion toxicity 
none 
GVHD 
none 
Leen et al.298 
2013 
Baylor 
50 
CMV 23 
EBV 9 
Adv 18 
Tri-virus specific 
AD5f35pp65 
vector 
transduction of 
EBV LCL 
2 x 107/m2,  
up to 6 
infusions,  
 
CMV  
4 not evaluable 
CR 9/19  
PR 8/19, 
EBV 
CR 2/9, PR 4/9 
Adv  
1 not evaluable 
CR 7/17, PR 7/17  
 
ORR 74% at 6 weeks 
Yes 
21/50 
Yes 4/6  
up to 12 w,  
(TCR 
sequencing 
Vβ chain 
analysis) 
Infusion toxicity  
none 
GVHD 
8/50 aGVHD (6 grade I, 
1 grade II, 1 grade III) 
1/50 cGVHD 
Other 
1 TAM 
1 secondary graft failure 
Vickers et al.306 
2014 
Edinburgh 
6 EBV  EBV LCL 
1-2 x 106/kg, 
up to 4 
infusions 
CR 4/6 
PR 2/6 
 Not 
reported  Not reported 
Infusion toxicity 
none 
GVHD 
1/7 aGVHD I 
Koehne et al.307 
2015  
MSKCC  
1 CMV 
Monovalent 
culture by 
overlapping 
peptide mix 
CMVpp65 
1x106/kg x 3 
infusions CR in 1/1   Yes Not reported  
Infusion toxicity 
none 
GVHD 
none 
Withers et al.308 
2017 
Westmead 
(REPORTED in 
Chapter 3 of this 
thesis). 
30 
CMV 28 
EBV 1 
Adv 1 
Monovalent 
cultures by 
overlapping 
peptide mix CMV 
pp65,  
EBV BZLF-1, 
LMP-2A,EBNA-
1  
Adv hexon 5  
2 x 107/m2 , 
up to 4 
infusions 
CMV 
CR 22/28, PR 5/28, 
NR 1/28 
EBV 
NR 1/1 
Adv 
CR 1/1  
 
ORR 93% at 12 m 
Yes 
Yes 8/11 
Up until 27 
days 
Infusion toxicity 
1/30 fever 
GVHD 
2 de novo aGVHD (grade 
II, grade IV) 
5 cGVHD  
Other 
2 PRES 
1 Stevens-Johnson 
syndrome 
2 Respiratory failure  
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Neuenhahn et 
al.295 2017 
Dresden/Munchen 
8 CMV  
MHC-streptamer 
isolated CMV 
epitope specific 
donor T-cells 
0.2-87x104 
CD3+/kg, 
purity 22-
99% 
CR 4/8 (50%), PR 
1/8, NR 3/8 Yes 3/8 
Yes 1/8  
Up to 3 m  
(VST HLA 
match 8/8) 
Infusion toxicity 
1/8 fever 
GVHD 
none 
Tzannou et al.299 
2017 
Baylor 
38 
45 
infections 
CMV 17 
EBV 2 
Adv 7 
HHV-6 3 
BKV 16 
Multi-virus 
culture using 
overlapping 
peptide mix: 
CMV IE-1, pp65 
EBV EBNA-1, 
LMP-2, BZLF-1 
BKV large T, 
VP-1 
HHV-6 U-11, U-
14, U-90 
Adv hexon, 
penton 
2 x 107/m2, up 
to 3 infusions 
CMV  
CR 6/17, PR 10/17, 
1/17 NR  
EBV 
CR 2/2 
Adv 
CR 4/7, PR 1/7,  
NR 2/7 
HHV-6 
1 Not evaluable 
CR 0/7, PR 2/3, 1/7  
BKV 
Virological CR 1/16, 
PR 15/16 
 
ORR 92% at 6 weeks 
 
  
CMV 
9/17 
EBV 
1/2 
Adv 
4/7 
HHV-6 
1/2 
BKV 
7/16 
Yes 11/16  
Up to 12 
weeks by 
STR/donor-
specific HLA-
restricted 
epitope 
peptides 
Infusion toxicity  
1/45 fever 
GVHD 
2 de novo (grade I-II 
skin)  
4 recurrent (3 grade I-II 
skin, 1 grade III gut) 
Other 
1 transient 
hydronephrosis and renal 
impairment 
Qian et al.297 2017 
de Lorraine 6 Adv 
IFN-γ capture 
(AdV5 hexon 
peptide pool) 
1-9 x103 
CD3+/kg 
CR 5/6  
NR 1/6 Yes 6/6 Not reported 
Infusion toxicity 
none 
GVHD 
2 recurrent (grade 1 and 
III) 
0 de novo 
Lindeman et al.309 
2018 
Essen 
1 CMV 
IFN-γ capture 
(CMV pp65 
overlapping 
peptide mixture) 
2.5 x 104 
CD3+/kg  
purity 42% 
PR 1/1 Yes 1/1 
No 
persistence at 
day 616 post 
VST 
Infusion toxicity 
none 
GVHD 
1 grade II gut and skin 
Muftuoglou et 
al.301 2018 
MDACC 
1 JCV/BKV 
Multi-virus 
culture using 
overlapping 
2x105/kg 
3 infusions CR 1/1  Yes 1/1 
Up to 250 
days by flow-
Infusion toxicity 
none 
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peptide mix BKV 
VP-1, VP-2, VP-
3, ST, LT 
HLA epitope 
chimerism 
GVHD 
none 
Abbreviations: CR, complete response; d, days; GVHD, graft versus host disease; m, month; MDACC, MD Anderson Cancer Center; NR, no response; PR, 
partial response; STR, short tandem repeats; TCR, T-cell receptor; y, year. 
^ Patients in multiple publications were only described in the table once 
* GVHD grading is described in Chapter 3, Supplementary Table S1 
Nine patients treated with CMV-specific third-party T-cells in 2015 were not included as the study details could not be ascertained (non-English 
publication)310. Seven patients treated with CMV, EBV or Adv-specific T-cells in 2016 were not included as patients were treated for compassionate use 311  
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1.3.4.3 VST product choice in the setting of partial HLA matching 
The fundamental principle underlying the use of partially matched third-party VST is 
ensuring at least a single HLA match between the VST product and the intended recipient. In 
the largest trials of third-party VST to be reported in HSCT patients, a single HLA match has 
been shown to be adequate for response298,299, and no significant difference in response rates 
were demonstrated when a high number of HLA molecule matches were compared to low 
(<4/8 HLA) frequency matches299. In the Edinburgh trial, comprising mostly solid organ 
transplant patients with EBV PTLD, high numbers of HLA matches were correlated with better 
response rates293.  
The imperative of a shared HLA allele becomes complex in the setting of an intended 
VST recipient with a history of a prior HLA-mismatched HSCT transplant. Choice of product 
HLA-matching in this situation may have the potential to influence efficacy. The optimal 
product choice is one in which at least a 1/6 HLA match is shared with both the HSCT donor 
and recipient HLA types. However this is not always feasible and a product may be provided 
matched to either the recipient or HSCT donor HLA type. In these cases, efficacy may 
theoretically be impacted due to factors such as: the degree of HSCT donor chimerism in the 
recipient potentially impacting the origin of latent cellular source of viral infection; prior 
conditioning therapy and duration post-transplant impacting on the origin of tissue resident 
dendritic cells; and the possibility of subclinical recipient tissue infection when treating 
DNAemia. Failure of third-party T-cell VST treatment has been reported in two patients treated 
for EBV PTLD, where the infused VST product was not HLA-matched to the HLA expressed 
by the lymphoma. One of the patients subsequently achieved complete viral response after a 
2nd EBV-specific VST infusion which was matched to the recipient HLA type expressed by 
the lymphoma305. This highlights the importance of choosing an appropriately HLA-matched 
VST product which is addressed in Chapters 2 and 3 of this thesis.  
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1.3.4.4 Issues relevant to the manufacture of a third-party donor virus-specific T-cell banks 
1.3.4.4.1 Regulatory Issues 
The international regulatory environment relevant to the production of cellular therapy 
products has changed significantly since the first trials of third-party T-cell products were 
reported in 2002. The introduction of good manufacturing practice (GMP) standards in 2005 
to ensure the high quality of cellular therapy products, resulted in third-party donor T-cell 
banks created prior to this time having to be abandoned306. The advent of these more stringent 
regulatory standards traditionally applied to commercial drug manufacturing, may have played 
a role in the slow initiation of third-party T-cell clinical trials following the initial publication 
in 2002, as manufacturing processes and quality management systems needed to be developed 
that could withstand regulatory scrutiny.  
The GMP standards and the regulatory bodies responsible for licensure and 
enforcement of these standards vary by region. In Australia, immunotherapy products 
containing human cells are regulated as biologicals. The manufacture of these products must 
be adhere to the “Australian Code of GMP for Blood and Blood Components, Human Tissues 
and Human Cellular Therapy Products” as set out by the Australian regulator, the Therapeutic 
Goods Authority (TGA). As part of regulating manufacture, regulation of donor selection and 
infectious disease screening is tightly controlled as per therapeutic goods order no. 88 
“Standards for donor selection, testing and minimising infectious disease transmission via 
therapeutic goods that are human blood and blood components, human tissues and human 
cellular therapy products”. Cellular therapy manufacturing and HSCT clinical programs can 
undergo voluntary accreditation with either of two international organisations: the Foundation 
for the Accreditation of Cellular Therapy (FACT) or the Joint Accreditation of the International 
Society of Cellular Therapy-Europe and the European Society for Blood and Marrow 
Transplantation (JACIE). These organisations have agreed to joint standards covering the 
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collection, processing and administration of haemopoietic cellular therapy products. 
Regulatory standards specific to VST manufacture and administration have recently been 
included under the umbrella of “immune effector cells”312.  
1.3.4.4.2 Choice of third-party donor 
To create the optimal bank of third-party VST products, donors with common HLA 
types are targeted. An understanding of immunodominant T-cell responses and HLA-
restriction of virus-specific epitopes is required. T-cell responses to viral antigens are 
hierarchical. Certain immunodominant antigens (e.g. CMVpp65) are responsible for 
generating stronger and more frequent T-cell responses in a large proportion of the population 
as compared with subdominant antigens186. A similar hierarchy of immunodominance is 
reported to extend to an individual’s HLA type. Hyun et al313 reported the most dominant T-
cell responses against CMV pp65 within a population of 50 healthy donors were restricted 
through class I HLA-A and B loci; HLA-A*02:01 and HLA-B*07:02 were most frequent 
alleles. CMV pp65 immunodominant T-cell responses were restricted through a single HLA 
locus in 46% of donors or two HLA loci in 28% of donors, despite a number of donors co-
expressing multiple dominant HLA molecules. An example is the frequently reported 
observation that individuals with co-expression of HLA-A*02:01 and –B*07:02 invariably 
show an immunodominant T-cell response restricted through viral antigen presentation on 
HLA-B*07:02 rather than HLA-A*02:0134,314. This knowledge can help in the targeting of 
donors for VST manufacture. To create a VST product with an A*02:01 restriction for 
presenting CMV epitopes, the targeted donor should express A*02 but not B*07:02. Thorough 
characterisation of VST products after manufacture is an important step to ensure antiviral 
specificity occurs through the expected HLA restriction. T-cell responses to other viral protein 
targets such as Adv hexon 5 or EBV LMP-1, while still immunodominant, do not engender the 
same strength or frequency of responses among seropositive donors as is reliably shown with 
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CMVpp65186. HLA matching and its implication on cell bank content is addressed in Chapter 
2. 
1.3.4.4.3 Manufacturing methods and optimal VST composition 
The manufacturing methodologies that have been used to produce third-party VST are 
similar to those used for the production of HSCT-donor derived VST described in Section 
1.3.2. T-cell culture and expansion has been favoured over direct selection, in the larger studies, 
as culture duration is less relevant when producing a product not intended for immediate use. 
GMP-compliant overlapping peptide mixtures have recently become available and are widely 
used due to the simplicity of use and ability to produce a polyclonal VST product of both CD4+ 
and CD8+ T-cells. The Baylor group pioneered the manufacture of multi-virus-specific third-
party VST products. Initially vector transduced LCLs were used, and more recently, 
overlapping peptide mixtures298,299.  
Third-party VST composition may be important for efficacy. The first trial of third-
party cells reported lower response rates at five weeks and six months with polyclonal EBV-
specific VST products containing <4.9% CD4+ cells compared to those with >5% CD4+ T-
cells administered to predominantly solid organ transplant recipients 293. The largest trial of 
third-party T-cells performed in 50 HSCT recipients with tri-specific CMV, EBV, and Adv-
specific T-cells, found no correlation between CD4+ T-cells and response, however only one 
of 18 VST products infused contained <5% CD4+ T-cells298. Successful clinical responses have 
been demonstrated in a small number of patients treated with third-party CD8+ virus-specific 
T-cells isolated using MHC class I multimer/streptamer-selection techniques274,295. A potential 
advantage of this method is the ability to isolate early differentiation virus-specific memory T-
cells. There is some evidence in animal models to suggest the superior capacity of central 
memory T-cell subsets for in vivo T-cell expansion and durability in comparison to late T-cell 
effector memory subsets315. As reviewed by Busch316, targeting less differentiated T-cells 
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subsets may improve adoptive T-cell therapy outcomes. These questions suggest that larger 
trials comparing methodology will be required to ascertain the optimal product composition in 
the setting of third-party VST treatment. 
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1.4 Conclusions and statement of thesis aims 
1.4.1 Conclusions 
x Viral infection causes significant morbidity and mortality in HSCT recipients due to 
delayed reconstitution of virus-specific T-cell immunity post-transplantation. 
x International transplant practices are evolving, with increased utilisation of mismatched 
and unrelated donors and the increased usage of T-cell depleting conditioning, with 
resultant delayed T-cell reconstitution post-transplant and increased risk of viral 
infection.  
x A number of early phase trials have shown that prophylaxis or therapy with HSCT 
donor-derived VST products is safe without an apparent increase risk of GVHD or other 
toxicities. Virological response in the majority of treated patients appears to correlate 
with in vivo expansion of the infused virus-specific T-cells.  
x The manufacture of HSCT donor-derived VST products is not possible for all HSCT 
patients and products are not always available in a timely manner. Third-party donor 
derived VST products may be advantageous in terms of improved accessibility for the 
large majority of HSCT patients and the potential for rapid therapy in setting of clinical 
urgency. 
1.4.2 Thesis Aims 
1. To create and characterise a bank of third-party donor-derived CMV, EBV, and Adv-
specific T-cells.  
2. To assess the safety and efficacy of partially HLA-matched, third-party VST as 
treatment for refractory CMV, EBV, or Adv infection in allogeneic HSCT recipients in 
a Phase I clinical trial.  
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3. To investigate and characterise the immunological consequences of third-party VST 
infusion including assessment of: immune cell frequencies, cytokine activity, virus-
specific T-cell immunity, and third-party T-cell post-infusion persistence. 
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A B S T R A C T
Hematopoietic stem cell transplantation (HSCT) donor!generated virus-speciﬁc T cells (VSTs) can provide effec-
tive treatment for viral infection post-HSCT but are not readily accessible to all patients. Off-the-shelf cryopre-
served VSTs suitable for treatment of multiple patients are an attractive alternative. We generated a bank of 17
cytomegalovirus (CMV)!, 14 Epstein-Barr virus (EBV)!, and 15 adenovirus (AdV)!speciﬁc T cell products from
30 third-party donors. Donors were selected for expression of 6 core HLA antigens expressed at high frequency in
the local transplant population. T cells were generated by co-culturing venous blood or mobilized hematopoietic
stem cell (HSC)!derived mononuclear cells with monocyte-derived dendritic cells pulsed with overlapping pepti-
des covering CMV pp65, AdV5 hexon, or EBV BZLF1/LMP2A/EBNA1 proteins. Addition of a CD14+ selection step
instead of plate adherence to isolate monocytes before culture initiation signiﬁcantly improved expansion in cul-
tures from HSC material. Phenotyping showed the CD8+ subset to have signiﬁcantly higher numbers of terminal
effector T cells (CD45RA+62L¡) and lower numbers of effector memory T cells (CD45RA¡62L¡) when compared
with the CD4+ subset. Increased expression of the immunoinhibitory markers PD-1 and TIM-3 was noted on CD4+
but not CD8+ cells when compared with the control group. VST showed antiviral activity restricted through a vari-
ety of common HLAs, and modelling suggested a suitably HLA-matched product would be available for >90% of
HSCT patients. Only a small number of carefully selected third-party donors are required to generate a VST bank
of broad coverage, indicating the feasibility of local banking integrated into existing allogeneic HSCT programs.
Crown Copyright © 2018 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Trans-
plantation. All rights reserved.
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INTRODUCTION
Viral infections are a major cause of morbidity and mortal-
ity following hematopoietic stem cell transplantation (HSCT).
The herpesviruses cytomegalovirus (CMV) and Epstein-Barr
virus (EBV) are the most frequent viral infections requiring
treatment in the ﬁrst-year postallogeneic stem cell transplant.
However, standard treatment options are limited with a handful
of effective antiviral drug therapies available, all associated with
treatment-limiting toxicities, signiﬁcant cost, and the potential
need for prolonged and/or recurrent treatment often in the inpa-
tient setting. Adoptive transfer of fully matched virus-speciﬁc T
cells (VSTs) generated on an individual basis from the patient's
HSCT donor is safe and effective, and has been shown to restore
speciﬁc antiviral immunity resulting in durable virological con-
trol. Pragmatic concerns with this approach include the need for
the HSCT donor cells to be seropositive for the target virus, and
the lengthy timeframe and/or cost of generating a product which
is then only available for a single recipient. We, and others, have
reported the successful use of cryopreserved partially HLA-
matched VST products generated from third-party donors to
treat patients with infections resistant and refractory to standard
antiviral therapy [1-12]. Here we describe the nature and opera-
tion of the ﬁrst third-party bank established in Australia com-
prising cryopreserved CMV-, EBV-, and AdV-speciﬁc T cell
products and situated within a working HSCT program.
METHODS
HLA Frequency and Model for Proposed HLA Coverage
The HLA types of 146 consecutive historical HSCT donors at Westmead
Hospital, Australia, were used to calculate a local HSCT population antigen
frequency histogram and coverage offered by the bank. Historic HSCT donors
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with the highest frequency HLA antigens where a VST product with demon-
strated antiviral activity through that HLA-restriction was available, were
removed from the donor list in a stepwise fashion to calculate HLA coverage
offered by each donor addition.
Third-Party Donors
Healthy third-party donors were recruited fromWestmead Hospital, Syd-
ney between 2012 and 2014, and underwent standardized assessment to
ensure eligibility for allogeneic donation. HLA typing was performed by the
Australian Red Cross Blood Service and was low resolution for class I loci and
resolved to 4 digits at the DRB1 locus. The study was approved by the Human
Research Ethics committee of Westmead Hospital. Informed consent was
obtained from all donors in accordance with the Declaration of Helsinki. The
study was registered on the Australian and New Zealand Clinical Trial Regis-
try (ACTRN12613000603718).
VST Manufacture
VST products were generated under good manufacturing practice (GMP)
conditions at Sydney Cellular Therapies Laboratory, Westmead Hospital. The
starting material for culture was peripheral blood mononuclear cells (PBMCs)
isolated by Ficoll-Paque Premium (GE Healthcare, Uppsala, Sweden) gradient
centrifugation from either 100 mL of venous blood or .5 to 1.0£ 109 total
nucleated cells of granulocyte colony-stimulating factor (G-CSF)!primed
apheresis hematopoietic stem cell (HSC) product. Monocytes were isolated
by plastic adherence or CD14 immunomagnetic bead positive selection. For
CD14+ selection, CliniMACS CD14 Reagent (Miltenyi Biotec, Bergisch Glad-
bach, Germany) was added to cells resuspended in CliniMACS Buffer (Milte-
nyi Biotec) supplemented with 1% human serum albumin (Albumex20, CSL
Behring Australia, Broadmeadows, Australia). CD14+ monocytes were isolated
by magnetic selection using an EasySep Magnet (STEMCELL Technologies,
Tullamarine, Australia) and the negative fraction was then set aside for cryo-
preservation. CD14+ purity was assessed by ﬂow cytometry aiming for >80%
in the CD14+ fraction and <5% in the CD14! fraction. Plastic- or CD14 selec-
tion-isolated monocytes were matured by culture in CellGro-DC medium
(Cellgenix, Freiburg, Germany) with 1000 U/mL granulocyte macrophage CSF
and 1000 U/mL IL-4 for 5 days, and 200 U/mL TNF-a (all cytokines from Cell-
Genix) on days 5 to 7 resulting in differentiation into monocyte-derived den-
dritic cells (moDCs). Mature moDCs were pulsed for 2 hours with 1 mg/mL of
overlapping MACS GMP PepTivators (Miltenyi Biotec) peptide pools (15mers
overlapping by 11 peptides) for either CMV pp65, AdV5 Hexon, or EBV
BZLF1/LMP2A/EBNA-1 proteins. Peptide-pulsed moDCs were irradiated and
co-cultured in AIM-Vmedium (Life Technologies, Camarillo, CA) + 10% autolo-
gous plasma or human AB serum (Australian Red Cross Blood Service) with
the autologous cryopreserved nonadherent (monocyte-depleted) or CD14!
cell fraction at a 10:1 mononuclear cell/moDC ratio. Cultures underwent
restimulation with antigen-pulsed moDCs at between 10 and 20:1 cell/moDC
ratio on day 7 with the addition of 20 U/mL IL-2 (Miltenyi Biotec) every 2 to
3 days from days 7 to 14, increasing to 50 U/mL of IL-2 from days 14 to 21. At
the completion of culture, the univalent expanded VST product was aliquoted
to meet a target dose of 2.0£ 107/m2 cells and cryopreserved.
Assessment of VST Products
Flow Cytometry
Flow cytometry was performed on VST products using monoclonal anti-
bodies directed against CD3, CD4, CD8, CD14, CD19, CD45, CD56, CD62L,
CD45RA, CD45RO, PD-1 (BD Biosciences, San Jose, CA), and TIM-3 (Biolegend,
San Diego, CA). Viability was assessed using 7-amino-actinomycin D (BD Bio-
sciences) or hydroxystilbamidine (Molecular Probes, Mulgrave, Australia).
Peripheral blood mononuclear cells from otherwise healthy individuals
undergoing venesection for hemochromatosis were used as controls to assess
percentage expression of PD-1 and TIM-3 on CD8+ and CD4+ T cells. Viral anti-
gen speciﬁcity and HLA-restricted epitope recognition on VST products were
assessed using phycoerythrin-conjugated virus-speciﬁc iTAg MHC class I
human tetramers (Beckman Coulter, Fullerton, CA) or by intracellular cyto-
kine ﬂow cytometry after stimulation of VST with overlapping peptide mix or
with individual epitopes as previously described [13]. The tetramers (Beck-
man Coulter), PepMix peptide pools (JPT Peptide Technologies GmbH, Berlin,
Germany), and custom peptide epitopes (Mimotopes, Clayton, Australia)
used for testing are described in Supplemental Table S1. Flow cytometry
data was acquired on a FACSCanto II or LSRFortessa (BD Biosciences) and ana-
lyzed with FlowJo software (version 10.0.8r1; Treestar Inc, Ashland, OR)
T Cell Receptor Sequencing
Unsorted cells from 3 CMV-speciﬁc VST products were examined by
high-throughput deep T cell receptor (TCR) sequencing using multiplex PCR
targeting the complementarity-determining region 3 to determine T cell
receptor gene rearrangement (Adaptive Biotechnologies). Analysis of the
sequencing output was performed using the ImmunoSEQ analyzer (Adaptive
Biotechnologies) to identify productive unique Vb gene sequences.
Administration of VST Products as Part of a Clinical Trial
Allogeneic HSCT patients with persistent or recurrent CMV, EBV, or AdV
replication or tissue infection after failure of standard antiviral therapy were
treated with third-party VST products in a multicenter, phase I, clinical trial.
Patients were monitored for 12 months from the ﬁnal infusion of VST for evi-
dence of clinical and virological response, toxicity, and immune cell recovery.
Inclusion and exclusion criteria, trial methodology, and results have been
published previously [1].
Statistical Analysis
Continuous variables with non-Gaussian distributions were compared
using a Wilcoxon matched-pairs signed rank test to determine signiﬁcance
for paired comparisons, and a Mann-Whitney test to determine signiﬁcance
for unpaired comparisons. Statistical analysis was performed using Prism 7
for Mac (GraphPad Software Inc, La Jolla, CA).
RESULTS
Considerations for Donor Selection
With the aim to inform our third-party donor selection pro-
cess and to maximize HLA coverage, we analyzed 146 HSCT
patient HLA types from our institution between 2006 and
2011. The top 15 HLA antigen frequencies are represented by
the black bars in Figure 1A. Using this information, HLA cover-
age could be predicted for various HLA antigen combinations.
Recruitment of an HLA-A*02 donor would be expected to allow
provision of a suitable single antigen match virus-speciﬁc
product to 48% of HSCT recipients. The addition of a product
from a donor expressing HLA-A01* increased the projected
coverage to 71%, and the addition of HLA-A24* to 82%. Donors
expressing less common antigens produced smaller incre-
ments in coverage. In addition, donors with certain HLA-anti-
gen restrictions did not improve coverage due to high
frequency groupings of some antigens inherited as a haplotype
(eg HLA-A*01 and -B*08). An important consideration was
whether products from donors selected on the basis of com-
mon HLA antigens would yield products that exert their antivi-
ral activity (demonstrate immunodominant T cell responses)
through the antigen of interest [14], and whether we had the
means to assess for antiviral activity through particular HLA
restrictions using commercially available tetramers or epitopes
for mapping. With these considerations in mind, modelling
suggested donors expressing 6 core HLA antigens (HLA A*01,
A*02, A*24, B*07, B*08, B*35) would result in coverage of at
least 90% of local HSCT recipients, as shown in Figure 1B. We
preferentially approached HSCT donors expressing these 6
HLA antigens where possible, as well as HLA-DRB1*0301 and
!DRB1*0701, given the high frequency of these antigens and
likelihood of generating adenoviral responses restricted
through these HLA antigens [15]. A total of 30 donors (median
age 39 years, 70% men) donated either HSC or venous blood to
generate 46 VST products. The third-party donor HLA types,
cell source, and antiviral speciﬁcity of the products generated
are reported in Table 1. As shown in Figure 1A, the top 15 HLA
antigen frequencies in the historical cohort were well repre-
sented by the HLA types of VST products (as shown by gray
bars) included within the third-party bank. The overrepresen-
tation of antigens HLA-A*01, B*08, and DRB1*03 resulted from
the presence of a common haplotype expressing these anti-
gens that was observed in 16% of the donor cohort.
Third-Party Donor Assessment
In an effort to streamline the creation of the bank by limit-
ing workload and cost associated with the screening of de-
novo donors, the majority (24 of 30) of donors were recruited
at the time of G-CSF!primed apheresis for HSC collection
intended for a related recipient. Family donors were only
recruited for the third-party bank if they satisﬁed the more
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rigorous criteria required for unrelated donation. Donor
assessment was performed as per the Therapeutic Goods
Administration cellular therapy standard for donor selection
and testing (transition to Therapeutic Goods order number 88)
and included donor questionnaire, interview, physical exami-
nation, and infectious disease testing performed within 7 days
of donation. The latter included: anti-human immunodeﬁ-
ciency virus (HIV)-1, anti-HIV-2, anti-hepatitis C virus, hepati-
tis B virus (HBV) surface antigen, human T-lymphotropic
virus-1/2 antibodies, Treponema pallidum (syphilis) serology,
and nucleic acid testing for HIV, hepatitis B virus, and hepatitis
C virus. Donors expressing common HLA antigens were ini-
tially targeted based on published HLA-restricted immunodo-
minant T cell responses against CMVpp65, EBV BZLF1/EBNA-1/
LMP2A, or AdV5 hexon [14]. Donor CMV and/or EBV seroposi-
tivity were conﬁrmed before product generation; however,
AdV seropositivity was assumed for all donors on the basis of
high community seroprevalence [14]. Each donor could thus
potentially generate between 1 and 3 monovalent cultures as
guided by seropositivity.
VST Manufacture and Expansion
The bank comprised 46 VSTs in total: 17 CMV-speciﬁc, 14
EBV-speciﬁc, and 15 AdV-speciﬁc T cell products. The preferred
starting material for culture was .5 to 1.0£ 109 total nucleated
cells of G-CSF!primed apheresis HSC product (representing
<2.5% of the total apheresis product donated), on the prerequi-
site that following removal of cells for VST generation the
remaining donation met a threshold of at least 2.5£ 106 CD34+
cells/kg required for the transplant recipient. We previously
reported that successful T cell expansion using viral protein vec-
tors for antigen presentation could be achieved using either
G-CSF!primed HSC product or venesected blood as a suitable
starting material [13]. However, using the current methodology
of peptide pools for antigen loading and plastic adherence to iso-
late monocytes, total cell expansion was noted to be signiﬁcantly
reduced when HSC was used as the starting material compared
with venous blood PBMCs for CMV- and AdV-speciﬁc products
(median total cell expansion of blood versus HSC-derived VST:
CMV 26 versus 2-fold, P = .0060; AdV 18 versus 1-fold, P = .0008),
as shown in Figure 2. G-CSF!stimulated HSCmaterial has a larger
Figure 1. Third-party donor selection targeting speciﬁc HLA antigens. (A) The black bars represent the 15 most frequent HLA antigens/alleles (HLA-A, -B, -DR) seen in
the historical cohort of 146 HSCT patients treated at our institution, and are compared with frequencies of the same antigen/alleles in the third-party VST bank repre-
sented by the gray bars. (B) Projected HLA coverage offered by core antigens covering each of the virus speciﬁcities is represented. Historic HSCT donors with the
highest-frequency HLA antigen where a VST product with expected antiviral activity through that HLA restriction was likely to be generated, were removed from the
donor list in a stepwise fashion, allowing calculation of the HLA coverage offered using the core HLA antigen (donor) combination.
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percentage of myeloid cells and monocytes. We hypothesized
that these cells in the G-CSF!primed HSC material may be con-
tributing to suppressed expansion in cultures [16]. The introduc-
tion of CD14+ selection (instead of plate adherence) to isolate
monocytes for maturation into moDCs for antigen loading, and
the use of the CD14-depleted fraction for co-culture signiﬁcantly
improved growth and expansion from HSC-derived cells equiva-
lent to cultures derived from venesected blood (median expan-
sion using CD14+ selection versus adherence: CMV 22 versus
2-fold, P = .0008; EBV 10 versus 1-fold, P < .0001; AdV 10 versus
1-fold, P = .0007), as shown in Figure 2. All further HSC-derived
cultures were expanded using antigen-loaded moDCs matured
from CD14+-selected monocytes cocultured with the CD14+ frac-
tion, as reported in Table 1. The average expansion for products
included in the bank was for CMV VST 23-fold (range, 3 to 52),
EBV VST 9-fold (range, 2 to 30), and AdV VST 9-fold (range, .4 to
35). VST products were cryopreserved in bags of 4 to 5£ 107
cells: enough to cover a single dose of cells (2.0£ 107 cells/m2)
for a large adult of BSA up to 2.5 m2. On average, 5 bags were
available for cryopreservation for each expanded VST.
Table 1
VST HLA Type, Source, Expansion Method, and Virus Speciﬁcity
VST ID HLA antigen/allele Source Expansion method Viral target of
products
A A B B DRB1 DRB1
SCTL 12-0018 01 02 08 51 0301 1301 Venous blood Adh CMV/AdV
SCTL 12-0019 02 03 18 18 0301 0701 G-CSF HSC Adh CMV
SCTL 12-0020 23 24 50 15 0301 1302 Venous blood Adh AdV
SCTL 12-0021 0205 11 4101 44 1305 10 Venous blood Adh CMV
SCTL 12-0022 02 02 07 13 0701 1501 G-CSF HSC Adh CMV/EBV/AdV
SCTL 12-0023 0101 1101 5701 1518 0301 1404 G-CSF HSC Adh AdV
SCTL 13-0002 01 02 08 49 0301 0401 G-CSF HSC Adh AdV
SCTL 13-0003 01 24 57 62 0701 1501 G-CSF HSC Adh AdV
SCTL 13-0004 01 02 41 44 0401 1302 G-CSF HSC Adh EBV
SCTL 13-0005 01 02 0801 4001 0301 1302 G-CSF HSC Adh CMV/AdV
SCTL 13-0006 02 32 07 55 0401 1501 G-CSF HSC Adh CMV/EBV/AdV
SCTL 13-0008 01 23 08 44 0301 0322 G-CSF HSC Adh CMV
SCTL 13-0013 01 32 08 51 1302 1501 Nonmobilized HSC Adh EBV
SCTL 13-0015 02 31 35 37 0101 0401 G-CSF HSC CD 14 CMV
SCTL 13-0017 03 29 07 44 04 15 Venous blood Adh CMV
SCTL 13-0019 02 02 46 60 9 11 Venous blood Adh CMV
SCTL 13-0021 01 03 07 08 0301 1501 G-CSF HSC CD 14 EBV
SCTL 13-0023 0301 2402 0801 4501 0301 0701 G-CSF HSC CD 14 AdV
SCTL 13-0024 02 03 5701 1501 0701 1301 G-CSF HSC CD 14 EBV
SCTL 13-0026 02 02 2705 1501 0103 1501 G-CSF HSC CD 14 EBV
SCTL 13-0028 0201 3301 3508 1402 080302 1201 G-CSF HSC CD 14 EBV
SCTL 13-0029 0206 2402 3501 1501 1202 1506 G-CSF HSC CD 14 CMV/EBV/AdV
SCTL 14-0002 02 03 07 51 0101 1501 G-CSF HSC CD 14 AdV/EBV
SCTL 14-0003 23 24 07 44 1454 1501 G-CSF HSC CD 14 CMV/EBV/AdV
SCTL 14-0004 0101 3201 0801 5001 0701 0701 G-CSF HSC CD 14 CMV/EBV/AdV
SCTL 14-0005 01 02 08 44 0301 0401 G-CSF HSC CD 14 EBV
SCTL 14-0006 01 02 08 44 0301 0401 G-CSF HSC CD 14 CMV/EBV
SCTL 14-0007 01 31 08 4001 0101 0301 G-CSF HSC CD 14 CMV/AdV
SCTL 14-0008 24 34 56 60 0403 1501 G-CSF HSC CD 14 CMV/AdV
SCTL 14-0010 01 02 08 13 0301 1501 G-CSF HSC CD 14 CMV
Adh indicates plate adherence.
Figure 2. VST expansion. Comparison of CMV-, EBV-, and AdV-speciﬁc VSTs expanded from venous blood, or mobilized HSCs with monocytes depleted by plastic
adherence or CD14+ selection. Bars and whiskers represent the median fold expansion (total viable cell count at culture harvest divided by viable cell count at culture
initiation) and 25th and 75th percentiles, respectively. Signiﬁcance was determined using a Mann-Whitney test. The ﬁgure includes expansion data from VST prod-
ucts excluded from the ﬁnal bank due to poor expansion and/or antiviral response.
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Immunophenotype of VST Products
All VST products consisted predominantly of CD3+ T cells
with a variable composition of CD8+ and CD4+ T cells (median
CD8+ versus median CD4+; CMV 52 versus 33%, EBV 36 versus
49%, AdV 29 versus 68%, respectively) as shown in Figure 3A.
The percentage of CD8+ T cells was higher than the percent-
age of CD4+ T cells in 11/17 CMV, 6/14 EBV, and 7/15 AdV VST
products. The contribution of B cells and monocytes was negli-
gible. Individual VST immunophenotypes are provided in
Table 2. Immunophenotyping investigating expression of T cell
memory and immunoinhibitory markers was performed on a
subset of 11 VST products (10 CMV-speciﬁc and 1 EBV-speciﬁc
product). Products were comprised of predominantly effector
memory (CD45RA¡62L¡) and terminal effector (CD45RA+62L¡)
T cells, although central memory (CD45RA¡62L+) and na€ıve
(CD45RA+62L+) cells were also present in small numbers. T cell
effector memory cells constituted a signiﬁcantly lower per-
centage of the CD8+ than CD4+ T cell subset (median 50%
[range, 22% to 87%] versus median 85% [range, 47% to 97%];
P = .0029). T cell terminal effector cells constituted a signiﬁ-
cantly higher percentage of the CD8+ than CD4+ T cell subset
(median 33% [range, 13% to 73%] versus 3% [range, 1% to 18%];
P = .0010). The immunoinhibitory markers PD-1+ and TIM-3+
were not signiﬁcantly elevated on CD8+ T cells when compared
with control PBMCs from healthy donors at steady state
(median CD8+PD-1+ 5.4% versus control 9.2%, median
CD8+TIM-3+ 2.1% versus control 0.4%; P > .05). However, these
markers were elevated on the CD4+ subset (median CD4+PD-1+
33.9% versus control 3.7%, P = .0005; median CD4+TIM-3+ 3.9%
versus control 0.1%, P = .0005). Expression of T cell memory
subsets and immunoinhibitory markers are shown in
Figure 3A.
Antiviral Activity and HLA-Restriction and HLA Coverage
Offered by VST Products
Class I MHC tetramers were used to map CMV speciﬁcity
restricted by the following CMV pp65 epitopes: HLA-A*0201
(NLVPMVATV, 4-35% of T cells n = 10), HLA-B*0702
(TPRVTGGGAM, 4-53% of T cells n = 3), HLA-A*2402 (QYDP-
VAALF, 0.2-6% n = 2) and HLA-B*3501 (IPSINVHHY, 4-30%
n = 2). CMVpp65 functional responses were additionally
mapped to HLA-A*0101, B*4402, DRB1*01, DRB1*04, DRB1*15
based on IFNg production in response to stimulation with a vari-
ety of individual epitopes restricted through these HLA anti-
gens/alleles. EBV and AdV functional responses were mapped
by IFNg production in response to stimulation with either indi-
vidual or pooled epitopes restricted through: HLA-A*0201,
A*2402, B*0702, and B*0801 HLA-B40 for EBV BZLF1/LMP2A/
EBNA-1 proteins; and A*0101, A*0201, A*2402 B*0702, B*3501,
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, and
DRB1*1501 for AdV5 hexon. In 24 of 46 (52%) products, mapped
responses were restricted through more than 1 HLA antigen.
Representative examples of mapped responses through multi-
ple HLA antigens are presented in Figure 3C. Unmapped
responses were accounted for by testing VST for overlapping
peptide mix!stimulated IFNg production, as not all HLA anti-
gens have commercial tetramers/epitopes available to test HLA-
restricted responses. HLA-restricted and unmapped antiviral
activity for all VST products is shown in Table 2.
VST TCR Sequencing
Three CMV-speciﬁc VST products (12-0022, 13-0015, 13-
0019) were analyzed for T cell receptor sequencing. VST
12-0022 was identiﬁed to contain 4 previously reported public
clones with CMV activity mapped to HLA-A*0201 and HLA-
B*0702 as shown in Supplementary Table S2. Products were
polyclonal, but the top 20 TCR clones contributed to between
63% to 87% of the overall TCR repertoire of each product as
shown in Supplementary Figure S1.
Using the known HLA-restricted antiviral activity of the
bank and the low resolution HLA typing from 146 historical
transplant patients, we were able to model the HLA coverage
offered by the bank. We predicted that bank VST products
would provide coverage to 96% of CMV-infected patients, and
this ﬁgure was conﬁrmed in practice. A suitable HLA-matched
VST product was identiﬁed for 28 of 29 CMV-speciﬁc product
requests. Predicted coverage at low HLA resolution was 90%
for EBV, and 97% for AdV (requests for EBV- and AdV-speciﬁc
products were too few to provide numbers for actual cover-
age). Of interest, despite the availability of VST with CMV or
AdV activity restricted through HLA-DRB1*1 and DRB1*4, addi-
tion of these antigens did not improve predicted coverage due
to co-inheritance with other higher frequency antigens already
represented in the model.
Efﬁciency of HLA Targeted Donors
The probability of generating a product with antiviral activ-
ity through the speciﬁc HLA antigens for which donors had
been targeted was variable as shown in Table 3.
CMV-speciﬁc responses restricted through HLA-A*01, A*24,
B*07, and B*35 were possible from most targeted donors. An
HLA-B*44 restricted response was identiﬁed in 1 of 5 B*44
donors. HLA-class II-restricted CMV pp65 epitope responses
were seen in addition to HLA-class I restricted responses in a
number of donors. HLA class II restricted responses were seen
most frequently in VST generated from DRB1*01 and *04
donors, and occasionally in VST generated from DRB1*15
donors.
Restricted activity for EBV was reliably generated from
HLA-A*02, A*24, and B*08 donors particularly after the intro-
duction of the CD14+ selection step, but VST responses from
HLA-B*07 donors were more variable (although donor num-
bers were small). Of 2 donors, only a single HLA-B*35
(B*3508)-restricted response was seen.
Adenoviral activity restricted through HLA-A*01, B*07,
B*35, DRB1*01, DRB1*07, and DRB1*15 occurred for most tar-
geted donors. An HLA-A*02-restricted AdV response was gen-
erated from a single HLA-A*0206 donor; the remaining 6
donors did not generate an HLA-A*02 mapped response. Ade-
noviral responses for HLA-A*24, DRB1*03 and *04 were
mapped in 33% to 50% donors.
Choice of Product
Banked VST products were available from 2013 onward.
Patient and the HSCT donor HLA type were used to facilitate the
best possible VST-recipient matching. Considerations for match-
ing included the virus being targeted, the type and match of the
prior HSCT transplant, the number of matching HLA antigens
between VST and recipient (a minimum of 1 of 6 HLA antigen
[HLA-A, -B, -DR] match was required), and the HLA restriction
of antiviral activity. Preference was given to the VST with the
highest number of HLA matches and consideration of mapped
antiviral activity through shared HLA antigens. Matching was
generally straightforward for patients who had undergone a
fully HLA-matched stem cell transplant. However matching for
haploidentical transplant patients required careful consider-
ation of the recipient and HSCT donor HLA type. Matching opti-
mally involved the choice of a VST expressing at least 1 HLA
antigen shared with both the recipient (tissue-expressed HLA
type) and HSCT transplant donor (hematopoietic-expressed
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Figure 3. VST phenotype and functional antiviral responses. (A) Percentage of total cells expressing CD3+, CD4+, CD8+, and CD3¡56+ (natural killer) for CMV-, EBV-,
and AdV-speciﬁc VSTs. Bars and whiskers represent the median and 25th and 75th percentiles, respectively. (B) Percentage of CD8+ and CD4+ expressing T cell mem-
ory or immunoinhibitory subset markers in 10 CMV-speciﬁc and 1 EBV-speciﬁc VST products (SCTL 12-0022, 13-0006, 13-0008, 13-0019, 13-0029 [EBV], 14-0003,
14-0004, 14-0006, 14-0007, 14-0008, 14-0010). T cell memory subsets were deﬁned as T terminal effector (CD45RA+62L¡), T na€ıve (CD45RA+62L+), T central memory
(CD45RA¡62L+), and T effector memory (CD45RA¡62L¡). Bars and whiskers represent the median and 25th and 75th percentiles, respectively. For the T cell memory
subset, comparisons signiﬁcance was determined using the Wilcoxon matched-pairs signed rank test. For the T cell immunoinhibitory marker expression, compari-
son between VSTs and healthy control cells, signiﬁcance was determined using a Mann-Whitney test. (C) Representative examples of VST products with speciﬁcity
demonstrated through multiple HLA restrictions. CMVpp65 speciﬁcity for VST 12-0022 was restricted through 2 HLA antigen/alleles as demonstrated by HLA-A*0201
NLVPMVATV and HLA-B*0702 TPRVTGGGAM iTAg MHC class I human tetramer expression (% of total cells). The antiviral activity of AdV-speciﬁc VST 12-0022 was
demonstrated by IFNg production (% of CD3+ cells) in response to stimulation with AdV5 hexon overlapping peptide pool, and IFNg responses to multiple individual
HLA-DRB1*07 and *15-restricted epitopes.
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Table 2
VST Phenotype and (HLA-Restricted) Antiviral Activity
CMV products
VST ID
Immunophenotype iTAG MHC Class I
CMV PP65!Speciﬁc Tetramer
(% of Total Cells)*
HLA-Restricted
Epitope IFNg
Response Detected*
CMV PP65 IFNg Response
CD3 (% of
Total Cells)
CD8 (%
of CD3)
CD4 (%
of CD3)
NK (% of
Total Cells)
% of CD3 % of CD8 % of CD4
SCTL 12-0018 96 70.5 25.6 3.2 A2 NLV 8% A1 YSE 6.4 2.9 14.4
SCTL 12-0019 93.6 79.4 16.6 2.1 A2 NLV 31% 6.4 6.6 4.5
SCTL12-0021 94.7 39 27.3 4.9 B44 SEH 1.3 1.3 1.4
SCTL12-0022y 98.7 31.7 59.6 0.7 A2 NLV 24%, B7 TPR 23% NT NT NT
SCTL 13-0005y 98 62.3 33 0.9 A2 NLV 19% A1 YSE 9.5 14.2 15.6
SCTL 13-0006y 96.4 75.7 20.3 3.3 A2 NLV 12% 4.6 5.8 6.2
SCTL 13-0008y 88.8 29.7 64.9 9.2 A1 YSE 10.0 5.2 16.0
SCTL 13-0015y 98.2 63 30.1 1 A2 NLV 4%, B35 IPS 30% DR1 KYQ, DR4 IIK 6.9 8.3 2.8
SCTL 13-0017 97.7 15.2 15.8 1.8 B7 TPR 4% DR4 ILK, DR15 LLQ 1.8 6.4 8.2
SCTL 13-0019y 98.5 51.8 39.4 1.5 A2 NLV 15% 8.4 5.4 10.7
SCTL 13-0029 99.4 81.7 14.5 0.3 A2 NLV 5%, A24 QYD 0.2%, B35 IPS 4% NT NT NT
SCTL 14-0003y 99 71.1 17.7 0.1 B7 TPR 53% DR15 LLQ 14.9 9.7 37.4
SCTL 14-0004y 98.3 14.6 82.4 1.2 A1 YSE 4.6 1.7 6.6
SCTL 14-0006y 99.4 32.3 61.1 0.5 A2 NLV 26% A1 YSE, DR4 IIK 8.2 6.1 10.7
SCTL 14-0007y 99.3 23.8 69.3 0.4 A1 YSE, DR1 KYQ 17.0 0.4 34.5
SCTL 14-0008y 96.2 54.6 38 1.6 A24 QYD 6% DR4 IIK 16.7 15.2 21.1
SCTL 14-0010y 98.9 48.6 45 0.2 A2 NLV 35% 11.4 25.1 3.6
EBV products
VST ID
Immunophenotype HLA-Restricted Epitope IFNg
Response Detected*
EBV BZLF1/LMP2A/EBNA-1 Pooled IFNg Response
CD3 (% of
Total Cells)
CD8 (%
of CD3)
CD4 (%
of CD3)
NK (% of
Total Cells)
% of CD3 % of CD8 % of CD4
SCTL 12-0022 98.7 31.7 59.6 0.9 No epitope response identiﬁed on testing 4.5 4.1 0.0
SCTL 13-0004 95.1 72.7 24.6 3.9 No epitope response identiﬁed on testing 17.2 15.7 1.1
SCTL 13-0006 83.9 17.6 74 14.3 No epitope response identiﬁed on testing 0.1 0.1 0.0
SCTL 13-0013 98.9 40.2 54.6 0.3 B8 RAK 0.3 0.5 0.4
SCTL 13-0021 98.6 29.2 46.1 0.2 B8 RAK 5.9 4.9 11.3
SCTL 13-0024 98.4 50.6 17.3 0.3 A2 FLY/CLG 6.2 4.6 8.2
SCTL 13-0026 92.4 42.5 40.4 0.9 A2 CLG 3.0 2.1 1.8
SCTL 13-0028 94.4 63.4 5.2 3.8 A2 FLY/QLL/LLS/LTA, B35 HPV 5.2 6.1 3.6
SCTL 13-0029y 99.2 61.4 27.2 0.2 A24 TYG 6.3 8.6 3.0
SCTL 14-0002 95.3 37.1 52.2 1 A2 pooled 0.9 1.4 0.5
SCTL 14-0003 96.2 34.8 12.3 0.2 A24 TYG, B7 IPQ 0.8 0.6 0.6
SCTL 14-0004 98.4 30.2 60.5 0.8 B8 RAK 0.1 0.0
SCTL 14-0005 95.4 19.4 58.2 3 A2 FLY, B8 RAK 0.5 0.4 1.2
SCTL 14-0006 98.9 21.3 64.4 0.7 A2 CLG, B8 RAK 6.5 7.6 8.4
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HLA). This was not possible in the case of 2 patients requiring
CMV-speciﬁc T cells. The choice was made to match with the
recipient (patient) HLA type based on the presumption that
infection would be best treated using VST responding to viral
antigen presented on infected recipient tissue.
The following criteria were required to be met before VST
release: negative bacterial and fungal contamination testing at
5 days, negative mycoplasma PCR, post-thaw viability of at
least 50% as assessed by trypan blue exclusion on light micros-
copy, and immunophenotypic assessment to ensure both
CD19+ and CD14+ percentages were <2%. Cryopreserved VSTs
were transported using already established HSC product trans-
port procedures, including use of a validated dry shipper with
a temperature data logger, and written instructions on thaw
and infusion procedures. VST products were shipped locally,
interstate and to New Zealand, with the majority of products
available for infusion within 3 days of VST request. The major-
ity of VST administration occurred in the outpatient setting,
requiring only a short period of postinfusion observation.
Clinical Response to VSTs
We recently reported the clinical outcomes of 30 allogeneic
HSCT patients treated with 50 third-party VST infusions for
persistent or recurrent CMV, EBV, or AdV replication or tissue
infection after failure of standard antiviral therapy [1]. Prod-
ucts from 15 VST donors (14 from the VST bank, and 1 multiva-
lent VST product retained from a prior clinical study [17]) were
utilized due to common shared HLA types across participants.
Of the 14 products used, 12 were CMV speciﬁc (used for 48
separate infusions), 1 was EBV speciﬁc, and 1 was AdV speciﬁc.
The top 7 most frequent HLA antigens matched between VST
and patient were HLA-A*02 and A*01, B*08, B*07, DRB1*0101,
DRB1*0301, and DRB1*0701. The HLA antigens with mapped
antiviral activity matched in order of frequency were HLA-
A*02 and A*01, DRB1*0101, B*07, B*35, DRB1*04, and A*24.
Third-party VST product infusion was shown to be safe and
effective. Complete responses occurred in 1 patient with AdV
infection and 22 patients with CMV reactivation (including 3
with CMV disease). Partial responses occurred in 5 patients
with CMV reactivation, and 2 patients had no response (1 with
CMV infection, 1 with EBV infection). Patients with partial or
no response received CMV-speciﬁc VSTs with mapped activity
through HLA-A*01 or A*02 apart from 1 product with HLA-
B*35 and DRB1*0101 speciﬁcity. One patient with no response
received an EBV-speciﬁc VST with mapped activity through
HLA-A*24. Clinical outcomes did not appear to correlate with
individual product characteristics such as CD8, CD4, orTa
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Table 3
Efﬁciency of VST Product HLA Restriction According to Donor HLA Expression
HLA Antigen HLA Antigen!Targeted Donors Generating VSTs
Mapped to the Target Antigen
CMV EBV AdV
A*01 88 (8) — 63 (8)
A*02 100 (10) 70 (10) 14 (7)
A*24 75 (4) 100 (4) 50 (6)
B*07 75 (4) 20 (4) 80 (5)
B*08 — 83 (6) —
B*35 100 (2) 50 (2) 100 (1)
B*44 20 (5) — —
DRB1*01 100 (2) 100 (2)
DRB1*03 43 (7)
DRB1*04 80 (5) 33 (3)
DRB1*07 100 (4)
DRB1*15 33 (6) 70 (10)
Values are % (n).
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tetramer positive T cell composition; of 7 VST products admin-
istered to partial or nonresponding patients, 6 products were
administered to multiple patients with both complete and par-
tial/nonresponse outcomes seen with each product.
DISCUSSION
The efﬁcacy of HSCT donor-derived virus-speciﬁc T cells in
the prophylaxis and treatment of viral infection following
HSCT is well established [7, 11, 18-25], but the treatment has
not yet become established as part of routine post-transplant
care. One of the likely barriers arises from perceived inefﬁ-
ciency due to the individualized nature of the therapy. In addi-
tion, a VST product can only be generated if the donor cells are
available and the donor is seropositive for the virus of interest.
Furthermore, even if a product is made at the time of stem cell
donation, manufacturing lag time may delay product availabil-
ity in the case of early post-transplant infection.
A number of these barriers have been overcome with the
advent of third-party cryopreserved VST therapy. Third-party
VSTs have shown promise as an effective and durable treat-
ment for viral infection post-stem cell transplant despite only
partial HLA matching between VST product and recipient. Infu-
sion appears to be safe without an increased incidence of
graft-versus-host disease [2, 3, 5-12, 15]. It is expected that a
number of third-party VST banks will need to be established
worldwide to make this therapy an option for all HSCT
patients. Exactly how these banks should be constructed and
what characteristics of banked products are most advanta-
geous is unclear.
A particularly desirable attribute of therapy using third-
party VST banks is the reduced requirement for HLA matching
between product and recipient. In contradistinction to banks
of hematopoietic progenitor cells that must contain large num-
bers of products to provide a reasonable chance of HLA match-
ing, data from a number of studies conﬁrm the efﬁcacy of
partially HLA-matched third-party VSTs. We utilized the fre-
quency of HLA types in our HSCT population to direct the
recruitment of donors for our bank. Despite the fact that we
treat a multiethnic patient population that is highly HLA poly-
morphic, we identiﬁed several key HLA antigens to target in
constructing the VST bank. For all 3 viruses we targeted, our
model suggested that inclusion of VST products acting through
only 6 common HLA antigens would provide coverage to over
90% of HSCT recipients requiring therapy. Our clinical results
have been achieved using third-party VST to treat mainly CMV
infection and clinical validation of the utility of a bank of VSTs
with limited HLA type would be necessary to conﬁrm our sug-
gested approach in other opportunistic infections. Targeting
additional HLA antigens is valuable though the incremental
beneﬁt reduces with each additional antigen. This model could
be employed by other centers to tailor donor recruitment and
bank characteristics to local HLA demographics using the mini-
mum number of donors required for the desired level of cover-
age, particularly if high-efﬁciency donors are targeted.
In practice, we recruited 30 donors and used products from
14 in a study in which we administered 50 infusions to treat
30 HSCT recipients with recurrent viral infections post-trans-
plant. Requests were predominantly for CMV-speciﬁc products
and multiple donors were required to replenish the bank with
HLA-A*01! and A*02!speciﬁc VSTs, which accounted for the
majority of mapped antiviral activity and matching. Only 15 of
the 50 infusions administered (in 11 patients) utilized products
not based on a match at either an HLA-A*01 or *02 antigen.
Class I HLA typing of the sibling donors used to set up the bank
was low resolution at the time the bank was established.
Despite this, we have reported high overall response rates and
a low incidence of graft-versus-host disease [1] following
treatment with the VST products described here, in keeping
with a number of other groups using different methodologies
and higher-resolution HLA matching [2, 3, 7, 8, 10, 11, 18].
Recruiting HSCT donors rather than normal individuals saved
time and costs as donor screening, work-up, and infectious dis-
ease testing were readily available at the time of consent. How-
ever, we amended local criteria for family donor testing
to reﬂect the fact that banked cells would be administered to
unrelated recipients. Regulatory requirements would need to
be assessed in each jurisdiction in which third-party banks are
established.
Our choice of overlapping peptide mixtures for antigen
loading on autologous moDCs was based on safety (low infec-
tious potential), efﬁciency, cost, and manufacturing timelines
[26]. Donation of a small portion of cells at the time of related
HSC donation in principle allowed for the generation of up to 3
VST products dependent on virus seropositivity. A CD14+
depletion step was added for all cultures derived from G-
CSF!mobilized HSCs following a series of poorly expanding
cultures. Robust expansion of CMV-, EBV-, and AdV-speciﬁc T
cells was achieved, though the generation of VSTs with speci-
ﬁcity for EBV and AdV was less reliable, and multiple donors
were required. Unlike CMVpp65, which stimulates predictable
T cell responses to a small number of immundominant anti-
gens, T cell responses to EBV proteins can be unpredictable
and occur in response to a broad range, of subdominant anti-
gens [14]. Whereas the use of LCLs to generate EBV VSTs ena-
bles exposure to all relevant antigens, at the time of bank
establishment there was limited availability of GMP-grade
EBV-overlapping peptide mixtures, which hampered the
efﬁciency of EBV-speciﬁc VST production. The recent
release of a GMP-grade EBV consensus peptide pool (PepTi-
vator EBV Consensus, Miltenyi Biotec) containing peptides
from 13 different EBV proteins restricted through a variety
of HLAs may resolve this issue and in our laboratory has
led to products exhibiting expanded epitope responses
(unpublished data).
Products were polyclonal on TCR sequencing with a small
number of dominant antigen!responsive clones, and many
small clones with no evidence of clinically relevant alloreactiv-
ity. As previously demonstrated in the generation of virus-spe-
ciﬁc T cells from normal donors, the products in our bank were
of both CD4 and CD8 type at various stages of T cell differentia-
tion. CD8+ T cells showed a higher percentage of terminal dif-
ferentiation. The CD4+ T cell subset showed increased
expression of PD-1 and to a lesser extent TIM-3. Despite the
fact that clinical trials with third-party VSTs have shown clear
efﬁcacy, the relevance of these phenotypic changes is unclear
and there remains insufﬁcient information correlating viral
response with product characteristics.
We present a streamlined and efﬁcient process for the
establishment of a third-party VST bank where a limited
number of donors can be utilized to create a bank of products
with broad HLA coverage using already-established local
HSCT practices and processes. With an understanding of local
HLA antigen frequencies, efﬁciency of targeted HLAs and
using the optimized overlapping peptide method the number
of donors required could likely be signiﬁcantly reduced. The
procedures we outline are within the capacity of most
medium-to-large Bone Marrow Transplantation programs
suggesting the feasibility of local banking of VSTs with the
opportunity for enhanced incorporation into routine trans-
plantation practice.
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Supplemental Data for “Establishment and Operation of a Third-Party Virus-Specific 
T Cell Bank within an Allogeneic Stem Cell Transplant Program”  
Supplementary Table S1. MHC tetramers and peptides  
 
MHC tetramers (CMV pp65) 
Epitope HLA restriction 
NLVPMVATV A*0201 
IPSINVHHY B*3501 
TPRVTGGGAM B*0702 
QYDPVAALF A*2402 
 
Virus/Protein Epitope Position HLA restriction 
CMV pp65 ACTSGVMTRGRLKAE 445-459 DRB1*01 
 AGILARNLVPMVATV 489-503 DRB1*11 
 CEDVPSGKL 232-340 B*4001 
 CPSQEPMSIYVY 103-114 B*35 
 DANDIYRIF 516-524 B*0801 
 HPTFTSQYRIQGKLE 366-380 DRB1*11 
   DRB1*13 
 IIKPGKISHIMLDVA 281-295 DRB1*04 
   DRB1*07 
 IPSINVHHY 123-131 B*3501 
 KYQEFFWDANDIYRI 509-523 DRB1*03 
 LLQTGIHVRVSQPSL 41-55 DRB1*15 
 NLVPMVATV 495-503 A*0201 
 QYDPVAALF 341-349 A*2402 
 RPHERNGFTV 265-274 B*0702 
 SEHPTFTSQY 364-373 B*44 
 TPRVTGGGAM 417-426 B*0702 
 VYALPLKML 113-121 A*2402 
 YSEHPTFTSQY 363-373 A*0101 
    
EBV BZLF1 APQPAPENAY 77-86 B*3501 
   B*3508 
 EPLPQGQLTAY  54-64 B*3501 
   B*3508 
 LPCVLWPVL 44-52 B*0702 
 LPEPLPQGQLTAY 52-64 B*3501 
   B*3508 
 QLLQHYREV 195-203 A*0201 
 RAKFKQLL 190-197 B*0801 
 SENDRLRLL 209-217 B*4002 
EBV EBNA1 FMVFLQTHI 562-570 A*0201 
 IPQCRLTPL 528-536 B*07 
 RPQKRPSCI 72-80 B*07 
 HPVGEADYFEY 407-417 B*35 
EBV LMP2A CLGGLLTMV 426-435 A*0201 
 CPLSKILL 345-352 B*08 
 FLYALALLL 356-354 A*0201 
 IEDPPFNSL 200-208 B*40 
   B*60 
 LLSAWILTA 447-455 A*0203 
 LTAGFLIFL 453-461 A*0206 
 PYLFWLAAI 131-139 A*2301 
   A*2402 
 RRRWRRLTV 236-244 B*27 
 SSCSSCPLSK 340-349 A*11 
 TYGPVFMCL 419-427 A*2402 
    
AdV Hexon ATETYFSLNNKFRNP 34-48 DRB1*15 
 ATFFPMAHNTASTLE 617-631 DRB1*04 
 DPYYTYSGSIPYLDG 696-710 DRB1*07 
 ENGWEKDATEFSDKN 436-450 DRB1*04 
 EWNFRKDVNMVLQSS 582-596 DRB1*03 
 EYLSPGLVQFARATE 22-36 DRB1*15 
 FKKVAITFDSSVSWP 718-732 DRB1*07 
 GASIKFDSICLYATF 605-619 DRB1*03 
 GNNFAMEINLNANLW 455-469 DRB1*04 
 GLRYRSMLL 542-550 A*02 
 GTAYNALAPKGAPNP 118-132 DRB1*01 
 GTFYLNHTFKKVAIT 78-92 DRB1*15 
 GWAFTRLKTKETPSL 677-691 DRB1*04 
 GYDPYYTYSGSIPYL 694-708 DRB1*07 
 IPYLDGTFY 705-713 B*35 
   B*53 
 KPYSGTAYNAL 114-124 B*0702 
 LLYANSAHAL 892-901 A*02 
 LMYYNSTGNMGVLAG 336-350 DRB1*07 
 LPGSYTYEW 575-583 B*5301 
 MPNRPNYIAF 250-259 B*07 
   B*35 
 MPNRPNYIAFRDNFI 167-181 DRB1*04 
   DRB1*07 
 PGSYTYEWNFRKDVN 576-590 DRB1*04 
 QWSYMHISGQDASEY 9-23 DRB1*01 
 SQWYETEINHAAGRV 209-223 DRB1*04 
 TDLGQNLLY 886-894 A*01 
 TETLTKVKPKTGQEN 423-437 DRB1*01 
 TGNMGVLAGQASQLN 342-356 DRB1*01 
 THDVTTDRSQRLTLR 53-67 DRB1*03 
 TLRFIPVDREDTAYS 65-69 DRB1*04 
 TYFSLNNKF 37-42 A*2402 
 VDCYINLGARWSLDY 514-528 DRB1*01 
 WSYMHISGQDASEYL 10-24 DRB1*01 
 YFSLNNKFRNPTVAP 38-52 DRB1*15 
 YVLFEVDV 917-925 A*02 
 YYTYSGSIPYLDGTF 698-712 DRB1*07 
Table S2. Top 20 TCR clonotypes and public TCR sequences  
SCTL 12-0022 SCTL 13-0015 SCTL13-0019 
% of total 
TCR 
templates 
Amino acid sequence % of total 
TCR 
templates 
Amino acid sequence % of total 
TCR 
templates 
Amino acid sequence 
13.74 CASSSHDSQGSSSPLHF 32.48 CASSPETAAHSGNTIYF 11.60 CASSYATGTAYGYTF 
9.41 CASSPSVTSVLYEQYF 20.79 CASSSGTAPNEKLFF 9.69 CASSGYYGYTF 
8.33 CASSPQTGTGGYGYTF 9.88 CASSYSPLVPGQGSNTEAFF 7.61 CASSFQGRGASPLHF 
7.69 CASSSANYGYTF 8.24 CASSTSGGPNEKLFF 4.75 CASSEAGAGTYEQYF 
6.91 CASSYDYEQYF 3.39 CASSPGSLFYGYTF 4.11 CASSQERRSNQPQHF 
4.66 CASSSANYGYTF § 2.57 CASSGQGGPNEKLFF 3.14 CASSYSTGTPASYTF 
4.44 CASSQDRPPTGTANTEAFF 1.92 CASSLGGPGDTQYF 2.81 CASSRTSGGYTGELFF 
4.34 CASSDGTRYEQYF 1.72 CASSVAGLAASGDTQYF 2.35 CASSSLTAWNIQYF 
3.36 CASSFRDRGRYEQYF 1.26 CASSPSTEPNEKLFF 2.11 CSASEVVASGGTYEQYF 
2.50 CASSYQTGASYGYTF‡ 0.85 CASSQAVAQGRAGEKLFF 2.02 CASSLVGQPQHF 
2.35 CASSSQTGTSYGYTF 0.67 CASSLGGPGDIQYF 1.98 CASSSAGTRKYF 
2.16 CASSVDSGQRTKLNSPLHF 0.66 CASARTGTEAFF 1.62 CASSAPGQGRYEQYF 
1.84 CASSLESSGPQETQYF 0.63 CASSISQGSTEAFF 1.39 CASSQGLAAPSVETQYF 
1.83 CASSVVNEQFF** 0.51 CSARNGGRNQPQHF 1.30 CASSPQTGTLYGYTF 
1.81 CASSNRDLGDYEQYF 0.38 CASSRTGAEAFF 1.24 CASSHGEGRYEQYF 
1.70 CASSLIGVSSYNEQFF† 0.32 CASSPGWEEKLFF 1.19 CASSYFPLGDGYTF 
1.27 CASSLKGISSYNEQFF 0.31 CASSPPAGTNYGYTF 1.18 CSARLDREYSPLHF 
1.04 CASSQEGREAFF 0.29 CAWSKPRQGVYEQYF 1.14 CASALGRGDYNEQFF 
0.92 CATVTANTGELFF 0.29 CAWSVGQGNSPLHF 1.10 CASSAGLPYEQYF 
0.79 CASSAGTSGTYEQYF 0.28 CASSPLPSGANVLTF 0.81 CASSQGSIYGYTF 
Phenotype and CMV-specific iTAg™ MHC class I tetramer expression (% of total cells) 
- CD8+ 32% and CD4+ 60% 
- HLA*A201 NLVPMVATV 24% 
- HLA*B702 TPRVTGGGAM 23% 
- CD8+ 63% and CD4+ 30% 
- HLA*A201 NLVPMVATV 4%, 
- HLA*B3501 IPSINVHHY 30% 
- CD8+ 52% and CD4+ 39% 
- HLA*A201NLVPMVATV 
15% 
Abbreviations: TCR, T-cell receptor; HLA, human leukocyte antigen. 
§ Public clonotype - NLVPMVATV specific amino acid sequence (HLA-A*0201)1  
‡ Public clonotype - NLVPMVATV specific amino acid sequence (HLA-A*0201)2  
** Public clonotype - NLVPMVATV specific amino acid sequence (HLA-A*0201)2  
† Public clonotype - TPRVTGGGAM specific amino acid sequence (HLA-B*0702)3 
  
 
Supplementary Figure S1. VST T-cell receptor clonality  
T-cell receptor sequencing was performed on 3 CMV-specific VST products. The 
percentage contribution (productive frequency) for each of the top 20 T-cell clonotypes 
to the T-cell receptor repertoire for each VST product is shown 
Supplementary References: 
1.  Zvyagin IV, Pogorelyy MV, Ivanova ME, et al. Distinctive properties of 
identical twins' TCR repertoires revealed by high-throughput sequencing. Proc Natl 
Acad Sci U S A. 2014;111:5980-5985. 
2. Miconnet I, Marrau A, Farina A, et al. Large TCR diversity of virus-specific 
CD8 T-cells provides the mechanistic basis for massive TCR renewal after antigen 
exposure. J Immunol. 2011;186:7039-7049. 
3. Koning D, Costa AI, Hoof I, et al. CD8+ TCR repertoire formation is guided 
primarily by the peptide component of the antigenic complex. J Immunol. 
2013;190:931-939. 
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Key Points
• Partially HLA-matched
third-party CMV-
specific T cells provide
long-term viral control in
HSCT patients with re-
sistant CMV infection.
• Viral control occurs in
the setting of recovery
of CD81 terminally dif-
ferentiated effector
T cells.
Donor-derived adoptive T-cell therapy is a safe and effective treatment of viral infection
posttransplant, but it is limited by donor serostatus and availability and by its personalized
nature. Off-the-shelf, third-party virus-speciﬁc T cells (VSTs) appear promising, but the
long-term safety and durability of responses have yet to be established. We conducted a
prospective study of 30 allogeneic hemopoietic stem cell transplant (HSCT) patients with
persistent or recurrent cytomegalovirus (CMV) (n5 28), Epstein-Barr virus (n 5 1), or
adenovirus (n 5 1) after standard therapy. Patients were treated with infusions of partially
HLA-matched, third-party, ex vivo–expanded VSTs (total 5 50 infusions) at a median of 75
days post-HSCT (range, 37 to 349 days). Safety, viral dynamics, and immune recovery were
monitored for 12 months. Infusions were safe and well tolerated. Acute graft versus host
disease occurred in 2 patients, despite a median HLA match between VSTs and the recipient
of 2 of 6 antigens. At 12 months, the cumulative incidence of overall response was 93%.
Virological control was durable in the majority of patients; the reintroduction of antiviral
therapy after the ﬁnal infusion occurred in 5 patients. CMV-speciﬁc T-cell immunity rose
signiﬁcantly and coincided with a rise in CD81 terminal effector cells. PD-1 expression was
elevated on CD81 lymphocytes before the administration of third-party T cells and remained
elevated at the time of viral control. Third-party VSTs show prolonged beneﬁt, with
virological control achieved in association with the recovery of CD81 effector T cells possibly
facilitated by VST infusion. This trial was registered at www.clinicaltrials.gov as
#NCT02779439 and www.anzctr.org.au as #ACTRN12613000603718.
Introduction
Opportunistic infections are a significant cause of morbidity and mortality in patients who undergo
allogeneic stem cell transplantation.1,2 Routine monitoring of the herpes viruses, Epstein-Barr virus (EBV)
and cytomegalovirus (CMV), allows preemptive therapy that prevents progression to tissue disease.
However, this approach has significant drawbacks. Antiviral medications are expensive, may require
inpatient treatment, and are associated with significant toxicity. Furthermore, antivirals do not address the
underlying immune defect and, consequently, many patients require prolonged or repeated treatment.3,4
Submitted 19 August 2017; accepted 25 September 2017. DOI 10.1182/
bloodadvances.2017010223.
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Adoptive T-cell therapy with virus-specific T cells (VSTs) derived
from the hemopoietic stem cell transplant (HSCT) donor offers an
alternative approach. It appears safe and effective,5-11 but requires
the HSCT donor to be seropositive for the virus of interest. Even
when the donor is seropositive, a specific product must be made for
each transplant recipient. In contrast, third-party VSTs can be used
without full HLA matching, meaning that a single product can be
stored and used for .1 transplant recipient. A recent trial using
third-party cells from a cryopreserved bank demonstrated safety
and short-term efficacy, with a 74% cumulative overall viral
response rate at 6 weeks.12 Longer-term safety and efficacy was
not examined. We generated a bank of cryopreserved VSTs and
treated 30 patients with CMV, EBV, or adenovirus (ADV) infection
or reactivation. We monitored adverse events, viral dynamics, use of
antiviral therapy, and virus-specific immune recovery for 12 months
after infusion. The intention of our study was to validate the previous
short-term data on safety and viral control, and to assess longer-
term questions of safety and response durability.
Methods
Study design and patients
The study was conducted as a multicenter, prospective, single-arm,
phase I trial. Allogeneic HSCT patients with viral replication and/or
tissue infection with CMV, ADV, or EBV that had failed standard
therapy were eligible for recruitment. Standard therapy was defined
as: $14 days of full-treatment dose of ganciclovir or foscarnet for
CMV; therapy, which may include Cidofovir, for ADV; or immuno-
suppression reduction, rituximab, and/or cytotoxic chemotherapy
for EBV or EBV posttransplant lymphoproliferative disorder (PTLD).
Treatment failure was defined as persistent or recurrent CMV
viremia at any level; or ,50% reduction in ADV or EBV viral load or
size of EBV lymphoma. Patients were excluded in the event of active
acute graft versus host disease (GVHD), treatment with .1 mg/kg
per day of prednisone or equivalent, treatment with anti-lymphocyte
globulin, Eastern Cooperative Oncology Group performance status
score .3, or deranged hepatic or renal function (detailed inclusion
and exclusion criteria are provided in the supplemental Methods).
The study was approved by the institutional research ethics committee
at each site before recruitment. Written informed consent was
obtained from all participants in accordance with the Declaration of
Helsinki. This study was registered on the Australian and New Zealand
Clinical Trial Registry as #ACTRN12613000603718.
Third-party donors and T-cell generation
Venous blood or granulocyte colony-stimulating factor–primed
apheresis product from healthy stem cell donors was used as the
starting material for ex vivo T-cell expansion. Donors with common
HLA types and positive CMV or EBV serostatus were recruited from
Westmead Hospital and underwent standard assessment to confirm
eligibility for allogeneic donation. HLA typing was performed by
the Australian Red Cross Blood Service and was low resolution for
class I loci and resolved to 4 digits at the DRB1 locus. Thirty-one
donors were used to generate a bank of 46 monovalent (17 CMV,
14 EBV, and 15 ADV) VST products under good manufacturing
practice conditions at the Sydney Cellular Therapies Laboratory,
Westmead Hospital, as previously described.6,13 Donor monocyte-
derived dendritic cells (moDCs) were pulsed with overlapping
MACS GMP PepTivators (Miltenyi Biotec) peptide pools (15 mers
overlapping by 11 peptides) for HCMV pp65, AdV5 Hexon, or EBV
BZLF1/LMP2A/EBNA-1 proteins. Irradiated peptide-pulsed moDCs
were used as stimulators in coculture with the monocyte-depleted
fraction of granulocyte colony-stimulating factor–primed apheresis
products or venous blood mononuclear cells isolated by Ficoll-
Paque (GE Healthcare) gradient centrifugation. Cultures were
restimulated with peptide-pulsed moDCs after 7 days and were
continued for up to 21 days, with the addition of 20 U/mL
interleukin-2 every 2 to 3 days, increasing to 50 U/mL of interleukin-
2 from day 14 to 21. VST products were cryopreserved in multiple
doses. One multivalent (CMV, EBV, ADV, and varicella-zoster virus)
VST product was retained from a previous clinical study14 and was
administered to patient 1. Standard VST product release criteria
were applied (see supplemental Methods for criteria and VST
shipping information).
Treatment and VST matching
Participants were treated with a dose of 2.0 3 107/m2 partially
HLA-matched CMV-, EBV-, or ADV-specific T cells based on
postthaw viability. VST-recipient matching required a minimum of 1
of 6 HLA antigens (HLA-A, -B, and -DRB1) shared between VSTs
and the recipient. The VST-recipient matching algorithm incorpo-
rated the viral specificity of the product, the number of HLAmatches
with the recipient, the specific HLA antigen through which antiviral
activity was mediated and demonstrated antiviral activity through a
shared HLA antigen. VSTs were chosen based on the highest
number of HLA matches with antiviral activity through the shared
HLA antigen(s), with secondary preference given to products with
the highest proportions of virus-specific major histocompatibility
complex (MHC)–tetramer CD81 cells or interferon-g (IFN-g)
response. In the event of persistent viral replication detected $2
weeks after a previous infusion and continued fulfillment of eligibility
criteria, patients were treated with #3 additional infusions of VSTs
generated from the same or a different third-party donor. The VST
dose could be increased up to 5.03 107/m2 cells if the patient had
tolerated a previous VST dose at 2.03 107/m2 without VST toxicity.
Antiviral therapy was administered according to local physician and
institutional preference. A cycle of antiviral therapy was defined as
the commencement or recommencement of full-dose antiviral
therapy or a change to a new antiviral agent.
Outcomes and follow-up
Patients were monitored for 12 months from the final infusion of
VSTs for evidence of clinical and virological response, toxicity, and
immune cell recovery. Clinical review and peripheral blood sample
collection were performed at regular time points, with resetting of
the review cycle after each infusion. The primary end point of the
trial was safety of the VST infusion. All adverse events were graded
according to the National Cancer Institute’s common terminology
criteria for adverse events, version 4.03. Secondary end points
included the incidence of acute and chronic GVHD, viral
reactivation, infection and organ damage, virus-specific immune
reconstitution, and use of antiviral therapy. Virological response was
defined as: complete response (CR) if the virus became undetect-
able by quantitative polymerase chain reaction (PCR) at any point
post–VST infusion with resolution of any symptoms related to tissue
or organ infection; and partial response (PR) if there was $50%
reduction from the immediate preinfusion viral load. If the patient did
not fulfill criteria for CR or PR, they were defined as having no
response (NR). GVHD was graded according to standard criteria
for acute and chronic GVHD (supplemental Tables 1-3).
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Virological and immune monitoring
Viral load was measured by quantitative PCR at individual centers
(for details of the CMV assays used, see supplemental Table 4).
CMV drug resistance mutations were identified using PCR
sequencing of the UL97 and UL54 genes.
Postinfusion immune monitoring was performed on batched
peripheral blood mononuclear cells (PBMCs) to minimize interassay
variability. Flow cytometry was performed on VST products or
postinfusion PBMCs using monoclonal antibodies directed against
CD3, CD4, CD8, CD14, CD19, CD56, CD62L, CD45RA, and PD-1
(BD Biosciences, San Jose, CA). Viability was assessed using
7-amino-actinomycin D (BD Biosciences) or hydroxystilbamidine (Life
Technologies). PBMCs from otherwise healthy individuals undergoing
venesection for hemochromatosis were assessed to provide a range
for the percentage of PD-1 expression onCD81 T cells. CD31, CD41,
CD81, and T memory subset cell counts were calculated by
multiplication of the subset percentage and the lymphocyte count
measured on the day of sample collection. Viral antigen specificity and
HLA-restricted epitope recognition on VST products were assessed
using phycoerythrin-conjugated virus-specific iTAgMHCclass I human
tetramers (Beckman Coulter, Brea, CA) or by intracellular cytokine
flow cytometry after stimulation of VSTs with overlapping peptide
mix or with individual epitopes, as previously described.13 Flow
cytometry data were acquired on a FACSCanto II or LSRFortessa
(BD Biosciences) and analyzed with FlowJo software (version
10.0.8r1; Tree Star, Inc., Ashland, OR). CMV-specific T-cell
immune recovery was monitored by IFN-g enzyme-linked immuno-
spot (ELIspot) assay, as described previously.13
Statistical analysis
The cumulative incidence functionwas used to estimate the cumulative
overall (CR and PR) and CR response rate to VSTs at the end of
follow-up, with death considered a competing risk. The peak CMV
pp65-specific T-cell responses, as measured by IFN-g ELIspot assay
before and after VST infusion, were compared using the Wilcoxon
matched-pairs signed rank test to determine significance. A compar-
ison of the percentage expression of PD-1 on CD81 T cells between
healthy individuals and trial patients before VST infusion was
performed using a Mann-Whitney test to determine significance.
Linear regression and Pearson correlation were performed to
determine the significance of the relationship between the time to
CR and the timing of the first VST infusion post-HSCT. Statistical
analysis was performed using Prism 7 for Mac (GraphPad Software,
Inc., La Jolla, CA). Cumulative incidence data were generated using
the Analysis of Censored and Correlated Data software, version 8.4.8
(Boffin Software, Sydney, NSW, Australia).
Results
Participant Characteristics
Thirty-one patients were recruited at 7 centers across Australia and
New Zealand (see supplemental Appendix) between February 2013
and August 2016. One patient with CMV reactivation did not receive
treatment because no suitably HLA-matched product was available.
Of the remaining 30 patients, 28 patients were treated for CMV
reactivation, 1 for ADV reactivation, and 1 for EBV reactivation. The
participant characteristics are described in Table 1. Of the 22
adults and 8 pediatric patients, 27 patients were transplanted for
hematological malignancy and 3 pediatric patients were transplantedT
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for immune deficiency syndromes. The majority of transplants were
performed with in vivo T-cell depletion (22 of 30 patients). Two-thirds
of CMV-seropositive recipients were transplanted from CMV-
seronegative donors. Of the 28 patients with CMV reactivation, 3
patients had a history of previous CMV disease, and 3 patients had
current CMV disease (2 patients with CMV enteritis and 1 patient
with CMV pneumonitis). Patients were heavily pretreated for viral
infection having received a median of 31 days (range, 14 to 113 days)
of antiviral therapy before the initial VST infusion. Eighteen patients had
$2 cycles of treatment, and 12 patients had been exposed to $2
different classes of antiviral therapy before the first VST infusion.
Mutations conferring resistance to CMV drug therapy were found in 5
of 11 patients tested before first VST infusion and in 1 patient tested on
day 7 after administration of CMV-specific T cells. Mutations in CMV
UL54were more frequent (5 of 6 patients) than UL97 kinasemutations
(2 of 6 patients), as detailed in supplemental Table 5.
Characteristics of the VST products
Fifty VST infusions from 15 of 31 available donors were administered
during the trial. Products from 8 donors were used in multiple patients
(Table 2). The most frequently shared HLA types were A2 and A1,
followed by B8 and B7 and DRB1 01:01 and 03:01. VST products
were predominantly CD31 (median, 98%; range, 92%-99%). The
median percentage of CD31 cells that were CD3181 was 58%,
(range, 14%-84%) and CD3141 was 39% (range, 15%-85%); 9 of
15 products were predominantly CD3181. The CD3181 subset
consisted predominantly of CD45RA–CD62L– effector memory
T cells. Viral epitope-specific MHC class I tetramers were available
for 10 products. The median percentage of total cells that were
tetramer positive was 24% (range, 6%-47%).
Administration of VSTs and VST matching
The median day of first infusion was day 75 (range, 37 to 349 days)
post-HSCT. The details of VST treatment and characteristics are
described in Table 2. A single infusion was administered to 17
patients, 9 patients received 2 infusions, 2 patients received 3
infusions, and 2 patients received 4 infusions. Eight patients were
administered VST products from .1 donor. The median VST cell
dose was 2.03107cells/m2 with a range of 1.37 to 5.03107cells/m2
(6 patients received increased cell doses after an incomplete
response to a previous dose of 2.0 3 107cells/m2). The median
HLAmatch of product to recipient was 2 of 6 HLA antigens; 11 VST
infusions were based on a single antigen or allele match. Sixteen of
the 50 infusions were matched at either a class I or class II HLA
locus, whereas the remainder were matched at both.
Safety and toxicity of VSTs
There were no immediate infusion-related toxicities attributed to
VSTs. One patient was hospitalized within 24 hours of infusion due
to fever and was found to have central line–related bacteremia.
Patients were followed up for a median of 12 months. No adverse
event was attributed to VST infusion. The majority of adverse events
were related to infections. All serious adverse events (SAEs) are
detailed in Table 3. All non–VST-targeted infections are described
in supplemental Table 6. Noninfective SAE included posterior
reversible encephalomyelitis syndrome in 2 patients (both on
calcineurin inhibitors), Stevens-Johnson syndrome attributed to
ganciclovir (n 5 1), respiratory failure due to fluid overload (n 5 1),
and respiratory failure with relapsed malignancy (n 5 1). Other
adverse events included transient paraproteinemia in 2 patients,
1 case of self-limited asymptomatic thyrotoxicosis, 1 case of Bell’s
palsy, 1 case of drug-related skin eruption, 1 case of idiopathic
facial edema, and 1 case of steroid responsive thrombocytopenia
A total of 9 deaths occurred during follow-up (Table 2). Overall
unadjusted survival at 12 months post–first VST infusion was 69%,
with median survival not reached. One patient died of presumed CMV
disease and is discussed below. Three patients died of relapsed
malignancy, including 1 patient who was given EBV-specific T cells for
Table 3. Serious adverse events
Patient
Days post–first
VST infusion Event
1 108 Rhinovirus RTI
180 Escherichia coli UTI
5 354 Respiratory syncytial virus RTI
6 314 Streptococcus pneumoniae pneumonia/sepsis
7 251 RTI (no organism identified)
9 45 RTI (no organism identified)
54 Rhinovirus and Influenza A(H3) RTI*
54 Pseudomonas putida pneumonia/sepsis†
56 Enterococcus faecium pneumonia/sepsis†
11 8 Disseminated ADV infection† (urine, blood, stool,
GIT)
21 Grade IV gut GVHD with hemorrhage†
12 29 Stevens-Johnson syndrome (skin, ocular, oral, and
genital mucosa)
41 Posterior reversible encephalopathy syndrome
13 9 Disseminated Toxoplasma gondii† (cerebral, CSF,
blood, and BMAT)
14 50 Serratia marcescens bacteremia (line-related)
15 190 Presumed Pneumocystis jirovecii pneumonia†
16 19 Respiratory failure due to fluid overload
32 Posterior reversible encephalopathy syndrome
17 23 Human metapneumovirus RTI
31 Enterococcus faecium pneumonia/empyema†
18 1, 16 Pseudomonas aeruginosa RTI
16 Rhinovirus RTI
19 80 Rotavirus diarrhea
20 126 RLL pneumonia, no organism identified
23 291 Enterococcus faecalis and Enterobacter cloacae UTI
24 7 Respiratory syncytial virus RTI
24 Orbital cellulitis, no organism identified
52 Pseudomonas aeruginosa bacteremia
53 Cerebral EBV PTLD†
65 Respiratory failure, Candida sp., Corynebacterium
sp., CMV PCR1, EBV PCR1 (BAL)†
26 11 Febrile, no organism identified
BAL, bronchoalveolar lavage; BMAT, bone marrow aspirate and trephine; CSF, cerebral
spinal fluid; GIT, gastrointestinal; RLL, right lower lobe; RTI, respiratory tract infection; sp.,
species; UTI, urinary tract infection.
*Rhinovirus and Influenza A(H3) RTI was initially diagnosed on day 34 post–VST infusion.
†Contributed to death.
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EBV reactivation in the context of EBV-associated NK/T lymphoma.
Two patients died of nonviral infections. Patient 24 died of presumed
cerebral EBV PTLD 80 days post–CMV-specific VST infusion. He was
not eligible for EBV-specific VSTs on trial at the time of the PTLD
diagnosis due to poor performance status.
Acute de novo GVHD occurred in 2 patients within 2 weeks of VST
infusion. Patient 9 had steroid responsive grade II acute GVHD
(stage 3 skin, stage 1 gut) that resolved before death due to
infection 71 days after VST infusion. Patient 11 received a CMV-
specific VST infusion 62 days after an HLA-B antigen–mismatched
matched unrelated donor (MUD) transplant. He died 35 days
postinfusion from refractory grade IV acute GVHD (gut) and
disseminated ADV infection. He was not eligible for ADV-specific
VSTs on trial due to active GVHD. Chronic GVHD (mild, n 5 2;
moderate, n 5 1; and severe, n 5 2) occurred in 5 patients.
Virological response and clinical outcomes
At 12 months, the cumulative incidence of overall response was 93%,
and the cumulative incidence of CR was 76% (Figure 1). Virological
response and outcomes for all patients are provided in Table 2.
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Figure 1. Cumulative incidence of response at 12
months post–VST infusion. (A) The cumulative time to best
overall response (OR) (either CR or PR) for all patients.
(B) The cumulative time to CR for all patients.
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Figure 2. Outcome of CMV enterocolitis in patient 5 post–
CMV-specific VST infusion. (A) Viral load, lymphocyte count,
and colonic biopsy in patient 5, who was treated with a single VST
infusion. The patient had persistent symptomatic biopsy–proven
CMV enterocolitis after a month of antiviral therapy. Post–VST
infusion, the symptoms resolved, the patient developed an absolute
lymphocytosis, and viral load fluctuated between negative
and below the level of quantitation (,150 cp/mL). (B) CMV
pp65-specific T-cell response as measured by IFN-g ELIspot.
(C-D) Photomicrograph of colonic biopsy with CMV immunostain
pre–VST (C) and post–VST (D) infusion (original magnification
3200, Olympus microscope, model BX43). LLQ, lower limit of
quantitation.
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CRs. Twenty-three patients achieved a complete virological
response at a median of 59 days (range, 1 to 175 days) post–first
VST infusion. All 3 patients with active tissue infection achieved a CR
after a single infusion. Figure 2 illustrates the CR seen in patient 5, in
whom positive immunohistochemical stains for CMV colitis resolved
coincident with a rise in the absolute lymphocyte count and an increase
in CMV-specific T-cell response. The patient treated for ADV
reactivation (patient 29) had a CR to a single infusion of VSTs.
Of the 23 patients who achieved a CR, 14 patients remained virus
PCR-negative (n 5 5) or below the level of quantitation (n 5 9) for
the duration of follow-up. An additional 5 patients had brief
episodes of quantifiable reactivation, but were not administered
additional VST or antiviral therapy after CR.
PRs. Five patients achieved a PR. Patient 1 achieved PR but
had persistent CMV infection refractory to additional VSTs and
multiple antiviral agents and died of presumed CMV disease. Of the
4 other patients that achieved PR, 3 died of subsequent non-viral
infections and 1 from disease relapse.
NRs. Two patients did not meet criteria for a CR or PR. One
patient had persisting low-level CMV in the blood 152 days
-120 0 120 240 360
Days
28
17
30 EBV
13
11
24
9
26
22
14
1
15
12
21
20
2
19
25
27
5
6
8
7
10
4
16
3
29 ADV
23
18
Pre-final VST infusion antiviral therapy
Post-final VST infusion antiviral therapy
Follow-up
Death
Figure 3. Antiviral therapy pre– and post–final VST
infusion. The numbers to the left of the red bars refer to the
patient number. The red bars on the left show the cumulative
days of antiviral therapy administered before the final infusion
(including therapy before the first VST infusion). The blue bars
to the right show the duration and number of blocks of antiviral
therapy administered over the course of follow-up after the
final VST infusion.
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28 patients treated for CMV reactivation.
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post–final VST infusion. The second patient was treated with EBV
VSTs for EBV reactivation, but died 2 weeks later with relapsed
EBV-associated NK/T lymphoma.
Use of antivirals before and after VST infusion is illustrated in
Figure 3. The median number of days since cessation of antiviral
therapy at last follow-up for all patients was 326 days (range, 0 to
412 days). Five patients recommenced antiviral therapy after the
final VST infusion. In 4 of these patients (patients 4, 11, 12, and 25),
this occurred in the context of high-dose steroids administered for
suspected or confirmed GVHD. Patient 1 received 44 days of
antiviral therapy after reinitiation and died of presumed CMV
disease. Figure 4 details the viral load after the final VST infusion for
all patients treated for CMV.
The presence of drug resistance mutations did not appear to affect
the virological response to VSTs with 4 of the 6 patients with UL54
or UL97 mutations achieving a CR and 5 of the 6 patients without
mutations achieving a CR.
Immune reconstitution
Of the 30 patients treated with VSTs, 18 patients were lymphopenic
preinfusion. Themedian lymphocyte count for all patientswas 0.83109/L
(range, 0.2 to 14.13109/L). Immunophenotyping performed in 26 of the
28 patients with CMV reactivation showed a rise in the CD31 count after
VST infusion. This was predominantly CD81 T cells (preinfusion median,
CD81 0.263 109/L, day 59 postinfusion median CD81, 0.913 109/L).
This rise coincided with the median time to CR (Figure 5A) and a shift
in the composition of CD81 T cells from effector memory
CD45RA–62L– T cells to terminally differentiated effector CD45RA1
62L– T cells (Figure 5B). In contrast, within the CD41 T-cell memory
subset, effector memory T cells were dominant throughout follow-up
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Figure 5. T-cell subset responses post–VST infusion. (A) Median cell number for CD31, CD41, and CD81 T cells for time points post–first VST infusion (3 109/L).
(B) Median cell number for CD81 T-cell memory subsets defined as T terminal effector (CD45RA162L–), T naive (CD45RA162L1), T central memory (CD45RA–62L1), and T effector
memory (CD45RA–62L–). (C) Median cell number for the CD41 T-cell memory subsets. (D) Percentage of CD81 T cells expressing PD-1. Bars and lower and upper whiskers
represent the median, 25th, and 75th percentiles, respectively. The results for healthy individuals at steady state are indicated by the dashed line (median) and gray shading (range).
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Figure 6. Correlation between the time to CR with timing of first VST infusion
post-HSCT. To assess whether virological responses may be explained by natural immune
recovery post-HSCT, linear regression and Pearson’s correlation were performed to determine
any significant relationship between the timing of the response and the timing of first VST
infusion post-HSCT in the 23 patients who achieved CR. No correlation was observed.
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(Figure 5C). The percentage of CD81 T cells expressing PD-1 before
VST infusion was significantly higher than healthy individuals at steady
state (preinfusion median, 28% [range, 5%-71%] of CD81 T cells;
healthy individuals’ median, 6% (range, 2%-10%] of CD81 T cells;
P 5 .005). Postinfusion PD-1 expression exhibited a downward trend
over the course of follow-up, but did not completely normalize (Figure 5D).
There was no correlation between the number of days post–stem cell
transplant and the time to complete virological response (Figure 6).
Functional CMV-specific immunity was measured by ELIspot in 23 of
the 28 patients treated for CMV. Preinfusion CMV pp65 T-cell
responses were almost undetectable with a median of 4 spot forming
cells (SFCs)/105 cells (range, 0-67 SFCs/105 cells). The median
peak CMV pp65-specific immunity occurred at a median of 44 days
(range, 0 to 309 days) after the first infusion and measured 49 SFCs/
105 cells (range, 3-921 SFCs/105 cells; P , .0001; Figure 7).
Discussion
Donor-derived VSTs have beneficial clinical effects when adminis-
tered prophylactically and therapeutically to allogeneic HSCT
recipients.5,6,8,9,11,15,16 Banked third-party, partially HLA-matched
VSTs have been explored as an alternative to minimize the
inconvenience and delay involved in generating specific donor-
derived products for each recipient. Several studies have
suggested that this approach leads to clinical benefit in the short
term,5,7,8,11,12 although long-term effects on viral control and overall
immune reconstitution have not been reported.
In this multicenter study of 30 patients, we used partially HLA-
matched third-party VSTs to treat viral infections that persisted or
recurred after an initial period of standard antiviral treatment. We
followed patients for a median of 12 months and studied viral
control and requirement for additional antiviral therapy as well as
parameters of immune reconstitution. As in other studies, we
observed no immediate infusion-related toxicities. Rates of GVHD
and SAEs during the 12 months of follow-up were within
expectations for the studied population. A lack of GVHD occurred
despite the fact that all infusions came from unrelated third-party
donors, 25 of the 50 infusions matched at 1 or 2 of 6 HLA antigens
or alleles, 8 patients received products from $2 different donors,
and infusions contained T-cell doses of up to 5.0 3 107/m2.
The overall virological response rate (CR and PR) for all patients at
12 months was 93%, and 76% of patients achieved a CR. One
patient who achieved a PR subsequently died of unconfirmed CMV
and thus could be considered a long-term NR. These high response
rates were achieved in a heavily pretreated population in which all
patients had standard antiviral therapy failure and drug resistance
mutations were frequently detected. Our findings corroborate those
of Leen et al12 who noted an almost identical CR rate in a similar
patient group. Complete virological responses were seen irrespec-
tive of drug mutation status, suggesting that mutations affecting the
action of traditional antivirals are not relevant when using cell
therapy to enhance immune reconstitution.
Late CMV disease post-HSCT is the result of defective CMV
immune function. The patients treated for CMV reactivation in our
study were at high risk for recurrent CMV reactivations and late
CMV disease.3,4,17,18 Despite this, we observed excellent control of
CMV over 12 months post–final T-cell infusion. Only 5 patients
reinitiated antiviral treatment, and in 4 patients, this occurred in the
context of steroid administration for presumed or proven GVHD.
The virological response coincided with a rise in the numbers of
CD31 cells, and specifically CD81 terminal effector memory cells, in
the blood and the time of peak CMV-specific T-cell immunity. CD81
T-cell reconstitution, in particular the CD81 terminal effector subset
(CD45RA162L– or CD45RA1CCR7–),19-21 is known to be impor-
tant in virological control post-HSCT.5,10 The recovery of CD81
T cells did not correlate with time posttransplant, suggesting that
VSTs were not acting purely as a bridge to coincidental hemopoietic
recovery. Rather, CD81 T-cell recovery was related to recent VST
administration irrespective of time after transplantation, implicating
VSTs in facilitating the recovery process, although confirmation of this
hypothesis requires additional study.
Before VST administration, the percentage of CD81 T cells
expressing PD-1 in the study population was high compared with
healthy individuals, and it remained elevated even at the time of viral
control. The significance of this finding is currently unclear. Chronic
antigenic stimulation (viral or alloreactive) may be responsible for
PD-1 upregulation and T-cell dysfunction. The fact that viral control
was observed without downregulation of PD-1 might imply that
immune checkpoint inhibitor therapy would be of limited value as an
adjunct to this form of cell therapy. Recent reports implicating PD-1
inhibitors in severe GVHD post-HSCT also suggest caution in
combining cell therapy and immune checkpoint inhibition after
allogeneic stem cell transplantation.22,23 More detailed assessment
of immunoinhibitory markers is warranted.
Our results validate previous reports of the safety and short-term
efficacy of third-party VST infusions. The novelty of our data lies in
the demonstration of long-term virus control in a group of heavily
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Figure 7. Peak CMV pp65-specific T-cell responses pre– and post–VST infusion.
Peak SFC count as measured by IFN-g ELIspot after the first VST infusion in 23 patients.
Bars and lower and upper whiskers represent the median, 25th, and 75th percentiles,
respectively. Significance was determined by the Wilcoxon matched-pairs signed rank test.
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pretreated patients, some with life-threatening tissue infections at the
time of cell administration. This efficacy is particularly notable given
the convenience and flexibility of third-party VST infusion using
products from cryopreserved cell banks to treat recipients of multiple
types of allogeneic HSCT. Over 95% of our patients were treated
within 3 days of request, mainly in the outpatient setting. The HLA
mismatching of third-party VSTs that can be tolerated means that
VST products derived from 15 donors were adequate to meet the
diverse HLA needs of our cohort. In many instances, the use of VSTs
provided an alternative to further prolonged antiviral therapy and
allowed the limitation of toxicity, especially the myelosuppression
present at study entry. Our results may have relevance for treating
multiple other viral and nonviral opportunistic pathogens occurring
after allogeneic transplant. The establishment of third-party virus-
specific cell banks could reduce the cost and complexity associated
with personalized donor-derived cell therapy while retaining its
efficacy and enhancing its practicality in routine transplantation.
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Methods 
Detailed participant inclusion and exclusion criteria  
1. Inclusion criteria 
• Recipients of myeloablative or non-myeloablative allogeneic transplantation for 
any indication. 
• Viral reactivation or infection with cytomegalovirus (CMV), adenovirus (AdV) 
or Epstein-Barre virus (EBV) must be present at the time of infusion as 
determined by: 
o For CMV 
- CMV detectable by antigen detection, polymerase chain reaction 
(PCR) or culture in peripheral blood or tissue biopsy or by 
immunohistochemical staining on tissue biopsy specimen 
o For AdV 
- Presence of AdV as detected by PCR, antigen detection or culture 
in body fluids including blood, stool, urine or nasopharyngeal 
secretions 
o For EBV 
- Elevated EBV detectable in peripheral blood by PCR or 
- Presence of documented EBV related post-transplant 
lymphoproliferative disorder (PTLD) diagnosed by tissue biopsy 
or 
- Elevated EBV detectable in the blood by PCR and clinical or 
imaging findings consistent with EBV lymphoma 
• Failure of standard therapy as defined by: 
o For CMV 
- The continued presence of detectable CMV virus or antigen after 
at least 14 days of antiviral therapy with intravenous Ganciclovir 
or Foscarnet 
- Recurrence of detectable CMV virus or antigen after at least 2 
weeks of prior antiviral therapy 
o For AdV 
- A less than 50% reduction in viral load in blood or any site of 
disease as measured by PCR or any quantitative assay despite use 
of therapy as determined by the treating physician; 
- Standard therapy may include intravenous Cidofovir within the 
limits of renal function 
o For EBV 
- A less than 50% decrease in the size of EBV lymphoma or 
- A less than 50% decrease in the EBV viral load in peripheral 
blood despite use of appropriate therapy as determined by the 
treating physician which may include: 
• Reduction in immunosuppression 
• Rituximab 375mg/m2 up to 4 infusions 
• Cytotoxic chemotherapy 
• Adequate hepatic and renal function (< 3 x upper limit of normal for AST 
(SGOT), ALT (SGPT), < 2 x upper limit of normal for total bilirubin, serum 
creatinine) 
• ECOG status 0 to 3 or Lansky score 30-100 
• Patient (or legal representative) has given informed consent. 
 
2. Exclusion criteria 
• Use of anti-lymphocyte globulin (ALG, ATG, anti-CD52 or other broad 
spectrum lymphocyte antibody) given in the 4 weeks immediately prior to 
infusion or planned within 4 weeks after infusion. 
• Grade II or greater graft versus host disease within 1 week prior to infusion. 
• Prednisone or methylprednisolone at a dose of > 1 mg/kg (or equivalent in other 
steroid preparations) administered within 72 hours prior to cell infusion. 
• ECOG status 4 or Lansky score <30 
• Privately insured in or outpatients in New South Wales participating centers  
 
3. Patients on corticosteroid and immunosuppressive medication must also adhere to 
the following rule: 
• Patients receiving corticosteroids at a dose of less than 1 mg/kg body 
weight should have received corticosteroids for 7 days without dose 
reduction prior to infusion of virus-specific T-cells. 
 
Virus specific T-cell (VST) product release criteria and shipping information 
1. Prior to release of VSTs for infusion the following quality control criteria will all be 
satisfied: 
• Post-thaw viability > 50% by trypan blue exclusion 
• Bacterial and fungal sterility on culture of pre-freeze product 
• PCR negativity for Mycoplasma antigens on pre-freeze product 
• Less than 2% CD19+, less than 2% CD14+ 
2. Cryopreserved VST products were transported to peripheral centers in a validated 
dry shipper with a temperature data logger and product storage and transport form, in 
accordance with local guidelines. 
	 	
Tables	
 
Supplementary Table S1. Acute GVHD - staging for organ involvement  
 
Stage Skin Liver Gut 
1 maculopapular rash <25% of body 
bilirubin 
25-40 umol/L 
diarrhea 500 - 1000 ml/day 
nausea/vomiting + biopsy 
2 25-50% of body 40-74 umol/L 1000-1500 ml/day 
3 generalized erythroderma 75-200 umol/L 1500-2500 ml/day 
4 bullae/desquamation >300 umol/L >2500 ml/day or severe abdominal pain or ileus 
 
Supplementary Table S2. Acute GVHD - overall clinical grading based on individual 
organ staging 
 
Grade Skin Liver Gut Clinical Performance 
I 1 to 2 0 0 Normal 
II 1 to 3 1 (&/or) 1 Mild decrease 
III 2 to 3 2 to 3 (&/or) 2 to 3 Marked decrease 
IV 2 to 4 2 to 4 (&/or) 2 to 4 Incapacitated 
 
Supplementary Table S3. Chronic GVHD – staging for organ involved  
 
 Mild (Score 1) Moderate (Score 2) Severe (Score 3) 
Skin 
<18% BSA with disease 
signs but NO sclerotic 
features 
19-50% BSA OR 
involvement with 
superficial sclerotic 
features “not 
hidebound” (able to 
pinch) 
 
>50% BSA OR deep sclerotic 
features “hidebound” (unable 
to pinch) OR impaired 
mobility, ulceration or severe 
pruritus 
Mouth 
Mild symptoms with 
disease signs but not 
limiting oral intake 
significantly 
Moderate symptoms 
with disease signs 
with partial limitation 
of oral intake 
Severe symptoms with disease 
signs on examination with 
major limitation of oral intake 
Eyes 
Mild dry eye symptoms 
not affecting ADL 
(requiring eyedrops <3x 
per day) OR asymptomatic 
signs of 
keratoconjunctivitis sicca 
 
Moderate dry eye 
symptoms partially 
affecting ADL 
(requiring drops >3x 
per day or punctal 
plugs), WITHOUT 
vision impairment 
 
Severe dry eye symptoms 
significantly affecting ADL 
(special eyeware to relieve 
pain) OR unable to work 
because of ocular symptoms 
OR loss of vision caused by 
keratoconjunctivitis sicca 
GI tract 
Symptoms such as 
dysphagia, anorexia, 
nausea, vomiting, 
abdominal pain or diarrhea 
without significant weight 
loss (<5%) 
Symptoms associated 
with mild to moderate 
weight loss (5- 15%) 
 
Symptoms associated with 
significant weight loss >15%, 
requires nutritional supplement 
for most calorie needs OR 
esophageal dilation 
Liver Elevated Bilirubin, AP*, AST or ALT <2 x ULN 
Bilirubin >3 mg/dl or 
Bilirubin, enzymes 2-
5 x ULN 
Bilirubin or enzymes > 5 x 
ULN 
 
Lungs† 
 
Mild symptoms (shortness 
of breath after climbing 
one flight of steps) 
FEV1 60-79% OR LFS 3-
5 
Moderate symptoms 
(shortness of breath 
after walking on flat 
ground) 
FEV1 40-59% OR 
LFS 6-9 
Severe symptoms (shortness of 
breath at rest; requiring 02) 
FEV1 <39% OR LFS 10-12 
 
LFS score calculated by adding FEV1 and DLCO score as follows:  ≥80% = 1; 70-
79% = 2; 60-69% = 3; 50-59% = 4; 40-49% = 5; <40% = 6. 
Joints 
and 
fascia 
Mild tightness of arms or 
legs, normal or mild 
decreased range of motion 
(ROM) AND not affecting 
ADL 
 
Tightness of arms or 
legs OR joint 
contractures, erythema 
thought due to 
fasciitis, moderate 
decrease ROM AND 
mild to moderate 
limitation of ADL 
Contractures WITH significant 
decrease of ROM AND 
significant limitation of ADL 
(unable to tie shoes, button 
shirts, dress self etc.) 
 
Genital 
tract 
Symptomatic with mild 
signs on exam AND no 
effect on coitus and 
minimal discomfort with 
gynecologic exam 
 
Symptomatic with 
moderate signs on 
exam AND with mild 
dyspareunia or 
discomfort with 
gynecologic exam 
 
Symptomatic WITH advanced 
signs (stricture, labial 
agglutination or severe 
ulceration) AND severe pain 
with coitus or inability to insert 
vaginal speculum 
This table is adapted from Figure 1 Organ scoring of chronic GVHD in Filipovich et al.1  
*AP may be elevated in growing children, and not reflective of liver dysfunction. 
†Pulmonary scoring should be performed using both the symptom and pulmonary function 
testing (PFT) scale whenever possible. When discrepancy exists between pulmonary 
symptom or PFT scores the higher value should be used for final scoring. Scoring using the 
Lung Function Score (LFS) is preferred, but if DLCO (adjusted for hematocrit but not 
alveolar volume) is not available, grading using FEV1 should be used. GVHD indicates 
graft versus host disease; ADL, activities of daily living; LFTs, liver function tests; AP, 
alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
ULN, upper limit of normal 
 
Supplementary	Table	S4.	CMV	assay	by	participating	center	
Participating Center CMV PCR quantitation assay 
Lady Cilento Children's Hospital, Brisbane Qiagen Artus® PCR kit 
Royal Adelaide Hospital, Adelaide 'In-house' PCR assay 
Royal North Shore Hospital, Sydney Roche COBAS®AmpliPrep/COBAS® TaqMan® 
CMV test 
Sydney Children's Hospital, Sydney Argene CMV R-gene® 
The Children's Hospital at Westmead, 
Sydney 
Argene CMV R-gene® 
Westmead Hospital, Sydney Roche COBAS®AmpliPrep/COBAS® TaqMan® 
CMV test 
Abbreviations:	CMV,	cytomegalovirus;	PCR,	polymerase	chain	reaction.	
Supplementary	Table	S5.	Detailed	CMV	drug	resistance	mutations	
Patient UL54 UL97 
1 Q578H, T700A, E756D, A834P M460V 
5 I726T ND 
6 ND ND 
10 ND ND 
11  L802M* ND 
12 I726T ND 
13 I726T ND 
14 ND ND 
15 ND A594V 
16 ND ND 
25 ND† ND 
27 ND ND 
Abbreviations: ND- no mutation detected. 
*CMV drug mutation 7 days after 1st VST. 
†No sequence results available for UL54 primer 1-4 due to technical issues. 
 
Supplementary	Table	S6.	Non-VST	targeted	infections	
Patient Viral  
1*, 10, 15, 18 Rhinovirus RTI 
2, 3, 6, 11, 22 EBV reactivation (quantitative) not requiring therapy  
2,4 Herpes zoster 
4 Hepatitis C-related liver cirrhosis (progression) 
5, 17* Human metapneumovirus RTI 
5*, 24* Respiratory syncytial virus RTI 
5*, 6*, 16* Herpes simplex virus 1 ulceration (oral) 
5, 11, 13 BK virus reactivation (urine) 
9* Rhinovirus + Influenza A(H3) RTI 
10 Rhinovirus  + Parainfluenza RTI 
11*† Disseminated adenovirus (blood, GIT, stool, urine) 
13* Polyoma virus (non-JC, non-BK) in CSF 
13* EBV PCR+ in brain, CSF and BMAT without viral cytopathic tissue change 
13* Polyoma virus in BMAT without viral cytopathic change 
19* Rotavirus diarrhea 
24* Human herpesvirus 6 (blood, marrow, CSF) 
24*† Cerebral EBV PTLD 
26 Adenovirus reactivation (blood) not requiring therapy 
27 Parainfluenza RTI 
Patient Bacterial  
1 Aeromonas in stool culture 
1* Escherichia coli UTI 
6* Streptococcus pneumoniae pneumonia/sepsis  
9*† 
Pseudomonas putida pneumonia/sepsis + Enterococcus faecium 
pneumonia/sepsis  
10 Pseudomonas aeruginosa (sputum) 
14* Serratia marcescens bacteremia (line-related) 
16* Enterococcus faecium UTI/sepsis 
17*† Enterococcus faecium pneumonia/empyema 
18* Pseudomonas aeruginosa RTI 
18*, 28 Clostridium difficile (stool) 
23* Enterococcus faecalis and Enterobacter cloacae UTI  
24* Corynebacterium species (BAL) 
24* Pseudomonas aeruginosa bacteremia 
Patient Fungal  
6 Candida albicans (sputum) 
8 Candida glabrata (vaginal thrush) 
9* Saccharomyces cerevisiae (BAL) 
9*, 12* Treatment for presumed respiratory invasive fungal infection 
15*† Presumed Pneumocystis jirovecii pneumonia 
24* Candida species (BAL) 
Patient  Presumed infection - no organism identified 
7* RTI 
20* RLL pneumonia 
24* Orbital cellulitis  
26* Febrile (not neutropenic) 
Patient Parasitic  
13*† Disseminated toxoplasma gondii (cerebral, CSF, blood and BMAT) 
Abbreviations: VST, virus-specific T cells; RTI, respiratory tract infection; EBV, Epstein-Barr 
virus; GIT, gastrointestinal; CSF, cerebral spinal fluid; BM, bone marrow; PTLD, post-
transplant lymphoproliferative disease; UTI, urinary tract infection; BAL, bronchoalveolar 
lavage; RLL, right lower lobe. 
*Associated with hospitalization or prolongation of hospitalization. 
†Contributed to death. 
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Chapter 4. Dynamics of immune response following treatment with third-party 
CMV-specific T-cells for resistant and refractory CMV infection following 
allogeneic HSCT  
4.1 Introduction   
CMV infection has a profound impact on post-transplant outcomes. Inferior 
outcomes persist despite the widespread adoption of early pre-emptive pharmacological 
therapy1. Large studies have confirmed an increased incidence of non-relapse mortality 
and decreased overall survival for CMV seropositivity in either the donor or recipient2,3. 
Studies in HSCT patients suggest delayed or impaired reconstitution of CD4+ and CD8+ 
CMV-specific T-cells puts patients at high risk of CMV infection and disease4,5. 
Development of a functional CMV-specific T-cell response is also important in 
controlling infection6,7. HSCT donor-derived immunotherapy trials link efficacy of 
treatment with CD8+ CMV-specific T-cell expansion and persistence of the infused 
cells8-11. Preliminary data from third-party specific T-cell therapy also suggest that 
CMV-specific T-cell expansion is required for adequate virological control. There are 
mixed results on persistence of transferred cells following third-party virus-specific T-
cell (VST) therapy, and it is unknown if persistence is required for efficacy12-14.  
The immunological consequences of CMV infection in the post-transplant setting 
are still being unravelled, but infection has been linked with impaired or dysfunctional 
immune cell recovery and persistent changes in the T-cell repertoire even one to two 
years after infection has cleared15,16. Indirect immunomodulatory effects of CMV 
infection have also been reported including increased risk of bacterial and fungal 
infection17. Further studies of the immune deficits contributing to resistant and 
refractory CMV infection are required. Investigation of the immunological 
consequences of adoptive T-cell therapy should help refine future VST therapy.  
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4.2 Aims 
1. To describe the kinetics of CMV DNAemia before and after treatment with 
third-party VST  
2. To characterise lymphocyte subset reconstitution at 30, 60, 90 and 120 days 
following allogeneic transplantation in patients not treated with third-party VST 
3. To characterise the lymphocyte subset profile in patients prior to third-party 
VST and compare with patients who did not receive VST 
4. To characterise changes in lymphocyte subsets in the 12 months following 
third-party VST 
5. To describe the recovery of functional CMV-specific immunity following third-
party VST using interferon-γ (IFN-γ) enzyme linked immunospot (ELIspot) 
6. To describe changes in plasma cytokine profile following administration of 
third-party VST 
7. To investigate the persistence of transferred third-party VST clones by TCR 
sequencing and high sensitivity chimerism 
8. To describe the lymphocyte subset profiles of patients exhibiting incomplete 
response to VST and investigate possible causes of failure: 
x VST-directed human leucocyte antigen (HLA) alloantibodies  
x mutation of HLA-restricted epitopes for VST-targeted viral antigens 
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4.3 Methods 
4.3.1 Study design and VST generation  
 The detailed inclusion and exclusion criteria and study design are described in 
Chapter 3 Methods and Supplementary Methods. Allogeneic HSCT patients with 
persistent or recurrent viral replication and/or tissue infection with CMV, AdV, or EBV 
that had failed standard therapy, were eligible for treatment with cryopreserved third-
party donor virus-specific T-cells (VST). The ex-vivo expansion method for generation 
of VST is described in detail in Methods, Chapter 2. In brief, donor monocyte-derived 
dendritic cells (moDC) were pulsed with overlapping MACS GMP PepTivators 
(Miltenyi Biotec) peptide pools for HCMV pp65, AdV5 Hexon, or EBV 
BZLF1/LMP2A/EBNA-1 proteins. Irradiated peptide-pulsed moDC were cultured with 
the monocyte-depleted fraction of G-CSF primed apheresis products or venous blood 
mononuclear cells isolated by Ficoll-Paque (GE healthcare) gradient centrifugation. 
Cultures were restimulated with peptide-pulsed moDC after 7 days and continued for 
up to 21 days. Participants were treated with up to four doses of 2.0-5.0x107/m2 partially 
HLA-matched CMV-, EBV-, or AdV-specific T-cells. Recipient matching required a 
minimum of one of six HLA antigens (HLA-A, -B, -DRB1) shared between VST and 
recipient. Patients were monitored for 12 months from the final infusion of VST for 
evidence of clinical and virological response, toxicity, and immune cell recovery. 
Virological response was defined as complete response (CR) if virus became 
undetectable on quantitative PCR at any point post-VST infusion with resolution of any 
symptoms related to tissue or organ infection; partial response (PR) if there was at least 
a 50% reduction from the immediate pre-infusion viral load. If the patient did not fulfil 
criteria for CR or PR they were defined as having no response (NR). Written informed 
consent was obtained from all participants in accordance with the Declaration of 
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Helsinki, and the study was approved by the institutional research ethics committee of 
each site. The study was registered on the Australian and New Zealand Clinical Trial 
Registry (ACTRN12613000603718).  
4.3.2 Virological monitoring  
Viral load was measured by quantitative PCR at individual centres (for details of 
the CMV assays used see Chapter 3, Supplemental Table S4).  
4.3.3 Immune monitoring by flow cytometry 
Post-infusion immunophenotyping was performed on batched cryopreserved 
peripheral blood mononuclear cells (PBMC) to minimize interassay variability. Flow 
cytometry was performed on VST products using monoclonal antibodies directed 
against CD3, CD4, CD8, CD14, CD19, CD45, CD56, CD62L, CD45RA, CD45RO, 
PD-1 (BD Biosciences, San Jose, USA), and TIM-3 (Biolegend, San Diego, USA). 
Viability was assessed using 7-amino-actinomycin D (BD Biosciences) or 
hydroxystilbamidine (Molecular Probes, Mulgrave, Australia). Fourteen patients who 
underwent HSCT without any cellular therapy interventions at the primary trial centre 
between October and December 2015 were recruited prospectively for assessment of 
lymphocyte subset reconstitution at day 30, 60, 90 and 120 post-transplant. Patients 
were recruited to this cohort sequentially; one patient was excluded due to enrolment 
in a cellular therapy trial during follow-up. Peripheral blood from otherwise healthy 
individuals undergoing venesection for hemochromatosis were also used as a 
comparator for percentage expression of PD-1 and TIM-3 on T-cells. Absolute cell 
counts were calculated by multiplication of the subset percentage and the automated 
lymphocyte count measured on the day of sample collection. Flow cytometry data were 
acquired on a FACSCanto II or LSRFortessa (BD Biosciences) and analysed with 
FlowJo software (version 10.0.8r1; Treestar Inc., Ashland, USA).  
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4.3.4 Interferon (IFN)-γ enzyme linked immunospot (ELIspot) assay 
Functional CMV-specific T-cell immune recovery was assessed by IFN-γ 
enzyme linked immunospot (ELIspot) assay. ELIspot was performed on batched 
cryopreserved PBMC to minimize interassay variability. Filtration plates (MAIPS4510 
96 well, Merck Millipore, Billerica, USA) were coated for 24 hours with IFN-γ ELIspot 
capture antibody (BD Biosciences), then washed and treated with AIM-V medium (Life 
Technologies, Camarillo, USA) with 10% human AB serum (Australian Red Cross 
Blood Service, Sydney, Australia) as a blocking medium. Thawed PBMCs were 
suspended in AIM-V/10% human AB serum at concentrations between 0.25 to 2x105 
cells/100ul, and added to the blocked plates for stimulation overnight with 1ug/ml 
CMV pp65 overlapping peptide mix (JPT Peptide Technologies, Berlin, Germany). 
Stimulation with PHA-L (Sigma-Aldrich, St Louis, USA) was used for the positive 
control. Following overnight stimulation, cells were discarded and IFN-γ ELIspot 
detection antibody (BD Biosciences) was added to washed plates. Extravidin and 
Sigmafast BCIP/NBT alkaline phosphatase substrate (Sigma-Aldrich) were used for 
spot development. Spots were counted used an AID iSpot ELIspot reader (Autoimmun 
Diagnosticka, Straβberg, Germany). Testing was performed in triplicate for each 
timepoint. Results were reported as spot forming counts (SFC)/105 cells, above 
negative control. 
4.3.5 Plasma cytokine measurement 
Plasma cytokine assessment was performed using the MILLIPLEX MAP Human 
Cytokine/Chemokine Magnetic Bead Panel 1 Kit (Merck Millipore) on batched 
cryopreserved samples. The nine-plex kit included reagents for assessment of 
interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, IL-15, IL-17A, IFN-γ, and tumour necrosis 
factor (TNF)-α. Cytokine measurement was performed as per the manufacturers 
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instruction. Sample acquisition was performed on a Luminex® 200 instrument 
(Millipore). Analyte concentrations were modelled by five-parameter log-logistic 
curve. Table 1 shows minimum detectable concentrations (MDC) in pg/ml as reported 
by the manufacturer. 
Table 1. Minimum detectable cytokine concentrations  
Cytokine IL-2 IL-4 IL-6 IL-7 IL-10 IL-15 IL-17A IFN-γ TNF-α 
MDCpg/ml 1.0 4.5 0.9 1.4 1.1 1.2 0.7 0.8 0.7 
 
4.3.6 Investigation of third-party T-cell persistence 
Persistence of VST in vivo was tested on unsorted PBMC from post-infusion 
peripheral blood by high-throughput deep T-cell receptor sequencing using multiplex 
PCR targeting the complementarity-determining Region 3 to determine T-cell receptor 
gene rearrangement (Adaptive Biotechnologies, Seattle, USA) or using a droplet digital 
PCR (ddPCR) chimerism assay with a limit of detection of 0.008%18. The detailed 
method for performing the ddPCR microchimerism assay is described in the article in 
Appendix 6.1. Briefly, genomic DNA was purified from PBMC using QIAamp DNA 
Mini Kit according to the manufacturer’s instructions (QIAGEN, Hilden, Germany). 
Informative insertions or deletions (indels) present in the VST, but not the VST 
recipient or transplant donor, were identified using a commercial qPCR kit (KMRtype 
Genotyping Primer/Probe Kit from GenDx, Utrecht, Netherlands). Informative indels 
in the post-infusion PBMC were quantified with ddPCR using the KMRtrack 
Monitoring Assay in FAM (GenDx) on the Bio-Rad QX200 droplet generation and 
reading platform (Biorad, Hercules CA). Post-transplant chimerism was performed 
using standard methods of PCR amplification and analysis of DNA short tandem repeat 
polymorphisms between transplant donor and recipient as described in Appendix 6.1.  
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4.3.7 HLA antigen typing and alloantibody detection 
HLA typing and alloantibody testing was performed by the Australian Red Cross 
Blood Service. Serological and molecular HLA typing was performed using standard 
methods19,20. HLA typing for VST products was low resolution for class I loci and 
resolved to 4 digits at the DRB1 locus. HLA class I and class II alloantibody testing 
was performed using bead-based multiplex assays performed on a Luminex® 
instrument. A LABScreen® Mixed bead assay (One Lambda, Thermo Fisher Scientific, 
Canoga Park, USA) was used for screening, and LABScreen® Single Antigen (One 
Lambda, Thermo Fisher Scientific) class I and class II beads were used to determine 
the specificity and mean fluorescence intensity (MFI) of HLA alloantibodies detected 
on screening. 
4.3.8 CMV pp65 sequencing analysis 
The QIAamp MinElute Virus Spin Kit (Qiagen, Hilden, Germany) was used to 
isolate DNA from 200ul of plasma according to manufacturer’s instructions. Primers 
were designed using the CMV 169 strain reference sequence. The region encoding the 
pp65 gene was amplified using primers (Sigma-Aldrich) as shown in Table 2. 
Table 2. Primer sequences 
Primer Name Nucleotide Sequence Position (CMV169 
reference strain) 
Forward 1 (F1) GGAGTCGCGCGGTCGCCGT 3-21 
Reverse 2 (R2) GCGCGTGCGGCGGGTGGCTC Non-coding region 3’end 
Internal Forward 3 (F3) GATAATCAAACCGGGCAAGA 840-859 
Internal Reverse 4 (R4) TCGTACTGACGCAGTTCCAC 1009-1027 
 
The primer pairs were F1 and R2, F1 and R4, F3 and R2. A 41ul mastermix solution 
was used comprising 1ul of 10mM dNTP (New England Biolabs, Ipswich, USA), 1ul 
of MgCl2 (Bioline Global, Smeaton Grange, Australia), 0.25ul of GoTaq DNA 
polymerase and 10ul of GoTaq DNA polymerase buffer (Promega, Fitchburg, USA), 
and 28.75ul of nuclease free dH20 (Promega). Primers, 2 ul each of forward and reverse, 
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and 5ul of either template DNA, or controls of nuclease-free water or PBS (Lonza, 
Walkersville, USA), were added individually. The reactions were performed on a 
Gradient Palm-CyclerTM (Corbett Life Science, Mortlake, Australia) using the 
parameters: 95°C for 2mins, 35 cycles of 95°C for 30s, 55°C for 40s, 72°C for 1.5mins, 
then final extension at 72°C for 2min. PCR products for sequencing were purified using 
the Purelink PCR purification kit (Invitrogen, Waltham, USA), as per manufacturer’s 
instructions. Sanger sequencing was performed by the Australian Genome Research 
Facility (Westmead, Australia) using the same forward primer used for amplification. 
Bioinformatics was performed using the Clone Manager Professional (Version 9.4, Sci-
Ed Software, Denver USA). The DNA sequence corresponding to 1597 bases of the 
pp65 coding region from the patient’s sample was translated and the amino acid 
sequence was aligned against nine CMV reference sequences (AD169, Merlin, HAN3, 
HAN20, JHC, 3157, BE27.2010, U8, and Towne). CMV pp65 epitopes restricted 
through HLA-A*01, B*08, and DRB1*03:01 were identified using the Immune 
Epitope Database and Analysis Resource (www.iedb.org). The sequence reference 
positions for relevant epitopes were compared with the reference position of identified 
sequence diversity in the patient’s pp65 strain to identify possible mutations affecting 
HLA-restricted T-cell binding sites. 
4.3.9 Statistical analysis 
Continuous variables with non-Gaussian distributions were compared using a 
Wilcoxon matched-pairs signed-rank test to determine significance for paired 
comparisons, and Mann-Whitney test to determine significance for unpaired 
comparisons. Statistical analysis was performed using Prism 7 for Mac (Graphpad 
Software Inc., La Jolla, CA). P-values of ≤0.05 were considered significant. 
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4.4 Results 
4.4.1 Viral load kinetics and antiviral therapy in patients treated with third-party VST  
A total of 28 patients were treated with third-party CMV-specific T-cells for 
recurrent or refractory CMV infection or disease. The clinical characteristics and 
clinical outcomes of these patients (patients 1-28) are reported in detail in Chapter 3, 
Tables 1 and 2. Due to the publication word limit of Chapter 3, the kinetics of CMV 
DNAemia before and after VST infusion were not fully reported and are presented here 
as shown in Figure 1. CMV DNAemia was first detected a median of 27 days (4-236) 
after stem cell transplant, which was a median of 54 days (17-148) prior to first VST 
infusion. The median peak viral load was significantly lower after VST therapy (pre-
infusion 40650 cp/ml (3990-7.3x106) versus post-infusion 11450 cp/ml (150-5.27x105), 
p=0.001). The median total days of pharmacological antiviral treatment was 
significantly higher prior to first VST infusion than after (31 days (14-113) versus 22 
days (0-141), P =0.0484). The median total days of pharmacological therapy (including 
maintenance therapy) after final VST infusion was 14 days (0-91). The median duration 
of antiviral drug treatment cycles was significantly lower after VST infusion (pre-
infusion 22 days (7-116) versus post-infusion 16 days (0-79), P=0.01).  
Differences in CMV DNAemia kinetics were compared between patients 
administered single or multiple VST infusions as shown in Figure 2. The duration of 
CMV DNAemia prior to VST therapy was not significantly different for those 
administered multiple VST infusions compared to single infusions. (62 days versus 39 
days, respectively, P=0.08). Median peak viral loads prior to VST infusion were similar 
for patients who were administered single versus multiple VST infusions (36850 versus 
43350 CMV copies/ml, P=0.57). 
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Figure 1. CMV DNAemia kinetics prior to and following first VST infusion 
Day 0 (red line) refers to the day of first VST infusion. CMV viral load 
(copies/ml) for individual patients are shown before and after VST therapy.  
 
There was no significant difference between the median days post-transplant at 
the time of first infusion in single versus multiply infused patients (68 versus 94 days 
post-transplant, P=0.11). Single VST recipients demonstrated earlier resolution and 
lower levels of CMV DNAemia post infusion compare to multiple infusion recipients. 
A number of patients had CMV DNAemia worthy of specific comment. Patient 1 had 
persistent CMV infection despite VST and antiviral therapy and died from presumed 
CMV disease 380 days post-transplant. Patient 2 had an initial complete response, but 
then required additional antiviral therapy and VST infusions for recurrent infection. 
After final VST infusion he remained clinically well despite persistent moderate viral 
load and did not require reinitiation of antiviral therapy. Patient 9 showed an initial 
partial response on maintenance antiviral therapy. He was admitted to hospital with 
bacterial sepsis following an episode of steroid-responsive GVHD. He had a rapid rise 
in CMV DNAemia but was unfit for further VST or antiviral therapy. He died from 
bacterial sepsis 138 days post-transplant.  
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Figure 2. CMV DNAemia kinetics comparing single versus multiple infusions 
Changes in CMV DNAemia pre and post first VST infusion for patients 
administered a single infusion only (top panel) or multiple infusions (bottom 
panel). Day 0 (red line) refers to the day of first VST infusion. CMV viral load 
(copies/ml) for individual patients are shown before and after VST therapy.  
 
4.4.2 Lymphocyte subset recovery post-HSCT in patients not treated with VST  
Thirteen patients who did not receive VST infusion or any cellular therapy were 
followed prospectively for four months post-allogeneic transplantation. Lymphocyte 
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for direct comparison with third-party VST recipients (treated at 37-349 days post-
transplant), but do provide a context for the interpretation of results. Of the 13 patients, 
seven patients were CMV seropositive and six were CMV seronegative prior to HSCT. 
Patient characteristics are shown in Table 3. CMV DNAemia occurred in five of the 
CMV seropositive patients, and none of the patients seronegative prior to 
transplantation. Acute GVHD (grade II-IV) occurred in six patients (two CMV-
positive, and four CMV-negative). Median absolute lymphocyte recovery (defined as 
an absolute lymphocyte count ≥1 .0 x 109/L) occurred by day 90 post-HSCT: median 
lymphocyte values were 0.85x109/L at days 30 and 60, and 1.1x109/L at days 90 and 
120. The dynamics of immunological recovery across a variety of lymphocyte subsets 
were characterized in the first 120 days post-HSCT as shown in Figure 3A. CD56+3- 
NK cells were the predominant subset seen at Day 30 with a median count of 
0.25x109/L, and decreased thereafter. A sharp rise in CD19+ B-cells occurred between 
day 60 and day 90 from a median 0.01x109/L to 0.1x109/L, which was then maintained. 
Between day 30 and day 60 CD8+ T-cells rose from a median count of 0.07x109/L to 
0.24x109/L and became the predominant cell type at D90 and beyond. Higher median 
CD8+ T-cell counts were seen in patients who reactivated CMV as shown in Figure 3B.  
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Table 3. Characteristics of allogeneic transplant patients not treated with VST ID Age Disea
se 
HSCT 
type 
TCD R/D First CMV 
DNAemia, Day 
aGVHD 
grade, Day 1 55 NHL RIC HREL No Pos/Neg None None 2 28 AML MAC 
MUD 
No Pos/Pos None None 3 55 AML RIC MUD ATG Pos/Pos CMV D45 None 4 71 AML RIC 
MMUD 
ATG Pos/Pos CMV D37 GVHD II-IV, 
D16 5 50 MDS RIC Sib No Pos/Neg CMV D31 None 6 64 NHL RIC Sib No Pos/Neg CMV D24 None 7 64 AML RIC MUD No Pos/Pos CMV D45 
 CMV colitis D54 
GVHD II-IV, 
D40 8 42 AML MAC SIB No Neg/Neg None GVHD II-IV, 
D72 9 44 AML MAC 
MUD 
No Neg/Neg None GVHD II-IV, D7 10 53 MDS RIC MUD No Neg/Neg None GVHD II-IV, 
D45 11 55 MDS/ 
AML 
RIC MUD No Neg/Neg None None 12 66 AML RIC MUD ATG Neg/Neg None GVHD II-IV 
D94 13 64 AML RIC MUD No Neg/Neg None None 
Abbreviations: AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; D, 
donor; GVHD, graft versus host disease; HREL, haploidentical related; HSCT, 
haemopoetic stem cell transplant; MAC, myeloablative conditioning; MDS, 
myelodysplasia; MMUD, mismatched unrelated donor; MUD, matched unrelated 
donor; Neg, negative; NHL, non-Hodgkin lymphoma; Pos, positive; R, recipient; RIC, 
reduced intensity conditioning; VST, virus-specific T-cells; 
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Figure 3. Lymphocyte subset recovery in the four months following allogeneic 
HSCT in patients not treated with VST  
(A) Absolute cell counts for NK, NKT, B, CD4+ and CD8+ T-cells, CD4+ T 
regulatory cells, and CD4+31+ T Naïve cells, and the median cell counts for 
CD4+ and CD8+ T-cell memory subsets are compared at day 30, 60, 90 and 
120 post-HSCT. Bars and whiskers represent the median, 25th and 75th 
percentiles respectively. CD4+ and CD8+ T-cell memory subsets defined as T 
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terminal effector (TEMRA) CD45RA+62L-, T Naïve (TN) CD45RA+62L+, T central 
memory (TCM) CD45RA-62L+, and T effector memory (TEM) CD45RA-62L-. (B) 
Median absolute CD8+ T-cell counts for patients with and without CMV 
DNAemia. The box and bar represent the interquartile range and median 
respectively, and whiskers the 10th and 90th centile. 
 
CD8+ terminal effectors were the predominant CD8+ T-cell memory subset seen 
over the duration of follow-up. This subset rose between day 30 (median count 
0.05x109/L) and day 90 (median count 0.22x109/L). CD4+ T effector memory cells 
were the dominant CD4+ T-cell subset. The absolute number of CD4+ T regulatory cells 
was small throughout follow-up, but peaked at D60 at a median count of 0.04x109/L. 
There was no rise in absolute counts of CD31+ naïve CD4+ T-cells (representative of 
recent thymic emigrants). This suggests thymic driven donor CD4+ T-cell proliferation 
was not prominent in the early post-transplant period in this group of adult transplant 
recipients.  
The expression of the T-cell immunoinhibitory receptors PD-1 and TIM-3 was 
analysed in patients post-transplant and compared with expression in healthy 
individuals. Average and median immunoinhibitory receptor expression on the T-cell 
subsets of five healthy individuals is reported in Table 4. In healthy individuals, PD-1 
expression was significantly higher in T-cell effector memory subsets compared to T-
cell terminal effector subsets (median PD-1 expression 12.6% vs 1.5%, P=0.002). 
As shown in Figure 4, PD-1 expression on CD4+ T-cells was significantly elevated in 
HSCT recipients compared with healthy individuals, across all timepoints. PD-1 
expression on CD8+ T-cells was not significantly increased when compared to healthy 
individuals from day 60 onwards. TIM-3 expression was very low on both CD4+ and 
CD8+ T-cells (median levels <0.9%).  
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Table 4. T-cell immunoinhibitory percentage expression in healthy individuals 
Subset Median (94% CI) 
CD8+PD-1+ T-cells 9.2 (1.9-10.0) 
CD4+PD-1+ T-cells 3.7 (3.1-7.9) 
CD8+PD-1+ TEM 16.6 (9.1-33.7) 
CD4+PD-1+ TEM 7.8 (5.9-15.3) 
CD8+PD-1+ TEMRA 4.1 (1.5-5.8) 
CD4+PD-1+ TEMRA 0.8 (0.5-1.5) 
CD8+TIM-3+ T-cells 0.4 (0.2-0.6) 
CD4+TIM-3+ T-cells 0.1 (0.1-0.3) 
 
 
 
 
Figure 4. T-cell subset immunoinhibitory protein expression in the four months 
following allogeneic HSCT  
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Percentage of T-cell subsets expressing PD-1 or TIM-3 as labelled. T-cell 
memory subsets defined as TEMRA CD45RA+62L and TEM CD45RA-62L-. Bars 
and whiskers represent the median, 25th and 75th percentiles respectively. 
Results for healthy individuals at steady state are indicated by the dashed line 
(median) and grey shading (94% confidence interval of the median). Significant 
variation, determined by a Mann-Whitney test, in PD-1 or TIM-3 expression 
when compared with healthy individuals is starred (*=P<0.05, **=P≤0.01, 
***= P≤0.001)  
 
4.4.3 Lymphocyte subset profile in third-party VST recipients 
Of the 28 patients treated for CMV infection, 18 were lymphopenic at the time of 
VST treatment, and the median absolute lymphocyte count for all patients was 
0.8x109/L (range 0.2-2.9). An increase in median absolute lymphocyte count from pre-
infusion was seen at all timepoints following the first VST infusion, and median 
absolute lymphocyte recovery to ≥1.0x109/L occurred on day 14 following first VST 
infusion. A significant increase in the absolute lymphocyte count was noted at day 59 
post-VST infusion as shown in Figure 5. Lymphocytosis >4.0x109/L developed in 11 
patients as early as 21 days (range 21-365 days) post-VST infusion.  
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Figure 5. Lymphocyte recovery post-VST infusion (absolute counts) 
The absolute lymphocyte counts for the 28 patients treated for CMV in the 12 
months following initial VST infusion. Median absolute lymphocyte recovery 
defined as a median count ≥ 1.0 x 109/L. Bars and whiskers represent the 
median, 25th and 75th percentiles respectively. Significant differences between 
timepoints was determined by a Wilcoxon matched-pairs signed-rank test 
(**=P≤0.01).  
 
The lymphocyte subset profile in the 12 months following first CMV-specific T-
cell infusion was available for 26 of 28 patients as shown in Figure 6. Patients prior to 
VST infusion demonstrated a high median absolute counts of NK cells (median 
0.28x109/L), low median absolute count of T-cells (median 0.33x109/L) (particularly 
CD4+ T-cells, median 0.08x109/L), and low median absolute count of B-cells (median 
0.03x109/L). The profile of high NK counts, with low T- and B-cells fits with an early 
post-transplant phenotype (day 30-60) demonstrated by the HSCT patients who did not 
receive VST therapy, as shown in Figure 6A. This was despite trial patients being ≥ 60 
days post-transplant at the pre-infusion time point; 12 patients were day 60 post-HSCT, 
five patients were day 90 post-HSCT, five patients were day 120 post-HSCT, and four 
patients were >150 days post-HSCT. CD4+ T regulatory cells (CD25high127low) were 
not increased in trial patients. T-cell memory subsets were also compared as shown in 
Figure 6B. Trial patients demonstrated low median absolute counts of effector and 
naïve CD4+ T-cells, with a related low absolute number of CD4+31+ naïve cells. The 
CD8+ T-memory profile of trial patients showed a higher median count of effector 
memory T-cells and a reduced ratio of median terminal effector T-cells to effector 
memory T-cells, compared with the VST untreated HSCT group.  
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Figure 6. Lymphocyte subset profile prior to and day 59 post VST infusion  
The median absolute counts of (A) lymphocyte subsets and (B) T-cell memory 
subsets for 26 patients prior to VST infusion and at 59 days post-VST infusion 
were compared to VST untreated HSCT patients measured at timepoints 30, 60, 
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90 and 120 days post-transplant. Grey-scale bars represent counts from VST 
untreated HSCT patients at day 30, 60, 90 and 120 post-HSCT, red bars 
represent counts from pre-infusion trial patients, green bars represent counts 
from day 59 post-VST infusion trial patients. T regulatory cells (T reg) were 
defined as CD4+25high127low. T-cell memory subsets defined as: TEMRA 
CD45RA+62L-, TN CD45RA+62L+, TCM CD45RA-62L+, and TEM CD45RA-62L-.  
 
Detailed changes in individual lymphocyte subset profiles for trial patients in the 
12 months following VST infusion are shown in Figure 7. In keeping with the rise in 
absolute lymphocytes, the CD8+ and CD4+ T-cells and B-cells subsets all rose over the 
course of the 12 months. There was a marked rise in absolute counts noted 59 days 
following VST infusion as illustrated in Figure 6. Although this rise was demonstrated 
across subsets, the change between day 28 and day 59 was most marked for the CD8+ 
effector subset which showed an average 7-fold expansion, followed by the CD8+ 
effector memory subset with an average 5-fold expansion, CD4+effector subset with an 
average 4-fold expansion, and B-cells with an average 3-fold expansion. The subsets 
with the lowest average expansions (<1.7-fold) were T-regulatory, NK, and CD4+ 
subset. The CD8+ effector subset became the predominant CD8+ T memory subset from 
day 21 post-VST infusion, and remained so throughout follow-up as reported in 
Chapter 3. Effector memory T-cells were the prevailing CD4+ T memory subset 
throughout follow-up. A late rise in recent thymic emigrants (CD4+31+ naïve T-cells) 
was seen after day 90, with the highest absolute counts demonstrated in paediatric VST 
recipients. The expression of the immunoinhibitory markers PD-1 and TIM-3 are 
presented in Figure 8. PD-1 expression in trial patients prior to VST infusion was 
markedly increased compared to healthy individuals. Expression of PD-1 was higher 
on CD4+ T-cells (median 55% of CD4+ cells) than CD8+PD-1+ (median 28% of CD8+ 
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cells) T-cells (P<0.0001). Expression of PD-1 on CD4+ and CD8+ T-cells reduced 
towards the end of the follow-up period but did not completely normalise. 
 
Figure 7. Lymphocyte subset profiles in the 12 months post-VST infusion 
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Lymphocyte subsets for 26 patients prior to and in the 12 months following VST 
infusion. Absolute cell counts for NK, B, CD4+ and CD8+ T-cells, CD4+ T 
regulatory cells, and CD4+31+ T Naïve cells. Bars and whiskers represent the 
median, 25th and 75th percentiles respectively. Median absolute cell numbers 
for CD4+ and CD8+ T-cell memory subsets defined as TEMRA CD45RA+62L-, TN 
CD45RA+62L+, TCM CD45RA-62L+, and TEM CD45RA-62L-. 
 
 
Figure 8. Immunoinhibitory marker expression on T-cell subsets following VST 
infusion  
Percentage of CD8+ and CD4+ T-cells expressing PD-1 and TIM-3. Bars and 
lower and upper whiskers represent the median, 25th, and 75th percentiles, 
respectively. The results for healthy individuals at steady state are indicated by 
the dashed line (median) and grey shading (range). 
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4.4.4 Recovery of functional CMV-specific immunity following VST infusion 
In the previous paragraphs, a rise in lymphocyte counts was demonstrated 
following VST infusion with a significant expansion of terminal effector CD8+ T-cells 
noted at 59 days post-infusion. Limited tetramer availability, lymphopenia at the time 
of infusion and restrictions on blood sampling volumes made obtaining useful 
information with class I HLA tetramers impossible. The recovery of functional CMV-
specific immunity was therefore assessed in 23 of the 28 patients treated with CMV-
specific VST based on IFN-γ release in response to stimulation with CMVpp65 
peptides. As shown in Chapter 3, peak functional CMV specific immunity was 
significantly increased when compared to almost undetectable functional immunity 
prior to VST infusion (increasing from median four spot forming cells (SFC) to 49 
SFC/105 cells after infusion). As shown in Figure 9A left panel, there was a marked 
rise in median functional immunity at 59 days post-infusion (median 25 SFC/105) 
compared to pre-infusion. This represents a heterogeneous group of complete 
virological responders and patients yet to respond reflected by an SFC range of 0-412 
SFC. A comparison of responders and patients yet to respond by D59 post-VST showed 
a trend towards higher functional immunity, although this was not significant (Figure 
9B right panel). In the patients yet to respond, some patients had already started to show 
functional immune recovery. Patient 1 who died from presumed CMV disease did not 
show any functional CMV-specific T-cell response (peak SFC 3 SFC/105) despite 
persistently high viral loads. One complete responder (Patient 16) demonstrated no 
functional immunity at day 59 after demonstrating a rapid drop in CMV viral load from 
60300 copies/ml pre-infusion to a level below the limit of quantitation by day seven 
post-VST and complete response by day 35. CMV was below the limit of detection on 
two other occasions over the course of follow-up and he had no further treatment. 
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Trends in functional immunity and CMV viral load for individual patients are shown 
in Figure 9B top and bottom panel, respectively. Patient 4 and Patient 20 are noted for 
their very high functional CMV responses relatively late after first infusion, in 
association with a fall in CMV titre and no further clinically significant infections. 
Patient 4 had CMV colitis and was on intermittent high dose steroids post-infusion 
which was associated with recurrent episodes of CMV DNAemia. The first episode of 
CMV DNAemia was treated aggressively with antivirals at the time of high steroid 
administration. Functional immunity fell despite an initial rise post-VST. A second 
recurrence of CMV DNAemia was not treated with antivirals and functional CMV 
immunity rose rapidly, with an associated resolution of CMV DNAemia. Patient 20 
showed in early rise in CMV functional immunity in response to an episode of CMV 
DNAemia, the CMV DNAemia was controlled but did not resolve and antiviral therapy 
was initiated with a drop in functional immunity seen around day 122. Functional 
immunity then rose again and there were no further episodes of clinically significant 
infection, apart from low-level CMV DNAemia during a period of steroid 
administration.  
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Figure 9. Functional CMV-specific T-cell recovery and trends in CMV 
DNAemia 
(A) Individual functional CMV-specific T-cell responses (black dots, SFC/105 
cells) are shown at pre-infusion, and post-infusion days 28, 59, 90 and 122 in 
the left panel. A comparison of peak SFC counts in complete responders by day 
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59 compared with patients yet to respond by D59 is shown in the right panel. 
Bars represent the median value. (B) Individual trends of functional CMV-
specific immunity (SFC/105) and CMV DNAemia (copies/ml) are illustrated for 
each patient. Significant differences were determined by a Wilcoxon matched-
pairs signed-rank test or Mann-Whitney test for unpaired comparisons. 
 
4.4.5 Persistence of infused third-party T-cells  
The persistence of third-party VST in the peripheral circulation was detected in 
eight of 11 patients as shown in Figure 10. T-cell receptor deep sequencing was 
performed in three patients. TCR sequences that were specific for the infused product 
(and not shared with the patient at the pre-infusion time point), were found in only one 
patient (Patient 6) and only at 24 h post-VST. Persistence was further investigated in 
nine patients using ddPCR to detect VST microchimerism at a limit of detection of 
0.008%18. Persistence of third-party VST was demonstrated in seven of nine patients 
(median peak 4 cp/100ng gDNA, range 1-22 cp/100ng gDNA). Persistence was less 
than three days in five patients. The remaining three patients had persistence of 21, 25, 
and 27 days duration. Patient 9 had cells detected up to 27 days post-first VST infusion. 
This was the last time point available for testing prior to the patient’s death from 
bacterial sepsis. Virological response did not correlate with persistence; the three 
patients without detectable persistence achieved virological complete response (CR), 
while Patient 9 who demonstrated persistence of third-party cells up to one month 
achieved a partial response.  
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Figure 10. Third-party T-cell persistence post-VST  
Persistence of infused VST as measured by either TCR sequencing or ddPCR 
over the course of follow-up. Patient 5 had both ddPCR (timepoints 2 hours, 
days 1-14) and TCR sequencing (timepoints days 7-92) performed. For 
timepoints with VST detected > 5cp/100ng gDNA the concentration is recorded 
below the relevant time point.  
4.4.6 T-cell clonotype tracking following VST infusion  
In all three patients investigated with TCR sequencing, the dominant TCR clones 
present at each timepoints after VST infusion were already present at low levels in the 
patient prior to VST infusion. Figure 11A shows the kinetics of the top 10 dominant 
TCR clones in each patient over the post-infusion period. These dominant post-infusion 
TCR clones were not present in the administered third-party VST products. Only a 
small number of low frequency clones were shared between each patient and their 
matched VST. No TCR clonotype detected in a VST product (including those shared 
with the patient pre-infusion) was demonstrated to expand to greater than 0.5% of the 
TCR repertoire at any timepoints post-infusion for any of the three patients. Patients 4 
and 5 were treated with CMV-specific T-cells for active CMV colitis. Both patients 
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demonstrated significant expansion of a small number of TCR clones. Patient 4 
demonstrated a rise from 9.1% of TCR repertoire at pre-infusion to 35.1% on day 35 
of CASSPQGNTGELFF. Patient 5 demonstrated a rise from 2.8% pre-infusion to 
42.2% at day 20 for CASSATRQGNTEAFF. Routine post-transplant chimerism 
performed on Patient 4 and 5 prior to VST infusion, on sorted peripheral blood T-cells, 
showed the T-cells were exclusively of transplant donor origin suggesting the expanded 
TCR clones were most-likely HSCT donor in origin. The dominant T-cell clones are 
not public Figure 11B. clonotypes and have not been reported to be CMV-specific, but 
both patients showed clinical recovery coupled with increase in CMV-specific 
immunity as measured by ELIspot and a fall in peripheral blood CMV titres at the time 
of clonal expansion in shown in Patient 6 did not demonstrate a dramatic clonal 
expansion as seen in the other two patients (maximum clone size was less than 8% of 
the TCR repertoire). The patient did not become CMV negative until timepoints after 
the TCR sequencing was performed.  
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(B) 
 
Figure 11. Dominant clone frequency post-VST infusion 
(A) The top 10 TCR clones in the post-infusion follow-up period are reported 
for each patient. Clones are measured as a percentage (productive frequency) 
of total TCR repertoire for each timepoints. None of the clones that expanded in 
vivo post-VST were present in the VST product. (B) Patient 4 (right panel) and 
Patient 5 (left panel) showed significant expansions of individual TCR clones 
(dominant clone shaded black) during the period of follow-up which coincided 
with an increase in CMV specific immunity (red line) measured by IFN-γ 
ELIspot, lymphocyte count, and virological complete response (CR). CMV titre 
(copies/ml, ND is CMV not detected) or CMV biopsy immunohistochemistry 
results are reported at the top of the bar for each time point.  
 
4.4.7 Plasma cytokine dynamics following VST infusion  
A small exploratory panel of plasma cytokines were investigated in the six weeks 
following initial VST infusion in five patients. It was hypothesised that VST infusion 
and virological control might be associated with a change from a suppressive (T helper 
2-like cytokines eg. IL-4, -6, -10) to an inflammatory (T helper 1-like cytokines eg. IL-
2, IFN-γ, TNF-α) cytokine milieu. The cytokines chosen for investigation were 
interleukin (IL)-2, 4, 6, 7, 10, 15, 17a, IFN-γ and TNF-α. Patient 4 and 5 were 
hospitalised at the time of VST treatment with severe CMV colitis, and both later 
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achieved complete virological and clinical response. Patients 3 and 8 were treated for 
persistent CMV DNAemia after more than three weeks of antiviral therapy, and later 
achieved complete virological response. Patient 1 was treated for refractory CMV 
infection after failing multiple courses of antiviral therapy, and while he met criteria 
for a partial remission, he later died from presumed CMV infection following further 
VST infusions and antiviral therapy. As shown in Figure 12, plasma IL-10 (blue) and 
TNF-α (red) were detected in all patients at the majority of timepoints. Fluctuations in 
plasma IL-10 correlated with CMV viral load fluctuations. TNF-α was the primary 
cytokine present at timepoints where the CMV titre was low or undetectable. The ratio 
of TNF-α to IL-10 appeared to be low at times when CMV viral load was rising or 
peaking, and would increase with a fall in viral load. Patient 1 had persistently high 
levels of CMV. In contrast to the other patients, Patient 1 had a higher IL-10 across 
timepoints (mean 30pg/ml versus means 4-15pg/ml), and TNF-α never became the 
dominant cytokine. IFN-γ (magenta) was not detectable until after day 21 post-VST 
infusion in three of the five patients, and not detectable at any time point in Patient 1. 
Plasma IL-6 (green) fluctuated in the patients with CMV colitis, and Patient 1. Patient 
8 was the only patient with detectable IL-4 (orange) levels which peaked at 140 pg/ml 
at day seven post-VST infusion and could not be correlated with a particular clinical 
event. IL-2, IL-15, and IL-17A were detectable only in Patient 4, with a peak on day 
59 post-VST infusion associated with a rising lymphocyte count and reactivation of 
hepatitis C with moderate liver function derangement. Plasma IL-7 was not detected in 
any of the tested samples. Cytokine fluctuations could not be correlated with changes 
in lymphocyte subsets.  
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Figure 12. Plasma cytokine fluctuations following VST infusion 
Plasma cytokines were measured in the six-week period following initial VST 
infusion for five patients treated for CMV infection or disease. The CMV viral 
titre is shown for the seven days prior to VST infusion, and in the post-infusion 
period. 
The lower limit of quantitation (LLQ) for CMV was 150 copies/ml represented 
by the dotted line. The lower limit of detection for each cytokine is reported in 
Methods however for clarity, cytokines that were not detected were assigned a 
value of 1.0 shown at the time point prior to detection or if the cytokine became 
undetectable at later timepoints. 
 
4.4.8 Investigation of incomplete virological response to VST therapy 
Criteria for complete virological response were not met in seven patients; six of 
whom were treated for CMV infection, and one patient treated for EBV infection. 
Patient characteristics and clinical outcomes are shown in Table 5. All had received 
transplants from alternative donors (MUD or haploidentical relatives), but there were 
no other clinical or demographic features that were common to the group. Two patients 
were diagnosed with relapse of primary malignancy within two weeks of VST infusion. 
Patient 30 was treated for EBV DNAemia in the context of an undiagnosed relapse of 
EBV-associated primary malignancy, and died from complications of relapse 14 days 
following VST infusion with no evidence of virological response. Patient 10 was 
treated for CMV infection and met criteria for partial response prior to relapse of 
primary disease 10 days post-VST infusion. 
4.4.8.1 Lymphocyte subsets in poor responders   
 Lymphocyte subsets were not analysed for the two patients with relapse of 
primary disease. Examination of lymphocyte subsets was performed on the remaining 
five patients; four patients who met criteria for partial response (include Patient 1 who 
later died from presumed CMV disease), and one patient with no virological response, 
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all of whom were treated for CMV infection. Individual patient lymphocyte counts 
(Figure 13A) and lymphocyte subsets (Figure 13B) counts are compared with the 
median values for 20 patients with CMV infection who achieved complete virological 
response following VST treatment. 
 Median peak lymphocyte expansion was only 1.5-fold in poor responders 
compared to 4.8-fold in complete responders. No common lymphocyte subset profile 
pre-infusion or during follow-up was identified in poor responders.  
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Table 5. Characteristics and outcomes of patients with incomplete VST response^  
ID 
Best 
resp
onse 
Indication, 
Condition-
ing & HSCT 
type 
Target 
viral 
infectio
n  
(tissue 
involve
ment) 
R/D viral 
sero-
status 
Immun
o-
suppre
ssion  
at 1st 
VST 
Prior 
anti-
viral 
thera
py, d 
Viral 
load 
pre-
VST, 
cp/ml 
Days 
post 
HSC
T at 
1st 
VST 
No. 
of 
VS
T 
VST 
product 
infused 
HLA 
matc
h 
VST 
to 
patie
nt 
HLA 
antigen/al
lele (s) 
matched 
between 
VST and 
patient* 
Clinical Outcome (day of 
death post VST) 
1 PR 
AML/MDS, 
RIC MUD + 
ATG 
CMV Pos/Neg Pred, TAC 55 55 000 171 3 
2011-18, 
RPT 
13-0008 
4/6 
4/6 
3/6 
A1, B8, 
DR 03:01 
Progressive CMV 
DNAemia despite VST 
and antivirals. Death - 
presumed CMV disease 
(209) 
9 PR B-NHL, RIC HREL 
CMV 
(prior 
colitis) 
Neg/Pos 
Pred, 
MMF, 
TAC 
22 4 680 67 1 13-0015 2/6 B35
‖, DR 
01:01‖ 
Progressive CMV 
DNAemia and CMV colitis 
while on steroids for 
GVHD. Not fit for further 
VST antivirals. Death -
bacterial infection (71) 
13 PR ALL, MAC MUD + ATG CMV Pos/Neg CSA 14 1 740 62 1 14-0007 3/6 
A1, B8, 
DR 03:01 
Decreasing viral load. No 
further antivirals. Death - 
toxoplasmosis (33) 
14 NR AML, RIC MUD + ATG CMV Pos/Neg CSA 21 281 69 2 
13-0015 
14-0010 
2/6 
1/6 
A2, DR 
04:01 
then A2, 
A2 
CMV DNAemia requiring 
antivirals. No antivirals 
after final VST. Alive. 
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17 PR AML, RIC MUD + ATG 
CMV 
(prior 
pneumo
nitis) 
Pos/Neg None 46 9 800 104 2 14-0004, RPT 
3/6 
3/6 
A1, DR 
07:01, DR 
07:01 
Progressive CMV 
DNAemia. No further 
antivirals. Death - 
bacterial infection (37) 
28 PR 
FA (MDS), 
RIC MUD + 
ATG (CD34 
selection) 
CMV Pos/Pos CSA 29 483 47 1 13-0019 3/6 A2, A2, B40 
Decreasing viral load. Off 
study 10 days post VST. 
Death - relapse (58) 
30 NR 
NK/T-NHL 
& HLH, RIC 
HREL 
EBV Pos/Pos None NA† 81 240 133 1 13-0029 1/6 A24 
Progressive CMV 
DNAemia. No further 
antivirals. Death - relapse 
(14) 
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; CR, complete response; 
CSA, cyclosporin; D, donor; FA, Fanconi's anemia; HLA, human leukocyte antigen; HLH, hemophagocytic lymphohistiocytosis; HREL, 
haploidentical related; HSCT, haemopoetic stem cell transplant; MAC, myeloablative conditioning; MDS, myelodysplasia; MMF, 
mycophenolate mofetil; MUD, matched unrelated donor; Neg, negative; NKT-NHL, natural killer cell/T-cell non-Hodgkin lymphoma; NR, no 
response; Pred, prednisolone; Pos, positive; PR, partial response; R, recipient; RIC, reduced intensity conditioning; RPT, indicates a repeat 
infusion of the same VST product; TAC, tacrolimus; VST, virus-specific T-cells; 
^For complete patient details refer Chapter 3, Table 2  
* In the column entitled 'HLA antigen/allele (s) matched between VST and patient', HLA match was low resolution for HLA-A and B, and 
allelic for DRB1. Antigens or alleles with HLA-restricted viral activity are marked in bold.  
¶ HLA allele of product matched to HLA allele of transplant donor (not recipient).  
†Patient 30 had EBV-associated NK/T-NHL and was treated with a full course of Rituximab prior to haploidentical stem cell transplantation. 
The patient had recurrent EBV DNAemia post-transplant managed with reduction of immunosuppression. 
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Figure 13. Comparison of lymphocyte counts and lymphocyte subsets in 
patients with complete and poor response 
Absolute lymphocyte count (A) and lymphocyte subsets (B next page) are shown 
for individual patients who met criteria for partial virological response (Patients 
1, 9, 13, 17) and no virological response (Patient 14). The median lymphocyte 
count and interquartile range (black circles) for 20 patients meeting criteria for 
complete response are shown for comparison. CD4+ and CD8+ T-cell memory 
subsets defined as TEMRA CD45RA+62L-, TN CD45RA+62L+, TCM CD45RA-62L+, 
and TEM CD45RA-62L-. For Patient 17 at day 21 and 28 timepoints the 
lymphocyte count was unquantified as the white cell count was 0.28x109/L and 
0.07x109/L respectively. To allow the low subset counts to be illustrated in (B), 
cell counts were calculated by multiplying the subset percentage by lymphocyte 
count value designated as 0.01.  
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4.4.8.2 HLA alloantibodies  
The possibility of alloantibody mediated rejection as a cause for reduced efficacy 
of third-party VST was investigated in six of the seven patients who did not meet 
criteria for complete response. Identified HLA alloantibodies are shown in Table 6. 
Three of six patients (Patients 1, 9, 28) did not demonstrate any class I or II HLA 
antibodies against HLA molecules expressed by the VST administered, including 
Patient 1 who died from presumed CMV infection. Patient 14, who did not meet criteria 
for viral response, was found to have a VST-directed alloantibody against the first of 
two VST products administered. The VST-directed alloantibody against HLA-A*31 
had an MFI of 2293. In our institutional practice, donor-directed HLA alloantibodies 
of <5000 MFI are not considered to be of clinical importance, however the literature 
correlating MFI threshold and risk of graft failure in HSCT is limited to small 
retrospective studies21,22. Patient 13 did not have any alloantibodies identified for HLA-
A, B, or DRB1 loci that were expressed on the VST administered. It is unknown if 
antibodies identified at HLA-Cw, -DP, and –DQ on Patients 13 and 14 may have been 
directed against antigens expressed on the on the VST administered as HLA typing on 
the VST products was only performed at the A, B, and DRB1 loci. Patient 17 had 
borderline non-specific class II reactivity that likely reflects a false positive testing 
result, however the presence of a low-MFI specific HLA antibody cannot be ruled out. 
 154 
Table 6. HLA alloantibodies in poor responders 
ID Time point Class I HLA IgG antibody Class II HLA IgG antibody   
A MFI B MFI Cw MFI DRB1 MFI DP MFI DQ MFI 
1 Pre-1st and -3rd VST Negative Negative 
9 Pre 1st VST Negative Negative 
13 Pre 1st VST 03 1488 13 3103 05 768 07 >2000 
  
A1*02:01 >2000 
23 4024 27:05 3454 07 949 
      
24 3184 37 2779 17 829 
      
25 2958 38 3250 
        
32 3608 44 4112 
        
  
45 813 
        
  
47 2504 
        
  
49 3151 
        
  
51 2868 
        
  
52 2495 
        
  
53 2736 
        
  
57 3570 
        
  
58 3475 
        
  
59 2514 
        
  
63 2697 
        
  
76 1575 
        
  
77 2606 
        
14 Pre 1 VST 03 2305 54 538 07 2759 
  
06 >500 A1*05:01 >500 
29:02 819 63 684 09 2009 
      
30 2289 
  
10 2216 
      
31 2293 
  
17 1236 
      
 155 
66:01 1228 
    
            
Pre-2nd VST Positive Negative 
17 Pre-1st VST Negative Borderline non-specific class II reactivity 
28 Pre 1st VST 
  
51:01 553 
  
Negative   
76 646 
  
Abbreviations: MFI – mean fluorescence intensity, IgG – immunoglobulin G
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4.4.8.3 CMV pp65 mutation affecting HLA molecule recognition  
Patient 1 died from presumed CMV infection following administration of three 
infusions of CMV-specific VST from two different donors with all products matched 
to the patient at HLA-A*01, B*08, and DRB1*03:01. CMV-specific VST were 
expanded using CMVpp65 as the target antigen. We investigated whether mutations in 
HLA-A*01, -B*08, and –DRB1*03-restricted CMVpp65 epitopes, may have 
contributed to diminished VST activity and poor virological response. DNA was 
extracted from the patient’s plasma on day 35 post-VST infusion when the CMV viral 
load was 126 000 copies/ml yielding the DNA nucleotide sequence shown in Figure 
14A. A multiple sequence alignment was performed comparing the patient’s translated 
pp65 amino acid sequence with the sequences of nine CMV reference strains. A single 
substitution was identified at position 433, where Alanine was substituted for 
Threonine (A433T) as shown in Figure 14B. This was the only sequence deviation 
identified. The reference position of the substitution did not overlap with the reference 
positions of any published pp65 epitopes restricted through HLA-A*01, -B*08, or 
DRB1*03:01.  
A 
GATACGCCGGTGCTGCCGCACGAAACGCGACTCCTGCAGACGGGTATC
CACGTACGCGTGAGCCAGCCCTCGCTGATCCTGGTGTCGCAGTACACG
CCCGACTCGACGCCATGCCACCGCGGCGACAATCAGCTGCAGGTGCAG
CACACGTACTTTACGGGCAGCGAGGTGGAGAACGTGTCGGTCAACGTG
CACAACCCCACGGGCCGAAGCATCTGCCCCAGCCAGGAGCCCATGTCG
ATCTATGTGTACGCGCTGCCGCTCAAGATGCTGAACATCCCCAGCATCA
ACGTGCACCACTACCCGTCGGCGGCCGAGCGCAAACACCGACACCTGC
CCGTAGCTGACGCTGTGATTCACGCGTCGGGCAAGCAGATGTGGCAGG
CGCGTCTCACGGTCTCGGGACTGGCCTGGACGCGTCAGCAGAACCAGT
GGAAAGAGCCCGACGTCTACTACACGTCAGCGTTCGTGTTTCCCACCAA
GGACGTGGCACTGCGGCACGTGGTGTGCGCGCACGAGCTGGTTTGCTC
CATGGAGAACACGCGCGCAACCAAGATGCAGGTGATAGGTGACCAGTA
CGTCAAGGTGTACCTGGAGTCCTTCTGCGAGGACGTGCCCTCCGGCAA
GCTCTTTATGCACGTCACGCTGGGCTCTGACGTGGAAGAGGACCTGACG
ATGACCCGCAACCCGCAACCCTTCATGCGCCCCCACGAGCGCAACGGC
TTTACGGTGTTGTGTCCCAAAAATATGATAATCAAACCGGGCAAGATCTC
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GCACATCATGCTGGATGTGGCTTTTACCTCACACGAGCATTTTGGGCTG
CTGTGTCCCAAGAGCATCCCGGGCCTGAGCATCTCAGGTAACCTGTTGA
TGAACGGGCAGCAAATCTTCCTGGAGGTACAAGCGATACGCGAGACCGT
GGAACTGCGTCAGTACGATCCCGTGGCTGCGCTCTTCTTTTTCGATATC
GACTTGCTGCTGCAGCGTGGGCCTCAGTACAGCGAGCACCCCACCTTC
ACCAGCCAGTATCGCATCCAGGGCAAGCTTGAGTACCGACACACCTGG
GACCGGCACGACGAGGGTGCCGCCCAGGGCGACGACGACGTCTGGAC
CAGCGGATCGGACTCCGACGAAGAACTCGTAACCACCGAGCGCAAGAC
GCCCCGCGTCACCGGCGGCGGCGCCATGGCGGGCGCCTCCACTTCCA
CGGGCCGCAAACGCAAATCAGCATCCTCGGCGACGGCGTGCACGGCG
GGCGTTATGACACGCGGCCGCCTTAAGGCCGAGTCCACCGTCGCGCCC
GAAGAGGACACCGACGAGGATTCCGACAACGAAATCCACAATCCGGCC
GTGTTCACCTGGCCGCCCTGGCAGGCCGGCATCCTGGCCCGCAACCTG
GTGCCCATGGTGGCTACGGTTCAGGGTCAGAATCTGAAGTACCAGGAGT
TCTTCTGGGACGCCAACGACATCTACCGCATCTTCGCCGAATTGGAAGG
CGTATGGCAGCCCGCTGCGCAACCCAAACGTCGCCGCCACCGGCAAGA
CGCCTTGCCCGGGCCATGCATCGCCTCGACGCCCAAAAGCACCGAGGT
TGAGCACGCG 
 
B 
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Figure 14. Identification of A433T mutation in Patient 1’s CMV pp65 protein 
Patient 1 died from presumed CMV infection following three infusions of CMV-
specific VST. An A433T mutation was identified on the CMV p65 protein 
isolated from the patient’s plasma on day 35 post first-VST infusion. The DNA 
nucleotide sequence identified from the PCR product is shown in (A) and in (B) 
the A433T mutation is identified in the patient’s sample when compared to 
amino acid sequence of nine CMV reference strains.  
 
4.5 Discussion 
Third-party virus-specific T-cells have been shown to be efficacious in the 
treatment of recurrent and refractory viral infection following haemopoietic stem cell 
transplant. Understanding the immunological response following VST infusion in both 
responders and non-responders may provide important insights into how VST therapy 
can be further improved and which patients should be targeted for therapy in future. 
Post-infusion viral kinetics, changes in lymphocyte number and subsets and plasma 
cytokines, and persistence of infused cells, were evaluated. Parameters were compared 
between complete responders and those with partial or no response. Other factors that 
may have contributed to poor response such as the presence of HLA alloantibodies 
against VST, and the mutation of T-cell binding sites on target viral antigens were also 
considered.  
The viral kinetics of patients prior to VST infusion confirmed that patients 
recruited for VST therapy were a poor prognostic group. Patients had high copy number 
and early post-transplant CMV DNAemia, factors which have been linked to an 
increased risk of death in the first year post-transplant23. They had prolonged antiviral 
treatment due to persistent CMV DNAemia which is known to be associated with 
recurrent episodes of CMV infection and late CMV disease24. No significant 
differences in pre-infusion viral kinetics were found between patients who received 
single versus multiple infusions, suggesting prior viral kinetics do not predict for VST 
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response, Patient 2 was noted to have an unusual post-infusion course where he 
demonstrated persistently elevated but stable CMV DNAemia over a prolonged period 
of follow-up, with no apparent clinical consequences and not requiring further therapy. 
The mechanism for development of this ‘new set point’ is unclear, but deserves further 
investigation. 
Lymphocyte subset profiles prior to and following VST therapy were available 
for 26 patients treated with CMV-specific T-cells. At the time of initial VST therapy, 
all patients were greater than day 60 post-transplant with 14 of 26 greater than day 90 
post-transplant. Despite this, analysis showed an early post-transplant phenotype of 
high NK cells, low B-cells and low T-cell counts similar to that seen between day 30-
60 in HSCT patients not treated with VST therapy. This suggests immune recovery post 
HSCT may have been delayed in trial patients. This applied particularly to CD4+ cells, 
but also to a lesser degree to CD8+ cells, given that all patients had prior viral CMV 
DNAemia which would be expected to have expanded CD8+ T-cell numbers6. T-cell 
memory subsets showed low effector numbers, high median CD8+ effector memory 
cell counts, and a reduced ratio of median CD8+ effector to effector memory cells. 
Expression of the immunoinhibitory marker PD-1 was significantly elevated on CD4+ 
T-cells when compared to healthy individuals at steady state, which likely reflects a 
contribution from chronic viral antigenic stimulus and post-transplant alloantigen 
activation25. Elevated expression of PD-1 was present throughout follow-up and the 
significance of this is unclear. Limitations of sample volume prevented delineation of 
the post-treatment T-cell memory phenotype and functional capacity of the identified 
PD-1 expressing T-cells populations. Possible impact on clinical response and viral 
control could be investigated in future studies. T-regulatory cells did not appear to be 
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overrepresented at Day 0, suggesting a T-regulatory phenotype was unlikely to have 
contributed to the pathophysiology of poor viral control demonstrated by trial patients.  
Median lymphocyte counts increased at all timepoints post-VST infusion with a 
significant lymphocyte expansion noted between day 28 and day 59 post VST infusion 
corresponding to the median time of virological clearance. This expansion translated to 
but was not equivalent in all subsets; CD8+ effector cells demonstrated a large-fold 
expansion, whereas NK and T regulatory cells barely expanded. We also demonstrated 
an increase in functional CMV-specific immunity at day 59 post-infusion coincident 
with the CD8+ expansion, which is in keeping with reports that CMV-specific T-cells 
exhibit a terminal differentiated effector phenotype26. The exact mechanism 
stimulating T-cell expansion is unknown, but is unlikely to represent third-party T-cell 
expansion as infused third-party cells were only detected in the peripheral blood at very 
low frequency for short periods of time after VST infusion in this cohort. This is in 
agreement with previous reports12,14, although there are isolated cases in which 
prolonged third-party persistence has been observed27,28. These cases may be explained 
by individual factors such as degree of recipient immune suppression that may prevent 
allorejection of mismatched VST. Investigation for persistence at alternative sites such 
as at the site of tissue infection, lymph nodes or spleen would be an important avenue 
of future study. The TCR clone tracking performed in three patients shows the dominant 
post-infusion T-cell clones were present at low frequency prior to VST infusion, and 
none of the third-party VST-derived T-cell clones expanded significantly post-infusion. 
Two of three patients demonstrated complete donor T-cell chimerism on routine testing 
prior to VST infusion. These data suggest the expansion in CD8+ cell numbers post-
infusion represents HSCT-donor derived cell expansion. The HSCT donors were CMV 
negative implying that CMV-specific immune recovery would require naïve HSCT 
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donor T-cells to undergo thymic education. This could not be assessed as these patients 
had low CD4+ naïve T-cell numbers precluding assessment of CD31+ expression. T-
cell receptor excision analysis (TREC) are unused excised DNA fragments in T-cells 
created as a by-product of passage through the thymus. A more sensitive assay 
including CD8+ TREC analysis may be required to detect the contribution of thymic 
activity to CD8+ T-cell reconstitution in future trials29.  
The plasma cytokine profile was investigated in five patients treated with VST, 
but no specific peri-infusional pattern was identified. Given the marked expansion in 
CD8+ cells it was hypothesized that increases in the levels of IL-2, -IL-7 or IL-15 might 
correlate with lymphocyte expansion however these cytokines were not detected in the 
majority of patients. The dominant cytokines detected in all patients were IL-10 and 
TNF-α. High levels of IL-10 were correlated with peak CMV titres, and increased ratio 
of TNF-α to IL-10 appeared to occur during periods of viral control. Induction of human 
IL-10 is a known immunoevasion strategy of CMV30,31. The viral IL-10 homolog 
cmvIL-10 is responsible for upregulation of human IL-10 secretion from monocytes 
and dendritic cells resulting in suppression of proinflammatory cytokines. Only human 
IL-10 was measured in the assay, but high levels might reflect viral IL-10 induction. 
The balance between IL-10 and TNF-α as a marker of viral activity has been reported 
in solid organ transplants and requires further investigation in the post-HSCT setting32. 
Patient 1, who later died from presumed CMV infection, demonstrated high IL-10 
levels in association with persistently high CMV titres, and demonstrated no divergence 
between TNF-α and IL-10 levels. It was interesting to note that Patient 1 (with 
suspected but not proven CMV tissue disease) and the two patients with CMV colitis 
all demonstrated fluctuations in IL-6, which has previously been identified as a marker 
of CMV disease33. Future studies may benefit from a larger panel of cytokines to further 
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investigate nuances of response in particular subgroups such as clinical reactivation 
versus tissue disease.  
Consideration of factors contributing to poor response included analysis of the 
lymphocyte subset profiles, and investigation of HLA alloantibodies and mutations 
with the potential to impact on VST efficacy. Peak lymphocyte expansion and function 
CMV-specific T-cell response was lower in poor responders, but no specific 
lymphocyte subset profile was identified in association with poor response. A single 
non-responding patient was identified to have a VST-directed HLA alloantibody 
(although at lower titre than usually considered clinically relevant), and two other 
patients had inconclusive results. It is unknown whether this impacted the efficacy of 
VST administration, but high resolution HLA matching and identification of VST-
directed antibodies should be incorporated into future third-party VST product 
selection protocols. CMVpp65 DNA was isolated from the plasma of Patient 1 to 
investigate for the presence of mutations. No mutations were identified at published 
epitopes identified to be restricted through HLA-A*01, -B*08, and –DRB1*03, which 
were shared between the patient, HSCT donor, and the administered VST. However, 
an A433T substitution was identified, which was not present in nine CMV reference 
strains, and it is unknown whether this may have interfered with T-cell recognition, 
binding, or activation. 
These results provide a detailed insight into the immunological profile of patients 
before and after treatment with third-party CMV-specific VST. Patients with persistent 
and recurrent high risk CMV showed stalled adaptive cellular recovery post-HSCT, 
which improved following VST treatment in the majority of patients. Improvement was 
characterised by a disproportionate expansion of CD8+ effector cell and a rise in CMV-
specific functional immunity. Importantly, this lymphocyte expansion was not 
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associated with increased rates of GVHD (reported in Chapter 3), concurring with other 
publications12,14,34,35. Response to third-party VST treatment was not determined by the 
detection of infused cells as shown by us and a number of other groups14,34-38. These 
data suggest third-party VST infusion may facilitate reconstitution of functional 
immunity from the transplant donor.  
The combined profile of IL-6, IL-10, and TNF-α may provide a snapshot of host 
viral control. A possible role for IL-6 as a non-invasive CMV disease-monitoring tool 
could be further investigated. There was no specific profile before or after VST 
administration that identified patients at risk of poor response. Of the seven poor 
responders, five died prematurely from either relapse or non-VST targeted infection 
suggesting that failure to respond to third-party VST portends an extremely poor 
prognosis. Mechanisms underlying the recovery of transplant donor derived CMV 
immunity by third-party CMV specific T-cells require elucidation. The use of multi-
virus-specific third-party VST and tumour antigen specific T-cells will likely be the 
next steps to improve patient outcomes.  
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Chapter 5. Conclusion and Future Directions 
5.1 Background 
Viral infection following allogeneic stem cell transplantation continues to 
cause significant morbidity and mortality1-3 despite the introduction of rigorous 
nucleic acid monitoring strategies and the widespread application of prophylactic and 
pre-emptive strategies using efficacious antiviral medications4-6. Antiviral medication 
use is complicated by drug-related toxicity, significant cost, difficulties of 
administration, and development of drug resistance which can render treatment 
ineffective7-10. Antiviral drug therapy does not address the underlying problem of 
latent viral reactivation due to impaired reconstitution of virus-specific T-cell 
immunity post-transplantation. The advent of HSCT donor-derived virus-specific T-
cell therapy has provided an alternative option to the use of antiviral medications, and 
multiple early phase studies suggest promising efficacy and minimal toxicity11-13. At 
this time, no phase III-controlled trials have been published to confirm the benefit and 
safety of this approach over antiviral medication. Generation of a HSCT-donor 
derived product may not be possible for all patients in the setting of a seronegative 
donor or if donor starting material is not accessible to due logistical reasons or issues 
of consent. Manufacturing lag time may prevent timely availability especially early 
post-transplant. The HSCT-donor derived product is intended for a single recipient, 
making it a labour and cost-intensive process, particularly if the product is not used, 
and this limits commercial feasibility. It also restricts application to tertiary centres 
and research facilities. These barriers have prevented the adoption of HSCT-donor 
derived VST into routine practice. 
The use of banked, cryopreserved third-party donor-derived VST offers 
several potential advantages over HSCT donor-derived VST. This thesis aimed to 
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investigate the feasibility of establishing a bank of third-party CMV, EBV, and Adv-
specific T-cell products and to demonstrate the safety, efficacy, and immunological 
consequences of use in a phase I multicentre clinical trial to treat aHSCT patients with 
recurrent and refractory viral infections.  
5.2 Overview of key outcomes and findings in response to thesis aims 
5.2.1 Aim: To create and characterise a bank of third-party donor-derived CMV, 
EBV, and Adv-specific T-cells  
In Chapter 2, the process for incorporating third-party donor T-cell 
manufacturing into an existing HSCT program was described in detail. An optimised 
method for VST generation and characterisation of the VST products was reported. A 
model for targeting third-party donors based on HLA was presented. 
Streamlining of third-party VST manufacturing included efforts to minimise 
cost and workload associated with the rigorous process of donor screening. Sibling 
HSCT donors were recruited requiring minimal additional screening to be performed 
to meet regulatory requirements over and above that required for stem cell donation. 
Use of a small portion of the apheresis material for third-party VST culture14 
minimised the impact on the donor and rationalised resources required. Use of 
existing HSCT transport processes allowed VST to be shipped to interstate and 
overseas centres within 3-5 days of initial product request. 
With the aim to maximize simplicity and speed of production, the 
manufacturing method chosen was a 21-day culture using GMP-grade overlapping 
peptide mixtures for antigen stimulation. Poor expansion exhibited in apheresis-
sourced EBV and Adv-specific cultures required optimization with a CD14 selection 
step. The availability of a new GMP-grade peptide mixture for EBV containing an 
array of dominant and subdominant antigens since the establishment of the bank used 
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in the current study may further improve manufacturing efficiency and facilitate 
virus-specificity testing for EBV-specific products for future use. Products were 
polyclonal CD4+ and CD8+ T-cell, with some expression of immunoinhibitory 
markers likely reflecting prolonged antigen stimulation associated with the culture 
method and a dominant effector memory subtype in the CD4+ population15. 
Correlation of product composition and efficacy was unable to be ascertained due to 
trial design and the low number of treatment failures, and should be a focus in future 
studies. Of note, several patients were successfully treated with infusions matched at a 
single HLA molecule. This is in contrast to the early trials of third-party VST in a 
predominantly solid organ transplant population, where a higher number of HLA 
matches correlated with efficacy16. It has been suggested that not all matched HLA-
restricted epitopes offer equivalent efficacy; epitopes presented by some alleles of 
HLA-B35 have been proposed to result in inferior efficacy17. Efficacy against CMV 
for trial patients was demonstrated irrespective of HLA-restricted epitope designation 
including single matches with antiviral activity restricted through HLA-A*01 YSE, 
A*02 NLV, and B*07 TPR. B*35 CPS could not be assessed as no VST infusions 
were restricted through this epitope alone. Beyond consideration of the impact of 
individual pp65 epitopes on efficacy, production of a multiple CMV-antigen 
stimulated product may offer some theoretical advantage over a single antigen 
approach. CMV IE-specific CD8+ T-cell immunity has been shown to offer additional 
protection over CMV pp65 T-cell immunity in preventing progression to CMV 
disease in solid organ transplant recipients18. A small study in the post-HSCT setting 
has also shown functional IE-specific CD8+ T-cell immunity to be integral in 
protection from recurrent CMV reactivation and disease19. Targeting multiple 
antigens in the T-cell product may also limit opportunities for immunoevasion20. 
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Offering broader antigen coverage in the manufactured product may improve efficacy 
and should be investigated in future studies. 
A model using local HLA frequencies was described to direct donor 
recruitment based on HLA type. The aim of the model was to generate a small 
number of VST products of dominant HLA types that could be used in a large 
proportion of the ethnically diverse local population. The bank of 46 products 
generated covered 97% of VST requests, and VST products from only 14 donors were 
used to treat the 30 trial patients administered 50 infusions. The number of products 
required for a successful bank with high HLA coverage could likely be reduced using 
the final optimised culture method. The optimisation of the method led to the 
generation of a number of extra products that did not contribute to better HLA 
coverage. Assuming immunodominant responses restricted through specified high 
frequency HLA types were established, the model suggested that as few as six donors 
could produce a VST bank capable of providing a single HLA matched VST suitable 
for 90% of local recipients. This requires confirmation in future studies.  
This research demonstrates the feasibility of a streamlined approach for 
establishing such a bank within an existing HSCT program. A model was put forward 
to guide the best possible choice of donors. A small bank of targeted products was 
adequate to service a large and HLA-diverse population. These results may encourage 
the establishment of more local third-party VST banks. Neuenhahn et al21 highlighted 
the importance of having banked products immediately available rather than trying to 
identify third-party donors at the time of need. Third-party donors for urgent VST 
generation were identified in only 14% of donor-negative HSCT recipients requiring 
treatment for refractory viral infection, and a number of patients died while awaiting 
donor identification. Banked products could improve the rapid accessibility to VST 
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therapy for many HSCT patients. An increased availability of products may assist the 
expansion of VST indications to other at-risk populations such as solid organ 
transplant recipients and patients with other immunodeficiencies. 
5.2.2 To assess the safety and efficacy of partially HLA-matched, third-party, VST as 
treatment for refractory CMV, EBV, or Adv infection in allogeneic HSCT recipients 
in a phase I clinical trial  
A multicentre clinical trial examining the safety and efficacy of third-party 
VST products for treatment of recurrent and refractory viral infections was reported in 
Chapter 3.  
The twenty-eight patients treated for persistent or recurrent CMV infection 
were a poor prognostic group in terms of propensity for recurrent viral infection, risk 
for late CMV disease, non-relapse mortality and overall mortality22-25. Transplant risk 
factors included a high proportion of mismatched and unrelated donors, T-cell 
depletion with ATG, and D-/R+ CMV serostatus26-30. A number of patients had prior 
or active CMV disease at enrolment with consequent risk for recurrent and late CMV 
disease25. Half of patients tested demonstrated antiviral drug resistance mutations, this 
is high compared to other studies, but the patients were clinically drug resistant by 
definition of eligibility22,31.  
Despite these poor prognostic features, the cumulative response rate at 12 
months was 93% for overall response and 76% for complete response. Overall 
survival at 12 months was 69%. Complete responses were demonstrated in patients 
with active CMV disease and drug resistance mutations. Responses were durable, 
although glucocorticoid administration was associated with the re-initiation of 
pharmacological antiviral therapy after final VST infusion in four patients. This 
highlights the negative impact of steroids on virological control as published in other 
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studies32,33. These results were comparable to the two other published studies of 
greater than ten patients treated with third-party VST for refractory infection34,35. At 
six weeks post infusion, the combined cumulative incidence of overall response for 71 
patients treated for CMV, EBV, and Adv was 84% (CR 42%, PR 42%). Leen34 
highlighted a dismal prognosis in eight patients for whom a suitably matched VST 
product could not be identified; 75% died from viral disease. 
There was no demographic or VST-related factor that correlated with lack of 
complete response in seven patients. Strikingly, the mortality rate in incomplete 
responders was 87%. At three months follow-up after final infusion, one non-
responder remained alive with stable CMV DNAemia which did not require re-
initiation of antiviral therapy. Of the six that died, five were infectious deaths (two 
bacterial, two viral, one parasitic) illustrating the degree of immune impairment in 
this patient cohort. Two patients died from VST-targeted infections. One patient died 
two weeks following EBV-specific VST infusion for EBV viremia, which was due to 
occult relapse of EBV-associated NK/T lymphoma. The reason for failure may be that 
VST control was outpaced by rapid malignant proliferation. The other patient was a 
long-term non-responder, following initial partial response, and died from presumed 
CMV disease despite three VST infusions and antiviral therapy over three months. 
This patient had an absent CMV-specific T-cell response throughout follow-up. HLA-
disparity between VST product, patient and HSCT donor has been identified as a 
cause for third-party VST failure 36. This was unlikely in this case, as antiviral activity 
was demonstrated to be restricted through an HLA antigen shared between the VST, 
HSCT donor and recipient. A single CMV pp65 mutation was identified, but not in a 
region thought to be associated with epitopes for the HLA-restrictions of interest. An 
indirect contribution to immune evasion cannot be ruled out.  
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Two complete responders treated with CMV-specific VST, died from EBV 
PTLD and disseminated adenovirus complicating severe gut GVHD, respectively. 
Neither patient was fit for treatment with on-trial VST. Non-VST targeted viral 
infection, particularly respiratory virus infection, was a significant cause of morbidity 
on the trial contributing to a third of the serious adverse event notifications. Recent 
studies have confirmed the high frequency of multiple virus infection post-transplant 
associated with high morbidity and mortality1,3. This data supports a multi-virus T-
cell approach used successfully in HSCT-donor and third-party donor VST 
trials34,35,37. Tzannou35 showed that dual viral infections could be successful treated 
with a single infusion of multi-specific third-party VST. Third-party VST have not 
been studied in a prophylactic setting. It is currently unclear whether a multi-specific 
product infused targeting a single infection, would provide protection against future 
viral infections, but is worthy of further investigation. 
Third-party VST treatment was not complicated by significant infusion-related 
toxicities and were not attributed causation for any serious adverse events. The overall 
rate of GVHD was within expectations for the studied population which concurs with 
findings of third-party VST trials as detailed in Chapter 1. Acute GVHD occurred at a 
rate of 7% comparable to the rate of 16% reported by the two other large studies of 
VST therapy34,35. This is an important finding as over half the VST infusions were 
highly HLA-mismatched, and subsequent infusions were often from different donors 
at high T-cell doses. A single report in the literature of potential bystander liver 
GVHD triggered by third-party VST was inconclusive as liver biopsy showed only 
cells from the HSCT mismatched donor and no infused VST38. In vitro alloreactivity 
of HLA-mismatched VST derived from the HSCT donor does not correlate with 
clinical GVHD, and this data suggests the same may be true for third-party VST39. 
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GVHD has been reported at low frequency but randomised controlled trials are 
required to confirm both the efficacy and safety of third-party VST treatment. 
5.2.3 Aim: To investigate and characterise the immunological consequences of third-
party VST infusion including assessment of: immune cell frequencies, cytokine 
activity, virus-specific T-cell immunity, and third-party T-cell post-infusion 
persistence. 
A detailed analysis of immunological consequences of VST infusion was 
presented in Chapter 4.  
Examination of the pre-VST treatment CMV viral kinetics confirmed the poor 
prognostic outlook and resistant status of infection at enrolment. Patients 
demonstrated early post-transplant, high titre CMV infection which is associated with 
high risk for CMV disease, high non-relapse and lower overall survival23-25. Patients 
developed CMV DNAemia that persisted or recurred over a median period of 8 weeks 
prior to VST therapy despite pre-emptive antiviral therapy. No significant difference 
in duration or peak CMV load prior to VST was noted between single or multiple 
VST infusion patients suggesting VST result in viral clearance irrespective of prior 
viral kinetics.  
A detailed immunophenotypic analysis was performed prior to VST therapy. 
Trial patients were frequently lymphopenic and exhibited a lymphocyte subset profile 
usually seen in patients 30-60 days post-transplant. This was surprising given that all 
patients studied were greater than day 60 post-transplant, and the majority of patients 
were greater than 90 days post-transplant. Absolute T-cell counts, particularly CD4+ 
T-cells, were low. CD8+ T-cells were lower than expected given that all patients had 
experienced CMV DNAemia which would normally result in expanded CD8+ T-cell 
numbers 30. T-memory subsets showed high numbers of CD8+ T effector memory 
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cells, and a reduced ratio of CD8+ T-cell terminal effectors to T effector memory 
cells. CD4+ terminal effector T-cells were also low. The high PD-1 expression on 
CD8+ and CD4+ T-cells may reflect the high T effector memory composition of these 
T-cell subsets15. Alternatively, PD-1 expression may represent T-cell exhaustion in 
response to chronic viral and alloantigen stimulus. CMV-specific T-cell immunity 
was undetectable in a significant number of patients. Information pooled from 
multiple small studies appears to suggest this profile of low CD8+ T-cells, reduced 
ratio of T terminal effector to T effector memory cells, and lack of functional CMV-
specific immunity is more frequent in D-/R+ compared to D+/R+ transplants and 
results in increased rates of refractory CMV infection and disease30,40,41. The low 
CD4+ count may have contributed to impaired reconstitution of CMV-specific CD8+ 
T-cells42. 
Following VST infusion, the impaired immune profile changed. There was a 
significant rise in the median absolute lymphocyte count at 59 days post-VST. This 
was due to a marked expansion of T-cells, specifically CD8+ terminal effector cells, 
and was associated with a significant increase in functional CMV-specific T-cell 
immunity. Although expansion of CD4+ effectors was seen there was no overall rise 
in CD4+ counts until after day 90. These changes coincided with median time to 
virological response for the entire cohort. This is consistent with other studies that 
have shown that a terminal effector phenotype exhibiting functional cytokine 
production is required for adequate control of CMV post-transplant40,41,43,44. Other 
studies of third-party VST studies have reported expansion of CD8+ T-cells correlated 
with virological response21,34,35.  
Examination of the origin of the expanded T-cells suggests they were not 
derived from the infused VST product. Using highly sensitive testing, persistence at 
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very low frequency was detected in three patients beyond three days, with the longest 
duration up to 27 days. Persistence did not correlate with virological response. 
Tzannou35 showed that 11 of 16 complete responders had measureable VST 
persistence, but there was no detectable VST persistent in five complete responders. 
Another study showed two of three complete responders had no detectable VST 
persistence21. VST persistence may not be a requirement for virological response.  
TCR clone tracking performed in three patients, showed that all T-cell clones 
that expanded to significant levels post-infusion were present in patients prior to VST 
infusion. Two of the patients were reported to have exclusive HSCT donor T-cell 
chimerism prior to VST infusion, which was also confirmed two months after VST 
infusion at the time of peak CD8+ expansion in one patient. Although not conclusive, 
this suggests T-cells that expanded following VST therapy were likely to be of HSCT 
donor origin rather than third-party donor origin. Another study has shown three 
patients treated with third-party VST developed expansion of CMV-specific CD8+ T-
cell present at low frequency prior to infusion. Persistence of third-party cells was not 
demonstrated in two patients using sensitive single-cell PCR CDR3 tracking on sorted 
CMV-specific T-cells, suggesting expanded cells were of HSCT donor, or less likely, 
recipient origin. Both patients developed complete response correlated to T-cell 
expansion which occurred around 60 days post-VST infusion21. Further investigation 
is required to confirm whether third-party VST infusion might stimulate HSCT donor 
T-cell expansion and transition to an effector phenotype, and to consider how this 
occurs.  
Of the plasma cytokines studies, VST infusion did not appear to be associated 
with any particular pattern of cytokine response. The dominant cytokines detected 
during follow-up were IL-10 and TNF-α; levels appeared to correlate with CMV 
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DNAemia. Human IL-10 is a suppressive cytokine, and induction is thought to be a 
CMV immune evasion strategy45. The high IL-10 levels in some patients may have 
contributed to the suppression of CD8+ T-cell effector functions46. The balance 
between IL-10 and TNF-α, and presence of IL-6 as a marker of CMV disease may be 
useful as rapid and simple biomarkers of viral control47,48. This would require 
validation in a large targeted study.  
Lymphocyte expansion and functional CMV-specific T-cell response were 
significantly lower in patients with partial or no response to virological therapy. One 
patient had a low titre HLA-antibody against a VST product and two other patients 
had inconclusive results. No other factors correlated with poor response.  
These results provide a detailed immunological profile of recipients of third-
party VST therapy and provide a number of avenues for further investigation.  
5.3 Strengths and weaknesses of this research 
The strengths of this research include: 
x a pragmatic model for integration of third-party VST therapy into existing HSCT 
programs was presented which may increase the number of centres capable of 
offering this type of ACT 
x the study presented in Chapter 3 is the first to report long-term safety and 
virological response following third-party VST therapy in a relatively large group 
of aHSCT recipients 
x the large group of patients treated with CMV-specific T-cell allowed a detailed 
investigation of the immunological consequences of the third-party VST therapy  
The weaknesses of this research include: 
x the lack of a control cohort did not allow determination of the true efficacy of VST 
therapy due to confounding antiviral therapy 
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x the use different donor VST products within a single recipient prevented 
correlation of VST product composition and efficacy 
x detailed examination of T-cell memory subsets was limited and could have been 
aided by the use of additional markers such as CD27 and CD28 to help further 
define phenotypic and functional capacities of products and post-VST responses 
x discussion of the possible origin of the expanding CD8+ T-cells was based on 
preliminary findings and requires dedicated assessment in a larger number of 
patients 
x low representation of patients with EBV and Adenovirus in the treated patients 
limited the assessment of VST therapy in these populations 
5.4 Future directions 
5.4.1 Assessment of efficacy in randomised trials of third-party VST 
The data presented in this thesis show the safety and durability of viral control 
achieved in the 12 months following third-party VST infusion. This is in concordance 
with the only other large trials of third-party VST treatment that have shown short-
term safety and efficacy in similar settings34,35. The lack of comparator arms and 
limited details of coincident antiviral medication in other studies during treatment 
with third-party VST makes it difficult to interpret the true efficacy of VST treatment. 
A trial of up-front third-party VST (<7 days of antiviral treatment) is currently 
underway and may provide supportive evidence of independent benefit for VST 
(ACTRN12618000343202). However, an unbiased assessment of efficacy requires a 
randomised controlled study comparing antiviral pharmacological therapy with third-
party T-cell treatment. Consideration of appropriate efficacy outcome measures will 
be required for future studies. This is illustrated by the use of third-party VST to treat 
BK infection where despite clinical improvement demonstrated in the majority of 
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treated patients the complete response rate was very low. “Complete virological 
response” used in third-party VST trials to date doesn’t capture all events of clinical 
importance and does not provide an assessment of viral recurrence after initial 
response34,49. A more useful measure may be “CMV infection requiring pre-emptive 
therapy or CMV disease” used in a recent study of CMV viral prophylaxis, which 
reflects a clinically relevant outcome and provides information on durability of 
response50. 
5.4.2 Expansion of pathogen targets and use of multi-virus specific products 
Infection with multiple viruses has been demonstrated in 62% of patients post-
transplant1,3. This leads to significant morbidity as demonstrated in Chapter 3; one 
third of trial participants had a serious adverse event due to viral infection 
(predominantly respiratory viral infection) and two patients died from infection with a 
virus that had not been covered by the prior mono-specific VST infusion. Expanding 
viral targets and creating multi-specific third-party VST should be a priority in future 
studies. The Baylor group recently reported the use of third-party T-cells multi-
specific for 5 viral targets including BK virus and HHV-6 virus35. A HSCT donor-
derived VST trial is currently underway targeting 6 viruses including Parainfluenza-3 
(NCT03180216), suggesting respiratory viruses could be the next target for 
incorporation into third-party VST trials. Pan-fungal T-cells have been successfully 
manufactured for clinical use in our laboratory51, and will used in an upcoming trial of 
third-party VST.  
5.4.3 Third-party VST in the setting of prophylaxis 
The focus of third-party VST studies has been on treatment rather than 
prophylaxis. This likely reflects the presumption that without persistence partially 
HLA-matched VST treatment is unlikely to provide benefit in a prophylactic setting. 
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The preliminary data presented in Chapter 4 suggests a possible role for third-party 
infusion in eliciting HSCT donor T-cell expansion. Prophylactic use of third-party 
VST in high risk patients with delayed T-cell recovery warrants further investigation. 
5.4.4 Targeting virus-associated malignancy  
5.4.4.1. Use of third-party VST genetically modified to target tumour antigens 
Relapse and infection are the most frequent causes of death post-transplant52. 
Recently, there has been a great deal of interest in combining VST with specificity for 
tumour antigens. VST can be genetically engineered to express chimeric antigen 
receptors (CARs) targeted to tumour antigens. Modified third-party EBV specific T-
cells expressing CAR-19 are currently under investigation for treatment of early 
relapse of CD19 positive lymphoproliferative disease post-allogeneic transplant 
(NCT01430390). Results for autologous CAR19 T-cells for treatment of acute lymphoid leukaemia have been very successful53. This is tempered by a severe systemic inflammatory toxicity known as cytokine release syndrome. It will be important to assess the toxicity profile of third-party CAR modified VST and observe for potential interactions with GVHD in the setting of partial HLA mismatch. 
5.4.4.2 Use of third-party EBV-specific VST to target primary malignancy or 
immunodeficiency not related to transplantation  A small number of patients have been treated with third-party VST for EBV-associated malignancy in the setting of congenital immunodeficiency syndromes54 or human acquired immunodeficiency virus (HIV)55. Results were mixed but dedicated trials are required. The use of third-party EBV-specific VST 
is under investigation for treatment of EBV-associated lymphoma or severe chronic 
active EBV (NCT02287311). Rejection of infused cells is a theoretical concern when 
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partially matched third-party VST are used in the setting of primary malignancy. This 
is addressed in this trial by the option of using lymphodepleting chemotherapy prior 
to third-party VST infusion. Another study is currently underway to examine the use 
of third-party EBV-specific T-cells in a variety of clinical situations including: EBV-
associated lymphoproliferative disease in HIV or congenital or acquired 
immunodeficiency; and EBV-associated malignancies such as nasopharyngeal 
carcinoma, haemophagocytic lymphohistiocytosis, and leiomyosarcoma 
(NCT00002663).  
5.4.4.3 Third-party VST in combination with drug therapies to target malignancy 
The combination of third-party EBV-specific T-cells with Ibrutinib, a small 
molecule Bruton’s tyrosine kinase inhibitor, is being investigated for treatment of 
EBV-associated lymphoma in patients with HIV (ACTRN12618001541291p). 
The combination of autologous EBV-specific T-cells with Nivolumab (PD-1 
inhibitor) is currently under investigation for relapsed and refractory lymphoma 
(NCT02973113). Nivolumab is a checkpoint inhibitor which acts by blocking binding 
to the inhibitory T-cell receptor PD-1. Checkpoint inhibitors have been used 
successfully in the treatment of melanoma, and more recently in the treatment of 
lymphomas56. Combination with third-party VST in the setting of EBV-associated 
malignancy or persistent EBV reactivation is worthy of investigation.  
5.4.5 Improving third-party VST composition 
Some investigators suggest that central memory T-cells have the optimal 
characteristics to prevent infectious complications post-transplant including high 
proliferative capacity and low capacity for causing GVHD. A study investigating the 
use prophylactic donor-derived central memory T-cell infusion infusions post-
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transplant has been completed and the published results are currently awaited (NCT 
02758223).  
Other potential options for improving third-party VST include modification 
resulting in resistance to steroids57, so VST could be used at times of high risk of viral 
reactivation such as during treatment for GVHD.  
5.5 Concluding statement 
This research provides a comprehensive description of the generation and use 
of third-party VST in aHSCT patients. A pragmatic and straightforward approach for 
establishment of local third-party VST banks is presented which may provide the 
opportunity for others to incorporate VST into their own HSCT programs. The long-
term safety and efficacy of using third-party CMV specific T-cells to reconstitute 
CD8+ T-cells and CMV-specific immunity was demonstrated in a group with high 
risk refractory CMV infection. Preliminary data suggests the mechanism of viral 
control may not be due to expansion of infused VST, and this presents opportunities 
for future research. These results provide a platform to justify the investigation of 
third-party VST in randomised controlled trials and investigation of therapy in other 
immunosuppressed populations.  
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A B S T R A C T
Current techniques to assess chimerism after hematopoietic stem cell transplantation (HSCT) are limited in
both sensitivity and precision. These drawbacks are problematic in the context of cellular therapies that fre-
quently result in microchimerism (donor chimerism <1%). We have developed a highly sensitive droplet digital
PCR (ddPCR) assay using commercially available regents with good performance throughout the range of clin-
ically relevant chimerismmeasurements, including microchimerism. We tested the assay using spiked samples
of known donor-recipient ratios and in clinical samples from HSCT recipients and patients enrolled on clin-
ical trials of microtransplantation and third-party virus-specific T cells (VSTs). The levels of detection and
quantification of the assay were .008% and .023%, with high levels of precision with samples of DNA content
ranging from 1 to 300 ng DNA. From the panel of 29 insertion-deletion probes multiple informative markers
were found for each of 43 HSCT donor-recipient pairs. In the case of third-party cellular therapies in which
there were 3 DNA contributors (recipient, HSCT donor, and T-cell donor), a marker to detect the cellular product
in a background of recipient and donor cells was available for 11 of 12 cases (92%). Chimerism by ddPCR was
able to quantify chimerism in HSCT recipients and comparison against standard STR analysis in 8 HSCT pa-
tients demonstrated similar results, with the advantage of fast turnaround time. Persistence of donor
microchimerism in patients undergoing microtransplantation for acute myeloid leukemia was detectable for
up to 57 days in peripheral blood and bone marrow. The presence of microtransplant product DNA in bone
marrow T cells after cell sorting was seen in the 1 patient tested. In patients receiving third-party VSTs for
treatment of refractory viral infections, VST donor DNA was detected at low levels in 7 of 9 cases. ddPCR offers
advantages over currently availablemethods for assessment of chimerism in standard HSCT and cellular therapies.
© 2018 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) pro-
vides a potentially curative therapy for a number of malignant
and nonmalignant hematological conditions. This treat-
ment relies on the establishment of donor hematopoiesis in
the recipient but can result in prolonged periods of mixed
donor and recipient chimerism. When HSCT is performed for
malignant disease, prolonged persistence or recurrence of
mixed chimerism is generally considered undesirable as it is
associated with disease recurrence. The use of cellular
infusions is becoming more commonplace in transplant
practice. These include third-party donor antigen-specific
T-cell infusions for treatment of infections and nonengrafting
adoptive cellular therapies such as natural killer (NK) cell
infusion [1,2] and microtransplantantation in acute myelog-
enous leukemia (AML) [2-8]. Depending on the clinical
situation, highly sensitive detection of states of mixed chi-
merism may assist in the detection of early relapse of
malignancy or could predict therapeutic benefit following cel-
lular therapies.
Sensitive methods of quantifying chimerism with preci-
sion and rapid turnaround are needed. Currently, short tandem
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repeat (STR)–based methods are utilized in many clinical
transplant laboratories. When optimized, this assay has a sen-
sitivity of .8% to 1.6% and is not suitable for assessment of
chimerism in the micro range (<1%) [9]. Quantitative PCR
(qPCR) methods [10] have inherent technical complexity lim-
iting their uptake in clinical laboratories. Droplet digital PCR
(ddPCR) methods that show improved sensitivity and pre-
cision compared with previous methods have been reported
[11-14], but the need to establish a set of informative targets
in house is beyond the scope of most clinical laboratories. To
address this, we sought to validate a sensitive and precise
ddPCR chimerism assay by using commercially available re-
agents for use in a general clinical transplant setting.
METHODS
The study was conducted with approval from Western Sydney Local
Health District Ethics Committee.
Study Participants
Blood from otherwise healthy individuals undergoing venesection for
hemochromatosis was used for validation assays. Three sets of clinical samples
were assessed (see Figure 1). First, peripheral blood samples obtained for
chimerismmonitoring from patients undergoing HSCT for AML frommatched
related or cord blood donors. This sample set included patients with AML
who underwent reduced intensity conditioning and were known to have
had mixed donor-recipient chimerism through the post-transplant course.
Second, peripheral blood from HSCT recipients who received 2 × 107 cells/
m2 virus-specific T cells (VSTs) from third-party partially HLA-mismatched
donors on a clinical trial (R3ACT trial; NCT02779439). This sample set in-
cluded triplets of the recipient, original transplant donor, and the third-
party VST donor. Third, peripheral blood and marrow samples from patients
with AML undergoing microtransplantation with partially HLA-matched un-
related donors after consolidation chemotherapy on a clinical trial (SCRAMBLE
trial; NCT02189824). These patients received 2 g/m2 of cytarabine twice a
day on days 1 to 3 of each of 3 consolidation cycles with 0.5 × 108 CD3 cells/
kg on day 5without the use of immune suppression. This sample set included
pairs of recipient and microtransplant donor. Clinical results of the clinical
trials are reported separately [15,16].
Figure 1. Clinical scenarios of samples used for this study and expected chimerism.
Panel 1. Samples obtained from healthy HSCT donors, recipients, and 2 cell banks were used in this study. Hematopoietic progenitor cell apheresis (HPCa) or
donor lymphocyte infusion (DLI) was directly administered to transplant recipients and additional material cryopreserved for later use. Cryopreserved HPCa
or DLI was entered into the cell bank when no longer needed by the original transplant recipient (SCRAMBLE trial cell bank). A portion of the fresh HPCa or
DLI was used for manufacture of VSTs for the R3ACT trial cell bank.
Panel 2. Standard hematopoietic stem cell transplantation resulting in mixed recipient-donor chimerism of variable degree depending on conditioning, post-
transplant immune suppression and disease status.
Panel 3.Microchimerism of third-party donor–derived VST (R3ACT trial). Patients who developed viral reactivation that did not respond to first line antiviral
therapy were administered third-party VSTs. This resulted in mixed chimerism with 3 DNA contributors (recipient, stem cell donor, and third-party T-cell
donor).
Panel 4. Microchimerism from microtransplantation (SCRAMBLE trial). Patients with AML in remission underwent 3 consolidation cycles comprising inter-
mediate dose cytarabine followed by infusion of partially HLA-matched unrelated donor cells (HPCa or DLI) from the cell bank. No immune suppression was
used and long-term engraftment was not expected.
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Genomic DNA Purification
Genomic DNA (gDNA) was extracted from peripheral blood or bone
marrow mononuclear cells from healthy donors and patients undergoing
transplantation, using the Promega Wizard SV Genomic DNA Purification
System (Promega, Madison,WI) or QIAsymphony automated system (QIAGEN,
Hilden, Germany). Flow cytometry sorted bone marrow cell subsets con-
taining up to 50,000 cells had gDNA extracted and amplified with REPLI-g
Mini kit (QIAGEN). gDNA was extracted from flow cytometry–sorted bone
marrow cell subsets with more than 50,000 cells using QIAamp DNA Micro
kit (QIAGEN). gDNA was quantitated using a Lambda Bio+ spectrophotom-
eter (PerkinElmer, Waltham, MA) or the Quant-iT PicoGreen dsDNA Assay
Kit (Thermo Fisher Scientific, Waltham, MA).
Real-Time PCR (qPCR) Typing
A commercial kit intended for the assessment of post-transplant chi-
merism using a real-time qPCR platformwas purchased fromGenDx (Utrecht,
the Netherlands). Typing of donor and recipient samples to determine in-
formative insertion and deletion polymorphisms (indels) was carried out
using the KMRtype Genotyping Primer/Probe Kit (GenDx). This kit con-
tains primer probe sets for an array of 28 polymorphic indels across 18
chromosomes as well as a Y-chromosome–specific locus. In brief, the 29 in-
dividual assays premultiplexed as ten 4× primer/probe mixes were pipetted
onto a hard-shell PCR plate in 10-μL aliquots. A total of 40 ng of template
DNA and 5 μL of HotStarTaq Plus (QIAGEN) mastermix were added to each
well. The plate was sealed and amplified in a qPCR thermal amplifier (CFX96
Touch, Bio-Rad, Hercules, CA) for 40 cycles: initial denaturation (95°C for
5 minutes), denaturation and annealing/extension phases (95°C for 15
seconds, 62°C for 1 minute, 40 cycles). Fluorescence was assessed for FAM,
CalOrange, and CalRed during the amplification cycles. Results were ana-
lyzed using CFX Manager Software to identify informative assays for each
donor-recipient pair, or in the case of third-party cellular therapies or double
cord transplant, the recipient/donor 1/donor 2 triplet.
Digital PCR
The commercial GenDx tracking assays were incorporated into a modi-
fied protocol to allow for analysis on a ddPCR platform instead of qPCR. The
tracking kit contains the 29 individual assays each using a FAM probe. Single-
target PCR was run individually for 2 tracking assays informative for recipient
and donor. To allow for calculation of chimerism as a duplex FAM/HEX re-
action in a single well, we modified the method to include the chimerism
assay in the FAM channel with a reference gene in HEX-PrimePCR ddPCR
copy number assay RPP30 (Bio-Rad; see Figure 2).
ddPCR analysis was performed on the Bio-Rad QX200 droplet genera-
tion and reading platform according to the manufacturer’s instructions. In
brief, ddPCR mixes were setup with final volume 22 μL with minor differ-
ences between the methods of quantitation as described subsequently. Each
reaction contained 11 μL (methods 1 and 2) or 10 μL (method 3) ddPCR
Supermix for Probes (no dUTP; Bio-Rad), 5 μL of the selected 4× KMRtrack
Monitoring Assay (Assays 1 to 28, 30) in FAM (GenDx), 1 μL 20× RPP30 Ref-
erence Gene in HEX for method 3 only, 2 μL HindIII-HF restriction enzyme
diluted 1:10 in CutSmart 10× buffer to a concentration of 2 units/μL (New
England Biolabs, Ipswich, MA), and 4 μL template gDNA to a maximum of
300 ng/well. Template gDNA extracted by REPLI-gMini or QIAamp DNAMicro
kits was diluted 1:4 in water before being added to the ddPCRmix to prevent
inhibition of the reaction by gDNA extraction/amplification kit reagents.
Samples were processed using the QX200 droplet generator and trans-
ferred to an Eppendorf twin.tec semi-skirted 96 well PCR plate (Eppendorf,
Hamburg, Germany), sealed and amplified in a C1000 touch thermal cycler
(Bio-Rad) using the following conditions: enzyme activation (95°C for
10 minutes), denaturation and annealing/extension cycles (94°C for
30 seconds, 62 for 1 minute, 40 cycles), Enzyme deactivation (98°C
for 10 minutes), ramp rate 2°C/second. Amplified droplets were then read
on the QX200 droplet reader and analyzed using QuantaSoft software
(Bio-Rad).
Quantification was performed 3 ways (Figure 2):
1. Single-probe, single-color assay. The absolute copy number per μL as
calculated by the in-built Poisson distribution algorithm was normal-
ized against the amount of input DNA in μg to give copies/μg as the
quantity of target detected.
2. Recipient and donor probe, single-color assay. Chimerism percentage was
determined using the calculation:
% chimerism recipient copies L
recipient copies L donor co
=
+
( )µ
µ pies Lµ( ) ×100
3. Dual-color assay with reference gene. Chimerism percentage was de-
termined using the calculation:
% chimerism copies L FAM channel copies L HEX channel= )
×
( )[ ]2 µ µ
100
(in the unusual situation of the indel being homozygous the concentration
of the FAM channel was not doubled).
Positive controls of 100% donor of interest, negative controls of 100%
recipient (with donor specific probe), and no template controls were in-
cluded with each run.
Cell Sorting
Bone marrow mononuclear cells were resuspended in phosphate buff-
ered saline (PBS) containing 5% fetal bovine serum (FBS) and 20% human
Fc receptor blocking reagent (Miltenyi Biotec Inc., Auburn, CA). Cells were
stained with CD3 FITC, CD19 PE, CD34 PE-Cy7 (all BD Biosciences, San Jose,
CA) for 20 minutes at 4°C. Cells were washed with PBS+5%FBS and resus-
pended in 100 μL PBS+5%FBS and labeled with DAPI (Sigma-Aldrich Corp,
St Louis, MO). Cells were filtered through a 35-μm nylon mesh cell strainer
and sorted on BD FACSAriaIII (BD Biosciences) using a 70-μm nozzle into
CD34+CD19–, CD19+CD34–, CD34–CD19–CD3+ and CD34–CD19–CD3–
populations.
STR
A total of 10 to 20 ng of DNA samples from donor and recipient were
amplified using 4 multiplex STRmaster mixes (developed in house) for iden-
tification of informative markers. The PCR products were then run on a 10%
polyacrylamide gel along with the 100-bp ladder and silver stained. The in-
formative markers were selected and used for follow-up samples. Amount
of donor and recipient in post-transplant samples were established by in-
tensity of the bands on 10% polyacrylamide silver-stained gel. Therefore,
results were reported as greater than or less than the percentage.
RESULTS
Informativity of Commercial Typing Assay in Recipient-
Donor Pairs and Triplets
Thirteen HLA-matched stem cell transplant donor-recipient
pairs (Supplementary Table S1) and 30 HLA-mismatched
transplant dual-donor triplets (Supplementary Table S2) were
assessed for informativemarkers using the commercial typing
kit according to the manufacturer’s instructions. Informa-
tive assays to detect the presence of donor or recipient DNA
were found for each pair, with a median of 6 informative
markers in HLA-matched transplants and 8 for mismatched
transplants. All of the 29 assays were informative in at least
1 case. For the dual-donor triplets (comprising stem cell trans-
plants followed by third-party cell therapies [R3ACT trial] and
1 AML patient having a double cord transplant), in 6 of 13
(46%) of the cases, informative markers were found to dis-
tinguish the recipient from each of the 2 donors. In 11 of 12
cases from the R3ACT trial, the third-party donor T cell product
was able to be detected in the mixed background of recipi-
ent and primary transplant donor cells (92%).
Sensitivity and Linearity
To test the sensitivity and linearity of the assay, we per-
formed serial dilutions of gDNA from 2 healthy individuals
(Table 1, Figure 2B). DNA from donor 1 was diluted in DNA
from donor 2 in the ratios 1:1, 1:9, 1:99, 1:999, 1:9999, and
0:1. The input DNA per well was standardized at 240 ng with
8 replicates for each of the 3 low-concentration dilutions (1:99,
1:999, and 1:9999). Assay 11 was found to be informative for
donor 1 and was used to detect the presence of donor 1 DNA.
In the blank DNA replicates (donor 2 only), 3 events were seen
in the 8wells, corresponding to a limit of blank (LOB) of .001%.
We calculated the limit of detection (LOD) as the LOB plus
3 SDs of the LOB, resulting in a value of .008%. Precision of
the assay was acceptable down to low levels of chimerism,
with the coeﬃcient of variation 16% at a dilution of 1:999
(Figure 1). Therefore, at a chimerism level of .1%, 95% of results
will fall within 32% of the actual value. The limit of
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Figure 2. Chimerism assay. (A) Chimerism assay using 3 methods for quantitation. See Methods section for details. (B) Single-probe, 1-color assay with serial
dilutions of DNA from 2 healthy donors. Donor 1 DNA was added to DNA from donor 2 and a probe informative for donor 1 was used (assay 11). Results are
expressed as copies of target per μg of DNA. Percent chimerism cannot be calculated with this method. (C) Dual probe, single-color assay used to calculate
percentage chimerism by comparing 2 informative indels to detect serial dilutions of healthy donor 1 (assay 11) and healthy donor 2 (assay 28). Percent chi-
merism can be calculated using results from the 2 tubes (see Figure 2A and text for formula, percentage chimerism shown in Table 1). (D) Two-dimensional
plot of 10%, 1%, .1%, and .01% dilution of healthy donor 1 in to donor 2. Assay 11 used for Channel 1, RPP30 reference gene for Channel 2.
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quantification was calculated using 2 different methods: (1)
the LOB + 10SD and (2) LOD × 3. Both resulted in a limit of
quantification of .023% (Table 1). There was excellent corre-
lation between the expected and calculated chimerism using
linear regression (R2 = 0.99; Figure 3).
Serial dilutions of donor 1 and 2 were used to demon-
strate the calculation of percentage chimerism using method
2 (Figure 2C) and method 3 (Figure 2D).
Results in Clinical Samples
1. Comparison of ddPCR with STR in patients undergoing
transplantation
Samples from 8 transplant recipients who had chime-
rism performed by STR as part of routine post-transplant
care were tested using the duplex ddPCR assay (Table 2).
STR and ddPCR results were comparable in most samples.
Figure 2. (continued)
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2. Microchimerism.
To assess the ability of the assay to detect small amounts
of DNA in patients undergoing cellular therapies we used
the ddPCR assay in clinical samples collected in 2
clinical trials in which very small amounts of donor DNA
was expected.
a. Microchimerism post third-party T-cell infusion (R3ACT
trial)
Twelve patients undergoing treatment with virus specif-
ic T-cell infusions for resistant viral infections were
assessed with ddPCR to determine the degree of persis-
tence in the peripheral blood. An informative marker or
markers targeting the third-party donor was selected after
genotyping. An informative marker was available in 11 of
12 cases (92%) and adequate sample was available in 9 of
these cases. Third-party donor DNA was detected in 7 of
9 cases at low levels (median peak 57 [range, 15 to 2015]
copies/μg of DNA; Table 3).
b. Microchimerism in a clinical trial of partially HLA-
matched cell infusions administered after consolidation
for AML (SCRAMBLE trial).
Eight cell infusions were administered to 3 patients with
AML after consolidation chemotherapy for AML.
Microchimerism was detectable in peripheral blood or
bone marrow after all infusions by the single probe assay
(Figure 2, method 1). Persistence was detected for up to
51 days (see Figure 4 for a representative example). There
were low peripheral blood cell counts in the early period
postchemotherapy; however, infusion product was de-
Table 1
Serial Dilutions of Two Healthy Blood Donors Were Used to Investigate the Performance of the Assay at Different Chimerism Proportions
Replicates Dilution (Donor 1:Donor 2) Expected Chimerism for Donor 1 Actual Chimerism for Donor 1 SD CV
4 1:1 50.0% 51.294% 5.226% 10%
4 1:9 10% 9.559% .327% 3%
8 1:99 1% .837% .077% 9%
8 1:999 .1% .069% .011% 16%
8 1:9,999 .01% .006% .003% 48%
8 Donor 2 only 0% .001% .002% 204%
NTC - 0% 0% - -
Figure 3. Assay linearity. Linear regression of ddPCR chimerism measure-
ments versus expected chimerism in serial dilutions of DNA from 2 healthy
donors using assay 11.
Table 2
Chimerism Percentage Measurements Comparing STRs and ddPCR in 8 Patients Undergoing Reduced Intensity HSCT for AML
Patient Sex Donor ddPCR Assay Time Point Chimerism by STR Chimerism by ddPCR
AML1 F UCB 14 1 >95 100
2 90 99.99
3 >95 96.14
4 >95 99.98
5 >95 99.58
AML2 M MRD 22 1 >90 76.96
2 90 81.76
3 >95 99.08
AML3 F MRD 16 1 90 71.60
2 50 53.72
AML4 F MRD 30 1 >95 99.88
2 >95 89.39
3 >95 99.91
4 >95 99.89
5 >95 99.86
AML5 F MRD 30 1 >95 98.29
2 98 98.54
3 >95 99.95
AML6 M MRD 13 1 >95 99.95
2 90 99.94
3 >95 100
AML7 M MRD 13 1 >95 99.94
AML8 M MRD 13 1 >95 99.99
2 >95 99.98
3 >95 99.97
F indicates female; UCB, unrelated cord blood; M indicates male; MRD, matched related donor.
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tected in samples containing less than 5 ng DNA (minimum
1.2 ng). Two of the 8 infusions were assessed by the duplex
microchimerism assay using the reference gene. The in-
fusion products accounted for .55% and .84% of peripheral
blood cells at 2 hours following each of the 2 infusions,
respectively.
One dimensional plot of microchimerism measured by
ddPCR in the peripheral blood of a patient treated with par-
tially HLA-matched unrelated donor cell infusion on the
SCRAMBLE trial. Assay 25, informative for donor DNA, was
used. Microchimerism was detectable to day 51.
Bone marrow from 1 patient on this trial known to have
mixed chimerism by single-probe ddPCR at 3.4 copies/μg DNA
was sorted into T-cell, B-cell, CD34, and myeloid/NK/other
populations (Figure 5A). Microchimerism was detected pri-
marily in the T-cell population at 7.2% compared with <.01%
in CD34, .01% in myeloid/NK/other cells and 0% in B cells
(Figure 5B).
DISCUSSION
We have developed a highly sensitive assay to assess chi-
merism in recipients of cell therapies including stem cell
transplantation on a digital PCR platform using commercial-
ly available reagents.
As the proportion of transplants utilizing reduced inten-
sity or nonmyeloablative conditioning increased, so does the
importance of routine post-transplant chimerism monitor-
ing. Falling donor chimerism can herald graft loss or
impending disease relapse. Persistent mixed or falling donor
chimerism may be actioned by the tapering of immune sup-
pression or the administration of donor lymphocyte infusions.
Reappearance of recipient chimerism after having obtained
full donor chimerism is associated with disease relapse in
myeloablative and reduced-intensity conditioned trans-
plants performed for hematological malignancy [17]. The use
of third-party T-cell therapies and NEACTs is increasing. In
this setting, donor-derived or third-party cells will be present
at very low levels, due to the lower cell dose or nonengrafting
nature of the therapy. Accurate and reproducible methods for
chimerism detection are required for these clinical settings.
The most common method in use today, capillary electro-
phoresis analysis of STRs amplified by PCR, is limited to the
detection of chimerism fractions >1% of blood ormarrow cells,
thus potentially missing clinically relevant low-level recip-
ient chimerism. qPCR is a highly sensitive method and the
detection of polymorphic indel loci in the human genome can
be used as a chimerism monitoring technique, including in
themicrotransplant setting [10,18]. The disadvantages of qPCR
include variable eﬃciency of PCR amplification and need for
extensive validation and standards to be run with each assay.
ddPCR possesses the advantages of being both highly sen-
sitive and reproducible, making it an ideal monitoring tool.
To take advantage of the sensitivity of ddPCR probes need
to bind target indels with high specificity to avoid back-
ground noise since that would limit accuracy at low target
percentage. We have used a prevalidated set of commercially
available probes that can easily be incorporated in a standard
clinical laboratory practicewithout the need for extensive val-
idation. We used the qPCR platform according to the
manufacturer’s instructions. At least 1 informativemarkerwas
found in all donor-recipient pairs regardless of HLA match-
ing.Ourpatient set included fullymatchedsiblingandunrelated
donors, andmismatched unrelated andhaploidentical related
donors.We assessed the informativity of the typing set in clin-
ical scenarios of highly mismatched dual DNA contributors
(single donormicrotransplantation) and triple DNA contribu-
tors (third-party T-cell infusions and 1 case of double cord
transplant). There were an increased number of informative
Table 3
Chimerism Measured by ddPCR Post-HSCT in Patients Treated with Third-
Party Virus-Specific T Cells (R3ACT Trial); Third-Party Donor DNA Was
Detected in 7 of 9 Patients Tested
Patient Time Post–Third-Party
T-Cell Infusion
Copies/μg gDNA
R3ACT1 2 h 7
D3 25
D10 0
D17 0
D21 0
R3ACT2 2 h 19
D1 0
D7 0
D15 0
R3ACT3 2 h 2
D1 73
D7 17
D16 6
D25 8
D66 0
R3ACT4 2 h 41
D1 24
D7 38
D14 20
D21 21
D28 0
D59 0
R3ACT5 2 h 40
D1 0
D13 149
D23 12
D27 07
R3ACT6 2 h 215
D1 0
D7 0
D15 0
R3ACT7 2 h 15
D1 0
D7 0
D14 0
Figure 4. Microchimerism in a patient undergoing microtransplantation.
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Figure 5. Microchimerism in a sorted bone marrow sample. Bone marrow with known mixed chimerism from a patient on the SCRAMBLE trial was sorted
into 4 compartments and percent chimerism measured using the single-tube dual-color method. (A) FACS plots showing gating strategy for cell sorting. Bone
marrow samples were sorted into T cells, B cells, myeloid/NK/other cells, and CD34+ stem cells. (B) One-dimensional plot of chimerism showing enrichment
of donor cells in the T cell compartment.
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markers formorehighlymismatchedpairs. In the case of triple
DNA contributors, the typing probe set included informative
markers for all 3 contributors in a triplet in only 46% of cases
but was able to identify the minor contribution of interest in
92%of cases. A larger set of indels in the typing setmay improve
the utility for triple DNA contributor scenarios.
We describe quantitation in 3 ways: by copy number using
a single-color probe, percentage using probes for donor and
recipient informative indels in a single color divided in 2
mastermixes run seperately, or percentage using a single
mastermix with the indel probe in one color and a refer-
ence gene in a second color. All methods can provide a copy
number result. Advantages of the ddPCR include increased
accuracy with more DNA divided into more tubes, the com-
partmentalization of reactions by limiting dilution, and use
of Poisson statistics to calculate the starting copy number. The
adaptability of the platform and commercial kit allows for
modification of the assay to fit the clinical or research sce-
nario. In the case of standard post-transplant chimerism, 1
or 2 tubes would be suﬃcient to provide measurement of
donor chimerism to the sensitivity relevant for this clinical
setting. Using fewer tubes minimizes clinical sample require-
ment and is more cost effective. The ddPCR assay is more
accurate in estimating the smaller proportion of the DNA con-
tribution so to achieve accuracy through the full range of
donor-recipient chimerism in standard clinical monitoring of
HSCT recipients we propose that an informative indel for both
donor and recipient be run at each monitoring time point.
The workflow and staff input requirements for the ddPCR
assay are not onerous. The assay can be performed and re-
ported on the same day, saving significant staff time and
improving result turnaround and facilitating more frequent
chimerism testing according to recent recommendations [19].
For microtransplantation and T-cell therapies, larger quan-
tities of DNA across more tubes can be used to improve the
sensitivity in cases where a very low level of the donor of in-
terest is expected. Although sensitivity is increased with
increased DNA input, care must be taken to not generate too
many positive droplets (or too few negative droplets) such
that Poisson statistics cannot be applied, leading to inaccu-
rate estimations of copy number. We did not reach assay
saturation with a maximum input of 300 ng of DNA per well.
In addition, false positive droplets in nontarget DNA and
nontemplate control wells were rare. This low background
noise allows for accurate quantitation at the lower end of the
dynamic range of the test with a quantity of DNA that is fea-
sible from a routine blood sample. Microtransplantation with
HLA-mismatched donor cells has been proposed as a means
of obtaining graft versus leukemia effect without the com-
plications of standard transplantation. Guo et al. [3,4,20]
demonstrated increased remission rate, reduced number of
days of neutropenia and reduced relapse in patients with AML
who were treated with microtransplantation without the de-
velopment of graft-versus-host disease. Microchimerismwas
detected for days to months in these patients, with a peak
within the first 2 weeks of infusion. Likewise, we were able
to detect the presence of small amounts of donor DNA in
microtransplant recipients for up to 51 days postinfusion.
Third-party banked VSTs have been used to treat refractory
post-HSCT infections [5-7]. The biological mechanism un-
derlying the therapeutic benefit of these mismatched T cells
has not yet been clearly elucidated. We have been able to
demonstrate the short duration of persistence of third-
party VSTs. This is in sharp contrast to long-lived engraftment
in patients receiving transplant donor-derived VSTs [21].
Chimerism is routinely performed post-HSCT in lineage
sorted peripheral blood samples to examine subset engraft-
ment. We successfully employed using sorted bone marrow
specimens in patients on the microtransplant study with op-
timization for DNA amplification in the case of low cell
numbers and DNA quantity.
Our study has focused on hematopoietic cellular therapy
applications in which this ddPCR chimerism assay per-
forms well. We propose that this assay may have applications
in non-HSCT scenarios such as solid organ transplant and
nonhematopoietic cellular therapies, with alternative
biospecimens such as tissue biopsies. The highly sensitive and
adaptable assay described in this study has potential for wide-
spread uptake to inform clinical decision making in HSCT and
to better understand the biology of cell therapies from 1 or
more donors.
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ABSTRACT
Cytomegalovirus (CMV) remains a major contributor to morbidity and mortality following allogeneic
haemopoietic stem cell transplant (HSCT) despite widespread use of viraemia monitoring and pre-
emptive antiviral therapy. Uncontrolled viral replication occurs primarily in the ﬁrst 100 d post
transplant but this high risk period can extend to many months if immune recovery is delayed. The
re-establishment of a functional population of cellular effectors is essential for control of virus
replication and depends on recipient and donor serostatus, the stem cell source, degree of HLA
matching and post-transplant factors such as CMV antigen exposure, presence of GVHD and
ongoing use of immune suppression. A number of immune monitoring assays exist but have not
yet become widely accessible for routine clinical use. Vaccination, adoptive transfer of CMV speciﬁc
T cells and a number of graft engineering processes are being evaluated to enhance of CMV speciﬁc
immune recovery post HSCT.
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Introduction
Cytomegalovirus (CMV) is a betaherpesvirus that main-
tains lifelong latency after primary infection. 50 to 90%
of the population are CMV seropositive, although this
ﬁgure varies with age and geographic location. CMV
reactivates when host immunity wanes in the context of
haemopoietic stem cell transplantation (HSCT) and
uncontrolled viral replication can lead to disease in a
number of tissues. Despite improvements in monitoring
and pre-emptive therapy with antiviral agents, CMV
remains a major contributor to post-transplant infec-
tious and overall morbidity and mortality.1 Recovery of
immune function is essential to control of reactivation.
Here we review what is known about CMV immunity
post HSCT, how it can be measured and interventions
that may facilitate more rapid immune recovery.
The clinical impact of CMV post-allogeneic HSCT
In recipients of HSCT, CMV is one of the major patho-
gens responsible for infectious morbidity and mortality.
Viraemia usually precedes clinically signiﬁcant tissue
injury. Uncontrolled viral proliferation can cause pneu-
monitis, gastritis, enteritis, colitis, hepatitis, bone marrow
suppression, retinitis and encephalitis.1 CMV disease is
deﬁned as the presence of symptoms and signs consistent
with CMV end organ infection together with detection of
the virus by a validated method including immunohis-
tochemistry or viral culture. PCR positivity in tissue
without other evidence of disease is not considered diag-
nostic of CMV disease.1 CMV infection in HSCT occurs
primarily due to reactivation of latent infection in recipi-
ents who are seropositive pre transplant. Primary infec-
tion of seronegative HSCT recipients occurs largely due
to infusion of a stem cell product from a seropositive
donor. Transfusion related primary infection is now rare
due to the introduction of screening for CMV serostatus
of blood donors and the use of leucodepleted blood
products.2The majority of CMV reactivation is observed
in the ﬁrst 100 d post transplant, but late CMV has also
become more frequent as a result of conditioning regi-
mens or graft vs. host disease that produce prolonged
immune suppression, and prophylactic or pre-emptive
therapy that delay immune reconstitution.3-6
Surveillance for viral reactivation and pre-emptive
therapy with ganciclovir or foscarnet for asymptomatic
viraemia is the most widely accepted approach to man-
agement of CMV post HSCT. Therapy is instituted with
the aim of limiting viral replication prior to the develop-
ment of organ damage. Routine surveillance for the pres-
ence of CMV viraemia is performed regularly during the
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period of high risk up to 100 days, and extended in cases
of GVHD and ongoing immunosuppression. Ganciclovir
used at the onset of detectable viraemia has been shown
to signiﬁcantly reduce the incidence of CMV disease at
100 d when compared with placebo.7 In clinical practice
the threshold viral load to trigger antiviral therapy may
vary depending on the presence of risk factors such as
the type of transplant, the use of corticosteroids or
presence of GVHD and physician preference. Threshold
triggers are not currently standardised and it is not
known whether withholding antiviral therapy may be
safe in some subgroups of patients with CMV reactiva-
tion such as those with measurable CMV speciﬁc cellular
immunity. A recent single center retrospective analysis
of a CMV monitoring and pre-emptive therapy regimen
in 926transplants with seropositive donors or recipients
demonstrates the ongoing burden of CMV. Post-
transplant CMV was monitored using quantitative PCR
and a treatment threshold viral load of 150IU/ml (using
the WHO standard). The CMV reactivation rate was
69% in the ﬁrst 100 d. Pre-emptive antiviral pharmaco-
therapy was initiated in almost all these patients but
progression to high viral titer (>500 IU/ml) and CMV
disease was not prevented in all patients. The cumulative
incidence of CMV disease was 11% at one year. The
direct CMV disease mortality was low (1%) but overall
mortality in patients who reactivated was higher than in
those that did not.8 The use of antiviral agents as a pre-
emptive strategy or as treatment in such a large propor-
tion of patients comes with signiﬁcant draw-backs. It is
ineffective in some cases due to viral resistance.9,10
Ganciclovir is myelosuppressive while foscarnet is neph-
rotoxic and causes renal tubular acidosis and electrolyte
disturbance.11 The burden of cost of monitoring and
treatment with currently available antivirals is high. The
overall increment of cost of CMV reactivation compared
to no reactivation is estimated in the tens of thousands
of dollars.12
Widespread adoption of surveillance and pre-emptive
treatment has led to a fall in the number of patients pro-
gressing to CMV disease, most commonly pneumonitis
which still has a fatality rate of 50%, from 70–90% prior
to the availability of antiviral pharmacotherapy.4,13-15
Nonetheless, patients who are seropositive for CMV or
who receive transplants from CMV seropositive donors
continue to suffer an excess of non-relapse mortality
after transplant.16-21
Given the impact of CMV post transplant, measures
aimed at prevention and early detection of CMV in
HSCT are warranted. Primary prevention includes the
early assessment of recipient CMV status, with the use of
leukodepleted blood products for all seronegative recipi-
ents. Due to the impact on transmission and risk of
CMV infection, as well as CMV-speciﬁc immune recon-
stitution (as discussed later), CMV status is an important
consideration in HSCT donor selection, particularly in
unrelated donor transplantation. Guidelines recommend
prioritising CMV seronegative donors for CMV seroneg-
ative recipients, and CMV seropositive donors for CMV
seropositive recipients.19,21,22
There is a clear need for alternative therapies for
CMV. A number of pharmaceutical alternatives are
under investigation. Brincidofovir, a lipid conjugated
prodrug of cidofovir, showed strong antiviral activity in
preclinical and early phase clinical trials. While a signiﬁ-
cant reduction in the incidence of CMV was shown in a
phase III trial, the therapeutic window was narrow with
unacceptable gastrointestinal side effects seen at higher
dosages.23 Maribavir, a benzimidazole antiviral agent
that inhibits viral replication, did not meet the endpoint
of prevention of CMV disease.24 Letermovir demon-
strates dose dependent antiviral activity and a favorable
safety proﬁle and a phase III study is underway.25
CMV immunity in the normal individual
CMV infection results in the development of an adaptive
immune response involving humoral and cellular factors.
The relative importance of humoral immunity in
humans is not clear, with conﬂicting indirect evidence.
Clinical observations imply that humoral immunity at
best plays only a part in the control of CMV. The pres-
ence of high titer antibodies has been associated with
protection from neonatal transmission of the virus26,27
and with improved outcomes in HSCT recipients with
CMV reactivation in one study,28 but not in another.29
Hyperimmune globulin used to treat pregnant women
with primary CMV infection improves foetal outcomes
and abrogates placental pathology,30,31 and is used in
solid organ transplant to reduce primary infection. Use
of hyperimmune CMV globulin in HSCT recipients is
not supported by strong evidence. Nonetheless, it is com-
monly administered as an adjunct to ganciclovir in pneu-
monitis where mortality remains high.32
There is overwhelming clinical evidence of the
central role of the cellular immune system in defense
against CMV. Cellular immune deﬁciency and predis-
position to CMV infection is seen in HSCT recipients,1
advanced HIV infection33 and in patients treated with
lympholytic chemotherapy such as the purine analogs
(ﬂudarabine and cladrabine) or the anti-CD52
antibody alemtuzumab.34-36 Reconstitution of CMV
cell mediated immunity via adoptive transfer of CMV
speciﬁc immune effectors has been shown to control
CMV infection in both animal models37,38 and human
trials.39-47
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In otherwise healthy individuals, both CD8C and
CD4C cells targeting multiple CMV peptides are impor-
tant in the control of infection. The proportion of the
immune response devoted to CMV increases with age in
seropositive individuals. CMV speciﬁc cells comprise up
to 10% of circulating CD8C cells in seropositive individu-
als,48 a disproportionate allocation given the large
number of pathogens to which the immune system must
respond. The immunodominant proteins pp65, pp50,
glycoproteins IE-1 and IE-2account for the majority of
the T cell repertoire and subdominant responses are
present to other CMV proteins including glycoprotein-H
and pp28.49-51 CD8C cells recognize epitopes of CMV
proteins in a predictable manner that is HLA deter-
mined. The major tegument protein pp65 and immediate
early protein-1 (IE-1) are the most extensively studied
immune targets in HSCT recipients.
CD4C cells also play a major role in the control of
CMV. Target proteins include pp65, glycoproteins B and
H, IE72, IE86and UL69.52,53 Evidence of the importance
of CD4C cells can be derived from clinical situations in
which CD4C lymphopenia is present, such as HIV
infection33 and in renal transplant recipients where
CD4C lymphopenia is particularly associated with CMV
reactivation.54 There is evidence that CD8C CMV
speciﬁc cells are insufﬁcient to control CMV in the
absence of CD4C cells.55,56
CMV immunity in HSCT recipients
In the HSCT population, measurable T cell recovery
occurs within the ﬁrst few months of transplant. Risk
from CMV is highest in the ﬁrst 100 d when immunity is
in the process of recovery after exposure to lympholytic
agents in pre-transplant chemotherapy and transplant
conditioning regimens, and in some cases T cell
depletion, either ex vivo or in vivo. The number and
quality of T cells transferred in the stem cell graft varies
with the source (peripheral blood stem cells > bone
marrow > cord blood). In patients undergoing sponta-
neous immune recovery post HSCT both CD8C and
CD4C T cell subsets recover together, and are quantita-
tively correlated with control of CMV reactivation.57
Adoptive immunotherapy trials support the assertion
that both CD4C and CD8C cells are important. Infusion
of CD8C clones was effective in clearing CMV, but cells
did not persist in patients who did not develop a CMV
speciﬁc CD4C response.58 Einsele demonstrated that by
infusing CD4C cells alone, CD8C cells were generated
in vivo.59
Lack of recovery of immune function in the context of
reactivation is associated with prolonged CMV viraemia
and adverse outcomes.57,60-62This is impacted by donor
serostatus (faster with DC), donor source (faster with
matched related bone marrow, slowest with cord blood
transplant), degree of match (slower with mismatch) and
conditioning regimen (slower with T cell depletion).
Numeric recovery of CMV speciﬁc immunity is not sufﬁ-
cient to control viral replication. The capacity to produce
multiple cytokines and establish longevity in the recipi-
ent (compartmentalised according to functional memory
subsets) is also required.63,64
The reactivating CMV virus strains are generally of
recipient origin, and control is mediated by donor
derived immune effectors.65-67 This explains the differen-
tial risk according to donor and recipient serotype. The
highest risk group is seropositive recipients (RC) with
seronegative donors (D¡) in which reactivation occurs
in up to 80% of cases. RC/DC are at moderate risk, R¡/
DC at lower risk, with reactivation rate less than 10%.
Primary infection in R¡/D¡ transplants is rare.19,60,68-70
In D¡RC scenarios immune recovery is slower but does
occur, with evidence that immune recovery is mediated
by na€ıve donor T cells derived from progenitors in the
graft.66 It has traditionally been held that T cells from
the transplant donor are the sole source of CMV control
as recipient immune effectors are ablated by the trans-
plant process. This may be the case for myeloablative
transplants but there is evidence that in stem cell trans-
plants conditioned with reduced intensity protocols
recipient CMV speciﬁc T cells contribute to CMV
immunity, particular early after transplant before
achievement of full lymphoid chimerism.71,72
Factors inﬂuencing CMV immunity post transplant
The immune recovery process is dynamic and inﬂuenced
by post-transplant events. There is a bidirectional rela-
tionship of viraemia to immune recovery. While immune
recovery is required for control, the presence of antigen
stimulation is required to stimulate clonal proliferation
of antigen speciﬁc T cells. Seronegative recipients are less
likely to develop detectable immunity presumably
because the lack of viral reactivation in the recipient does
not provide a source of antigen stimulation.57,66,73 In
adoptive cell therapy studies, in vivo T cell expansion is
associated with episodes of detectable antigenaemia.46In
the absence of GVHD, CMV speciﬁc immune recovery
is stable and long-lasting. GVHD and associated treat-
ment adversely affect immune recovery and can lead to
prolonged problems with CMV74,57 (see Fig. 1).
During viral reactivation, massive in vivo expansion of
CMV speciﬁc clones occurs to the detriment of other
immune subsets, such as na€ıve T cell subsets including
recent thymic emigrants.75 These expanded clones are
largely CMV speciﬁC-terminally differentiated effector
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cells as measured by gene expression analysis and TCR
sequencing of single cells sorted by ﬂow cytometry.74
Early clonal expansion produces a period of oligoclonal-
ity with a small number of CMV speciﬁc clones compris-
ing a large proportion of all CD8C cells early post
transplant. It is possible that this represents expansion of
clones transferred with the graft on exposure to antigen
in the host.74 Later in the recovery process the TCR
diversity expands with new clones derived from stem cell
graft progenitors.66CMV serostatus has a strong impact
on the pattern of global immune recovery, such as the
ratio of B cells to T and NK cells, in addition to the well
known effects on T lymphocytes.76 NK cell subsets
recover early post transplant and are involved in the
response to CMV, as are Vd2-negative gdT cells.77,78 It is
likely that NK cells contribute to control of CMV infec-
tion with expansions of IFN-g producing NK cell popu-
lations reported in response to and after resolution of
CMV reactivation post HSCT.79,80
While CMV is the most common virus to cause clini-
cal problems post transplant, concurrent infection with
more than one double stranded DNA virus is common
in a number of transplant settings, particularly following
cord blood and T cell depleted transplant, and is associ-
ated with adverse outcomes such as increased overall
mortality.81 Reactivation of one or more viruses may
Figure 1. CMV immune recovery post-allogeneic HSCT. (A and B) Absence of CMV reactivation does not stimulate clonal expansion of
CMV speciﬁc T cell clones and detectable CMV immunity is low or undetectable. When CMV-VSTs are administered prophylactically no
expansion of the transferred clones is observed. (C and D) Low level CMV reactivation is controlled by CMV-VSTs that recover in the ﬁrst
few months post-HSCT. Prophylactic or pre-emptively administered CMV-VSTs are seen to expand in vivo and produce long-lasting sta-
ble immunity that is detectable up to 10 y after transplant. (E) CMV immunity recovers and controls CMV without treatment in the ﬁrst
few months. Subsequent development of GVHD and administration of corticosteroids and other immune suppressive medications
results in loss of CMV immunity and recurrent CMV reactivation requires treatment with antiviral pharmacotherapy. (F) After failure to
establish an effective cellular immune response spontaneously, either due to treatment (as in E) or donor seronegativity, donor-derived
or third party banked CMV-VSTs administered therapeutically can rescue patients refractory to standard therapies.
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reﬂect global cellular immune deﬁciency81-84 or may
stem from the fact that CMV infection itself results in
contraction of the immune repertoire post transplant
thus predisposing to other viral infections.75,81 It is not
possible to distinguish these possibilities using presently
available information. Recovery of CMV speciﬁc
immune function has been postulated as a biomarker for
overall immune recovery but no causal link between this
single pathogen-speciﬁc and global immune recovery
has been shown.85
There is a growing body of evidence that polymor-
phisms in the genes encoding molecules involved in the
CMV-host interaction affect the incidence and natural
history of CMV post transplant. These include SNP (sin-
gle nucleotide polymorphisms) in the chemokine recep-
tor 5 (CCR5), monocyte chemoattractant protein 1
(MCP-1), interleukin (IL) 10, toll-like receptors (TLR) 8
and 9, dendritic cell-speciﬁc molecule-3-grabbing non-
integrin (DC-SIGN) and IL-28B genes. SNPs in these
genes in donor and recipient have been associated with
the occurrence of CMV reactivation, its duration, the
peak levels of CMV DNAaemia and the development of
CMV disease.86-89 To date study ﬁndings have been
inconsistent, limited by small numbers and mechanistic
data is lacking. Larger conﬁrmatory studies are required
before recipient and donor SNPs can be to used for risk
stratiﬁcation or to guide therapeutic interventions.
Detailed assessment of global immune recovery post
transplant is currently underway using powerful tools
such as multidimensional ﬂow cytometry and mass
cytometry. Availability of new methods for single cell
analysis, gene expression and bioinformatics tools to
map TCR will facilitate ever more detailed interrogation
of post-transplant immune function.
Measurement of CMV speciﬁc immune function
in the clinic
A variety of methods are available to characterize CMV
speciﬁc immunity. Fluorescently-labeled MHC multi-
mers loaded with individual immunodominant CMV
epitopes which bind with high afﬁnity to the TCR allow
for speciﬁc and rapid identiﬁcation of CMV speciﬁc
T cells using multiparameter ﬂow cytometry. However,
this approach is limited by the HLA type, knowledge of
individual epitopes, the frequency of multimer positive
cells and will only give an indication of a proportion of
the immune response. Multimer-based assessment pro-
vides no indication of functional responsiveness, and
thus numeric thresholds may provide false reassurance
of immunity in the early post-HSCT population.90-92
Functional assays include the enzyme linked immunoas-
say (ELISPOT),60 cytokine production assays57,93,94 and
cytotoxicity assays (including Chromium release,
degranulation assays or direct vizualization assays).95
ELISPOT has the advantage of reproducibility and is
semi-quantitative so it can show change in immune
function over time. However it is limited by the lack of
individual cellular phenotype information and the need
to standardise assays performed at different times. Cyto-
toxicity assays require large cell numbers and are rele-
vant only for research purposes. Quantitative ﬂow
cytometry assays use intracellular ﬂow cytometry to
measure production or expression of IFN-g, TNF,
CD107 and IL-2from CMV-stimulated PBMCs; reacting
cells are then quantiﬁed using absolute CD3C, 4C and 8C
cell counts. Lilleri et al used quantitative ﬂow cytometry
to assess immune reconstitution over time in 131
patients.57 This study had a relatively high threshold
CMV copy number for initiation of pre-emptive treat-
ment (>30,000 copies/ml) so is helpful in understanding
the natural history of CMV immune recovery in the
absence of therapeutic intervention. It should be noted
that the majority of patients were young recipients of
bone marrow grafts and few had cord blood or T cell
depleted transplants that are associated with higher risk
of uncontrolled CMV infection. This study showed that
patients with CMV speciﬁc immunity above a predeter-
mined cut off (1 and 3 CMV speciﬁc CD4C and CD8C
cells/ml, respectively) were able to control reactivation
without the need for antiviral chemotherapy. The only
failures were associated with treatment for GVHD. Time
to development of both CD4C and CD8C immunity was
correlated with time to control of CMV. Similar observa-
tions have been made in other studies utilizing quantita-
tive or semi-quantitative methods for measurement of
CMV immunity.57,93,94
All of these methods are technically demanding and
standardisation has not been achieved thus far. Studies
using cut-off thresholds for CMV immunity are there-
fore not easily applied in routine clinical use. The only
assay approved for clinical use for CMV immune moni-
toring is the QuantiFERON-CMV (Qiagen, Valencia,
CA, USA), where whole blood is stimulated with CMV
peptides and IFN-g release is quantiﬁed by ELISA. This
assay is analogous to the QuantiFERON-TB assay that
has been widely adopted for tuberculosis. Although Qan-
tiFERON-CMV is less sensitive than ﬂow cytometry
assays,96it is simple and reproducible and has been vali-
dated in HSCT recipients with similar results to other
immune monitoring assays.97 There are no studies that
yet conclusively demonstrate the safety of ceasing CMV
monitoring based solely on the demonstration of CMV
immunity. A future challenge is to integrate assessments
of immune recovery into clinical algorithms of CMV
management identifying patients in whom monitoring
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can be reduced or eliminated and in whom pre-emptive
antiviral therapy can be safely withheld.
Interventions to improve CMV immune
reconstitution
Given the impact on mortality and cost, attention has
focused on ways of improving CMV speciﬁc immunity
as a means of improving overall outcome in transplant
recipients.
Vaccination
The observation that antigenaemia is associated with
improved CMV speciﬁc immune reconstitution
implies that vaccination with antigen may improve
immunity early post transplant at the time when
patients are at risk of CMV.98 No CMV vaccine has
regulatory approval for prevention of CMV infection
in normal individuals but a number of vaccine candi-
dates are under investigation. A recombinant glyco-
protein B vaccine was trialled in seronegative and
seropositive solid organ transplant recipients prior to
transplant with signiﬁcant improvement shown in
antibody titres in both serogroups, along with a reduc-
tion in duration of viraemia and antiviral treatment
required in DC/R¡ patients who reactivated post
transplant.99 ASP0113 is a bivalent vaccine containing
2plasmids that encode CMV glycoprotein B and tegu-
ment protein PP65. In a phase 2randomized placebo
trial of ASP0113 in which 40 allo HSCT CMV sero-
positive patients were administered the vaccine prior
to conditioning and at 1, 3 and 6mths post transplant
there was a reduction in overall CMV viraemia, delay
in viremic onset and reduced risk of recurrence. How-
ever there was no reduction in use of antiviral therapy
and no signiﬁcant improvement in measured CMV
speciﬁc immunity.100 A planned HSCT donor vaccina-
tion arm for this study had to be abandoned due to
logistical problems with identifying and vaccinating
donors prior to transplant. This compound is now
under investigation in a phase 3 study with planned
recruitment of 500 participants (Clinicaltrials.gov ID
NCT01877655). An alternative vaccine candidate is a
peptide vaccine conjugated to a toll like receptor ago-
nist that has been administered to 18 HLA-A201
CMV seropositive allogeneic stem cell transplant
recipients at day 28 and day 56as part of a random-
ized phase 1 clinical trial. A CMV-speciﬁc CD8C T
cell response was noted without an antibody response
and both risk of CMV reactivation and duration of
CMV antiviral therapy were reduced compared to the
control arm. An increase in relapse-free survival was
also demonstrated.101
Adoptive transfer of CMV speciﬁc T cells
Infusion of unmanipulated donor lymphocytes after
transplant can improve antiviral immunity but it does so
at the cost of increased GVHD.102CMV speciﬁc immune
reconstitution via adoptive transfer of ex vivo isolated or
expanded donor derived virus speciﬁc T cells (CMV-
VSTs) has now been performed successfully in a number
of clinical trials.39-47,58,59 CMV-VSTs can be manufac-
tured in a variety of ways. Time consuming ex vivo
culture methods using limiting dilution cloning or EBV
transformed lymphocytes as antigen presenting cells
(APCs) have largely been replaced with more rapid tech-
niques using alternative APCs (activated monocytes, rap-
idly matured monocyte derived DCs or artiﬁcial APCs),
various antigen sources and shorter culture times.
Ex vivo culture duration can range from 10 d to a num-
ber of weeks. Direct isolation methods using activation
markers, cytokine capture or multimer selection are able
to generate a clinical product within 48 hours. There are
no studies comparing these methods directly, but it
appears that cellular persistence depends on the presence
of CD4C cells either within the adoptive cell product or
generated from the stem cell graft.103 Adoptive cell ther-
apy appears safe, with no evidence that it increases the
risk of GVHD in single arm studies and a cohort
study.104 Two randomized studies of prophylactic/
preemptive adoptive immunotherapy have been
performed using direct capture methods for generation
of donor-derived CMV VSTs (CMV»IMPACT and
CMV»ASPECT) that have been reported in abstract
form.105,106Adoptive therapy appeared to be safe in both
studies, and a signiﬁcant expansion of CMV-speciﬁc cells
was reported over controls for the ASPECT study. How-
ever, reductions in the rates of reactivation, recurrence
and duration of therapy in the IMPACT study failed to
reach signiﬁcance, likely contributed to by a lower than
expected CMV event rate in the control group.
Routine prophylaxis with transplant donor-derived
CMV-VSTs is currently expensive, and may not be
needed in patients who would never reactivate CMV.
Thus, a pre-emptive strategy using rapidly generated
CMV-VSTs may be a preferable approach although the
methodology for cell generation is not yet widely avail-
able. An alternative approach is to use partially-HLA
matched banked third party CMV-VSTs. To date, the
treatment of over 75 patients with active CMV infection
and disease utilizing banked non-donor derived unre-
lated (third party) CMV-VSTs have been reported.107-110
The 3 largest studies showed a high complete response
rate, and did not ﬂag any safety concerns; in particular
the rate of GVHD was not higher than expected. In con-
trast to donor-derived adoptive transfer, these third party
partially-matched donor cells do not appear to persist
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beyond a few weeks, yet effect long-term CMV control.
With a median follow up of 6 months, few patients
required retreatment with antiviral therapy after the ﬁnal
dose of third party cells.109,110 Further studies of third
party cells are needed to elucidate the mechanisms of
this clinical effect.
Engineering of the graft to improve immune recovery
As an alternative to the use of VSTs, graft engineering
strategies may maintain antiviral immunity while reduc-
ing the risk of GVHD associated with transplantation of
unmanipulated stem cell products. These include add-
back of ex vivo allodepleted T cells and na€ıve T cell
depletion of stem cell products via CD45RA or TCRa/b
depletion.111-113 Incorporation of safety switches into
T cells prior to infusion allows selective deletion of gene-
modiﬁed cells if GVHD occurs.114,115 Other immuno-
modulatory approaches to GVHD include induction of
anergy or administration of regulatory T cells but the
effect of these strategies on CMV immunity has not been
studied.116,117
CMV immunity and AML relapse
Donor seropositivity for CMV has been associated with
lower relapse rate in AML in a number of observational
studies dating back to the mid 1980s.118-123 CMV reacti-
vation in patients undergoing transplant for AML was
associated with reduced relapse risk with a proposed
hypothesis of immune mediated anti-leukemic activity.
In response to these studies the CIBMTR has performed
an analysis of the impact of CMV reactivation on relapse
in 9,469 patients with haematological malignancies,
including 5,310 with AML.19 No association was found
between CMV reactivation before day 100 and reduced
risk of relapse. An association of CMV reacivation with
reduced AML relapse risk in a transplant subgroup can-
not be absolutely excluded. In contrast, CMV reactiva-
tion was associated with increased transplant related
mortality and reduced overall survival.
Conclusion and future directions
With few exceptions, studies show that recovery of both
CD4C and CD8C cellular immunity are required for pro-
tection from CMV viral replication. CMV seropositive
recipients with donors who are seropositive for CMV
have fewer, shorter and later viraemic episodes compared
with those with seronegative donors. Regular monitoring
with pre-emptive antiviral therapy has reduced the rate of
CMV disease and direct mortality but at a cost of morbid-
ity and ﬁnancial burden. Despite clear efﬁcacy in mini-
mizing CMV tissue infection, pre-emptive anti-CMV
therapy has not eliminated the adverse effect of CMV
reactivation on non-relapse and overall mortality and
CMV remains a major contributor to poor post-transplant
outcomes. It is not yet clear which patients with CMV
reactivation can safely be left to clear virus without
pharmacological intervention. The use of more speciﬁc
measurements of immunity may facilitate better case
selection for pharmacotherapy. Graft engineering strate-
gies promise to preserve graft mediated anti-CMV activity
but more rapid reconstitution of CMV immunity after
transplant seems most likely to result from donor and/or
recipient vaccination and adoptive immunotherapy.
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Case Report
Adoptive T Cell Immunotherapy for Treatment of
Ganciclovir-Resistant Cytomegalovirus Disease
in a Renal Transplant Recipient
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Cytomegalovirus (CMV) is a significant cause of
morbidity, mortality and graft loss in solid organ
transplantation (SOT). Treatment options for ganciclo-
vir-resistant CMV are limited. We describe a case of
ganciclovir-resistant CMV disease in a renal transplant
recipient manifested by thrombotic microangiopathy-
associated glomerulopathy. Adoptive T cell immuno-
therapy using CMV-specific T cells from a donor bank
was used as salvage therapy. This report is a proof-of-
concept of the clinical and logistical feasibility of this
therapy in SOT recipients.
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stem cell transplant; moDC, monocyte-derived den-
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Introduction
Cytomegalovirus (CMV) is a significant cause of morbidity,
mortality and graft loss in solid organ transplantation (SOT).
Treatment options for ganciclovir-resistant CMV typically
include cidofovir and foscarnet but are limited due to
possible cross-resistance in the case of cidofovir and issues
of nephrotoxicity with both agents (1). In renal transplanta-
tion, this is particularly concerning due to the possibility of
graft loss.
Due to these concerns, adjunctive therapies such as CMV-
specific immunoglobulin (CMVIg), artesunate and lefluno-
mide have been used (1) and novel therapies such as
maribavir, letermovir and brincidofovir are currently being
studied but data are limited regarding their use in SOT (1,2).
Despite increasing interest in immune manipulation through
CMV-specific adoptive cell therapy (ACT), clinical data are
limited to hematopoietic stem cell transplant (HSCT) recipi-
ents (3–5) and a case report in a lung transplant recipient (6).
Wedescribe the use ofCMV-specificACT in a renal transplant
recipient with ganciclovir-resistant CMV disease.
Case Report
A 61-year-old man presented with deteriorating renal
function and CMV viremia 9 months following receipt of
a six HLA-mismatched deceased donor renal transplant.
The donor was CMV seropositive and recipient CMV
seronegative. The patient had undergone bilateral nephrec-
tomy and cystoprostatectomy for transitional cell carcino-
ma 5 years earlier. Renal-adjusted valganciclovir was used
as CMV prophylaxis but 4 months posttransplant the
patient had an initial episode of CMV colitis with diarrhea
and a peak serum CMV viral load of 1 797 190 copies/mL.
Valganciclovir was increased to treatment dose (450mgbd)
with a subsequent improvement in symptoms and
decrease in viral load to a nadir of 24 210 copies/mL
following 3 months of therapy (Figure 1). Immunosuppres-
sion remained stable and included mycophenolate 500mg
bd (area under the curve 33.7mgh/L), prednisolone 7.5mg
daily and tacrolimus with levels of 4.3–7.1 ng/mL.
After 4 months of treatment with valganciclovir, the patient
developedmild gastrointestinal symptoms and a CMVDNA
viral load of 160 951 copies/mL (Figure 1) was noted.
Despite reductions in tacrolimus dose and level, mycophe-
nolate to 750mg daily and prednisolone to 5mg daily,
2 weeks later the CMV DNA viral load had risen to
906 210 copies/mL. Mycophenolate was ceased and
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replaced with leflunomide (100mg per day for 5 days then
40mg per day) and the patient was admitted to hospital for
administration of IV ganciclovir induction therapy (150mg
daily, as adjusted for renal function). CMV resistance
testing showed a L595S UL 97 mutation conferring high-
level ganciclovir resistance. Ganciclovir was ceased and
CMVIg was commenced.
Oneweek later the patient developed an acute kidney injury
(creatinine 3.1mg/dL from baseline of 2.15mg/dL) andmild
thrombocytopenia (80–100#109/L). A renal transplant
biopsy demonstrated glomerular thrombotic microangiop-
athy (TMA) with fibrin thrombi in capillary loops, CMV
inclusion bodies in endothelial cells and minimal interstitial
inflammation (Figure 2). Hematological markers were
Figure 1: CMV viral load, clinical course and in vitro analysis of the generated T cell line. Panel 1: The figure demonstrates the CMV
viral load and gives an overview of the timing of different therapeutic agents, with specific note of the institution of ACT and the subsequent
fall in CMV viral load. Other clinical characteristics such as the renal function and platelet count are also shown. Panel 2: Specificity and
function of third-party CMV-specific T cells. (A) Interferon-g production by CD8þ and CD4þ T-cells in response to direct re-stimulation with
CMV pp65 overlapping peptides or with no antigen (negative control). (B) Interferon-g production by CD8þ and CD4þ T-cells was assessed
after re-stimulation with partially HLA-matched antigen presenting cells (three of six HLA-matched at A3, B18 and DRB1!0701) loaded with
CMV pp65 peptides or with no antigen (negative control) to assess non-HLA-A2 restricted CMV directed activity. (C) Cytotoxic activity of
CMV-specific T-cells was determined using the Chromium51 release assay. Specific lysis of CMV pp65 peptide loaded target cells was
measured at effector to target (E:T) ratios of 1.25:1 to 40:1. Target cells loaded with CMV pp65 peptides were autologous PHA blasts (6/6
HLA match) or partially HLA-matched PHA blasts (three of six HLA-matched at A3, B18 and DRB1!0701) to determine non-HLA-A2
restricted CMV directed cytotoxicity. No cytotoxicity was observed against target cells not loaded with CMV pp65 peptides.
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consistent with the TMA noted on renal biopsy (platelets
113# 109/L, LDH 618 IU/L, hemoglobin 111 g/L with rare
red cell fragmentation, haptoglobin 0.26 g/L). In response to
the TMA, plasma exchange was instituted, tacrolimus was
ceased, prednisolone dose was increased to 37.5mg daily
and then gradually weaned.
Ten doses of CMVIg 1.5 million units (CMV Immunoglobu-
lin-VF, CSL Limited, Broadmeadows, Australia) were
administered on alternating days with plasma exchange.
Two weeks later, the patient required dialysis and had a
CMV DNA viral load of 5 583 636 copies/mL. A repeat
biopsy showed acute tubular necrosis and persistent TMA
Figure 1: Continued.
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with endothelial CMV inclusion bodies. There were no
symptoms or clinical findings of gastrointestinal, respiratory
or ophthalmological CMV disease. Despite being dialysis
dependent, the patient maintained approximately 700mL
urine output per day. The nephrological opinion was that
preservation of residual renal function was necessary. As
such, foscarnet use was avoided and a trial of intravenous
artesunate (200mgbd for 1 day then 100mg daily) was
commenced. Leflunomide (20mg) and prednisolone
(15mg) doses were reduced and dialysis and plasma
exchange continued. ACT was considered due to lack of
response to other salvage therapies.
T cell line generation
Partially HLA-matched CMV-specific T cells were generat-
ed from a third-party donor using cells removed from a
mobilized hematopoietic progenitor cell collection as
previously described (7,8).
Briefly, monocyte-derived dendritic cells (mo-DC) were
loaded with a pool of overlapping 15mer peptides covering
the entire CMV pp65 protein (Miltenyi BiotecMACS1GMP
PepTivator1) and co-cultured with autologous T cells. T cell
cultureswere restimulated after 7 dayswith peptide loaded
mo-DC plus low dose IL-2 (20U/mL) for 7 days and high
dose IL-2 (50U/mL) for a further week. The completed
culture was cryopreserved and stored as part of a third-
party bank of CMV-specific T cells for the treatment of
refractory viral infections.
The product consisted of predominantly CD3þ T cells
(93.6%) with both cytotoxic CD8þ T cells (79.4%) and
CD4þ helper T cells (16.6%). Specificity towards CMVwas
determined by MHC tetramer staining, intracellular cyto-
kine production in response to pp65 and cytotoxicity against
matched and partially matched target cells (phytohemag-
glutinin blasts). 31.3% of T cells in the final product
recognized the immunodominant HLA-A2 restricted epi-
topeNLVPMVATV. However, as the intended recipientwas
not HLA-A2 additional testing was performed to confirm
CMV-directed activity through other shared HLA. Firstly,
overall responseswere assessed by stimulating T cellswith
a peptide pool covering the entire pp65 protein and looking
for the production of interferon-gamma by intracellular
Figure 2: Histopathological findings on renal transplant biopsy pre and post-ACT. (1) Hematoxylin and eosin stain 40# of renal
biopsy performed 20 weeks post-CMV viremia detection demonstrating evidence of thrombotic microangiopathy with fibrin in capillary
loops. (2) Immunoperoxidase stain 40# of renal biopsy performed 20 weeks post-CMV viremia detection with double mouse anti-CMV
monoclonal IgG antibodies specific for CMV, highlighted CMV inclusion bodies in 12 of 14 glomeruli suggestive of CMV glomerulopathy.
(3) Hematoxylin and eosin stain 40# of renal biopsy performed following ACT at 27 weeks post-CMV viremia detection shows a dense
interstitial mononuclear inflammatory cell infiltrate, composed mainly of T cells, in a ratio of 1:4 CD 4:8. (4) Immunoperoxidase stain 10#
with double mouse anti-CMV monoclonal IgG antibodies specific for CMV of renal biopsy also performed at 27 weeks post-CMV viremia
detection now showed a reduction in the number of CMV inclusions with involvement of one of eight glomeruli.
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cytokine flow cytometry. Interferon-gamma production
was observed from both the CD8 (5.7% of CD8þ
T cells) and CD4 (5.6% of CD4þ T cells) T cell subsets.
To demonstrate CMV activity through non-A2 HLA-allele the
T cell product was stimulated with partially HLA-matched
(matched at A3, B18 and DRB1!0701) antigen presenting
cells loaded with no antigen or with a pp65 peptide pool
(Figure1).Weobserved interferonproduction in thepresence
of CMV pp65 (1.3% of CD8þ and 2.5% of CD4) that was
higher than that observed in the control conditions (0.2% of
CD8 and CD4 T cells with no antigen). Furthermore, the T cell
product was able to specifically lyse partially HLA-matched
target cells using a standard Cr51 cytotoxicity assay. We
observed 11.3% specific killing of the partially HLA-matched
(3/6) target cells at a ratio of 40 cytotoxic lymphocytes (CTL)
to 1 target cell compared to 51.3% killing of 6/6 matched
target cells loaded with CMV pp65 overlapping peptide pool.
As expected, this demonstrated that themajority of cytotoxic
activity was mediated through HLA-A2 but that activity
restricted to A3 and B18 was also present.
Use of CMV-specific adoptive cell therapy
Three weeks following diagnosis of TMA, written informed
consent was obtained from the patient and ACT with third-
party CMV-specific T cells matched at three of six HLA loci
(A, B and DRB1) was administered at a dose of 1.6# 107 T
cells/m2. A mild fever of 38.18C was noted following
infusion. Leflunomidewas ceased.Nineteen days following
administration of ACT, CMV DNA viral load was
185066 copies/mL. Plasma exchange was ceased due to
resolution of hematological features of TMA (platelets
269# 109/L, LDH 369 IU/L, no red cell fragments on blood
film), but the patient remained dialysis-dependent. A repeat
renal transplant biopsy 3 weeks following ACT administra-
tion demonstrated organizing TMA, with 50% sclerosed
glomeruli, mild acute tubular necrosis and CMV inclusion
bodies were now seen in only one of eight glomeruli. There
was a diffuse interstitial infiltrate without tubilitis, com-
posed of T cells in a ratio of 1:4 CD4:CD8 (Figure 2).
Artesunate was continued until discharge from hospital
1 week later. Four months post-ACT, CMV DNA viral load
had decreased to 682 copies/mL and the patient remained
asymptomatic. At 1 year, CMV DNA viral load was
73 copies/mL and the patient remains dialysis dependent
although he continues to have a urine output of approxi-
mately 700mL/day.
Discussion
Treatment of ganciclovir-resistant CMV disease in SOT
recipients is associated with a high failure rate. This has led
to an increasing interest in the use of alternative therapies
such as ACT. In HSCT recipients, infusion of donor-derived
CMV-specific T cells controls CMV reactivation and disease
and reduces the need for and duration of CMV-directed
pharmacotherapy when given prophylactically (7). The
experience in SOT recipients has been limited in this
setting due to the use of deceased donors. More recently,
banked third-party partially HLA-matched CMV-specific T
cells have shown efficacy in treating refractory viral
infections (4). Our case demonstrates that third-party
partially HLA-matched CMV-specific CTLs are a feasible
treatment for refractory or drug-resistant CMV disease in
SOT recipients.
The development of ganciclovir-resistant CMV disease
limited treatment options and the disease was refractory to
a number of alternative therapies, likely due to high disease
burden as reflected by highCMV viral load. Leflunomide has
been shown to have efficacy in cases of refractory CMV
disease (1). As in our case however, higher peak viral load
and higher viral load at the start of leflunomide therapywere
associatedwith failure to suppress viremia. Artesunatewas
also trialled on the basis of previous reports (1) but was
ineffective. Use of novel agents such as maribavir,
letermovir and brincidofovir was considered but these
agents could not be accessed in a timely fashion and
there were concerns regarding possible cross-resistance
in ganciclovir-resistant CMV disease in the case of
brincidofovir (2).
Use of ACT derived from transplant donors or recipients is
hampered by unavailability of cells from deceased donors
and delays in expanding and quality controlling T cells ex
vivo, a process that can take weeks and is not practical in
cases of life-threatening disease requiring urgent thera-
py (6). Reports of efficacy of banked virus-specific T cells in
the setting of HSCT (4,9) remove the delay involved in cell
administration. Our case is a proof-of-concept that ACT
using banked partially HLA-matched virus-specific cells is
both clinically and logistically feasible. Despite the multifac-
torial manifestations of CMV disease in our case, there was
a significant and durable reduction in CMV viremia following
infusion of third-party CMV-specific T cells (Figure 1)
without complete clearance. Whilst the patient remains
dialysis dependent, the significant reduction in CMV DNA
viral load was associated with resolution of TMA.
The efficacy of the therapy may be related to the donor
source and HLA matching (10). We were able to use cells
from a healthy unrelated donor as opposed to autologous
ACT as previous described in a lung transplant recipient (6).
The cells infused were matched at three of six major HLA
antigens. The duration of the response suggests that the
cells continue to exert an antiviral response in the setting of
on-going mild immunosuppression potentially contributing
to prevention of complete elimination of the infused cells.
Haque et al studied the use of ACT in SOT recipients to treat
refractory PTLD secondary to EBV and noted an association
between the number of HLA matches and clinical
response (10). It has been noted in HSCT that donor-
derived CTLs survive long term in recipients and can control
reactivated persistent EBV infection up to 18 months
after infusion (11). There are difficulties in distinguishing
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between emergence of natural immunity and persistence
of infusedCTLs (12). Future investigation of this therapywill
require better characterization of the kinetics of CTL
persistence, including discrimination between donor-de-
rived and host immunity. The possible effects of repeated
infusions should also be taken into account. ACT carries
concerns regarding toxicities, including graft rejection and
the possibility of CTL-versus-host disease (6). In our patient
only a mild self-limited fever was noted following the
infusion with no other immediate adverse events. There
have been no further adverse events noted over 12months
of follow-up, in particular no evidence of CTL-versus-host
disease. The preservation of residual renal function
suggests no adverse impact upon the graft, however the
absence of a further renal biopsy makes this difficult to
ascertain with certainty.
In summary, we have shown that ACT from a donor bank
can be safely used to treat resistant CMVdisease in an SOT
recipient. The use of multiple therapeutic agents makes it
difficult to attribute the observed response to ACT alone
but disease progression was reversed only after its
commencement. No significant toxic effects from ACT
were observed. These findings suggest that novel
techniques for generating virus-specific CTLs and the
development of donor banks may make this a feasible
future therapeutic option in SOT recipients and warrants
further investigation.
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Viral infections remain a major complication after hemato-
poietic stem cell transplantation (HSCT); however, over the
past 25 years, investigators around the world have shown that
ex vivo-expanded virus-speciﬁc T cells (VSTs) are an attractive
option for refractory cytomegalovirus (CMV), Epstein-Barr
virus (EBV), and adenoviral infections and for various other
transplantation-related viruses. Recent advances in this
approach, such as activated T cell and multimer selection, have
reduced the time required from 2 to 3 months to overnight [1].
However, the overnight methods, besides requiring recollec-
tion of the transplant donor who must be seropositive for the
virus of interest, support a limited cell dose, and the number of
VSTs collected typically precludes additional doses.
Yet another option is the use of third-party, off-the-shelf
VSTs. First published by Haque et al in 2002, [2] this approach
has gained popularity over the past 5 years, with larger phase
1 and phase 2 studies being reported [3]. Importantly, at least
2 companies, Atara Biotherapeutics and Viracyte, are pursuing
the commercialization of off-the-shelf VSTs; Atara is currently
sponsoring a phase 3 trial using EBV T cells for post-transplan-
tation lymphoproliferative disorders after solid organ trans-
plant or HSCT, and Viracyte is sponsoring CMV, EBV,
adenovirus, BK virus, and human herpesvirus 6-speciﬁc T cells
in a phase 2 trial. However, until these products are commer-
cialized, many centers worldwide still rely on a handful of aca-
demic centers or clinical trials run through such organizations
as the Pediatric Blood and Marrow Transplant Consortium,
which sponsors a clinical trial testing VSTs as treatment for
pediatric patients with viral infection before or after HSCT.
The fact that these therapies are only available at a handful
of centers worldwide is a testament to the knowledge and
experience required to build a VST cell bank and effectively
utilize this bank. In this issue, Withers et al [4] elegantly detail
what is required to establish a bank and use it to effectively
treat patients with viral infection. Critically, the authors
address one of the most controversial questions about T cell
banks: how large the bank needs to be to provide adequate
coverage. Leen et al [3] reported treating 50 patients with a
bank of 32 T cell products, but only 18 of those products were
used to treat those 50 patients. In contrast, O’Reilly et al [5]
reported a bank of more than 100 CMV-speciﬁc and 300 EBV-
speciﬁc third-party VSTs.
To evaluate the number of products that would be required
for their local bank, Withers et al evaluated a historical cohort
of 146 HSCT recipients treated at their institution and com-
pared this cohort with their third-party VST bank. With this
information, they then strategically identiﬁed donors with
desirable alleles, such as HLA-A01 and HLA-A24, which would
increase the coverage of their bank to 82%. They used knowl-
edge of HLA-restricted antigen speciﬁcity for each of the
viruses to determine which third-party VST products target
the virus of interest through a given allele, and then used
modeling to determine that donors expressing 6 core HLA anti-
gens (HLA-A01, -A02, -A24, -B07, -B08, and -B35) would pro-
vide coverage for approximately 90% of HSCT recipients in
their region. In practice, the bank they created used 30 donors,
among whom 14 were used to treat 30 HSCT recipients with
recurrent viral infections post-transplantation.
The strategic targeting of donors used in this study demon-
strates that a VST bank with as few as 6 products (or fewer if
shared alleles between donors and activity through each of the
alleles) would provide a product for most of the local HSCT
population. However, as demonstrated by the actual bank cre-
ated by this group, having a larger bank is still more practical,
for several reasons. First, some reports suggest that increased
matching between VST product and recipient results in better
outcomes. Other groups claim that having antigen speciﬁcity
through the shared alleles is most important, although a com-
bination of shared alleles and antigen speciﬁcity is likely the
best option. Second, according to this study, 10% of patients
would still have recurrent viral infection lacking other thera-
pies. Finally, regions of the world with more homogenous pop-
ulations will inherently require fewer donors; however, more
heterogeneous populations with rare alleles will likely require
larger banks.
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Until third-party VSTs are a commercial option, the ability
to build a third-party VST bank will be of great use for HSCT
centers worldwide that are looking for alternative antiviral
treatments that are rapid and more cost-effective than donor-
directed VSTs. Witmer et al provide a framework for building a
useful third-party VST bank and takes a pragmatic approach to
determining the diversity and size of this bank.
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